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It is the purpose of this thesis to develop a course of 
study for pharmacy schools on drug regulation by the Food 
and Drug Administration (FDA). A summarization of the 
history of the development of the Food and Drug Administration 
(FDA) and of pharmacy education reveals a lack of interface 
· between the two. The necessity for the interface of phai·-
macy education and the agency which has significant control 
over the products forming the basis of the pharmacy profes-
sion will be made apparent. A period of residency through 
which the course of study on drug regulation by the :F.DA was 
to be developed, will be described. This description details 
the responsibilities and functions of the various segments 
of the FDA involved in the regulation of drugs as acquired 
through discussion with agency officials during the residency. 
It is intended to be used as the textual material for the 
didactic portion of the course of study to be offered at 
schools of pharmacy. Based upon the experience, recommen-
dations will be made regarding the applicability of the course 
of study to include possible residencies for pharmacy students 
at the agency. 
Development of the Food and Drug Administration 
Affecting every American, the Food and Drug Administration 
1 
(]'DA) has broad responsib:Lli ties e.s a consumer protection 
agency. The FDA furwt:i.on'3 to protect the public health 
2 
llnd welfaxe by insuring that: .food is safe, pm:-e, and 
wholesome; human and animal d:eugs, biological prc,d:c:.cts and 
therapeutic devices are safe ru.1d effective; eor,me~;:i.cs are 
harmless; radiological products and their use do not re~1ult 
in unnecessary exposure to radiation; any food, drug, device, 
or cosmetic that :Ls adulterated or misbranded is prohibited 
from introduction into interstate commerce (1). 
The FDA 1 s mission is an important one, but the absolute 
enforeement of the above is almost impossible, considering 
the nwnber of food, drug, and cosmetic products ·that are on 
the rrt8J:•J!.~~';.;i:; today,. IJ•o augment its X'Ggula.i;c•:ey Eieti yj:t;i6S ~ i;ht~~ 
e.gen.cy vJor}\:s· to as;;}ure that the mai-J.LLfc:tctuT~.trs have g<jocl 
quality control measures so that they will hasc tiv~ <<b:Uity 
to ·identify problems that may occv.x·. _ 'l'he. e:;cpQilsi,o:Q of the 
industry han led to continual increases :i.n the size of' the 
J!'DA and rramber . of ree;ulations. In the thirty-four years 
beh1een 191J.O m1d 1974, the number of employees has increHs&d 
from seven hundred to over six thomwn.d. To obtain better 
pm·spec.tive as to the fm1ct.j.ons performed :t;odc.-1y by the D.gcncy, 
au u.~d,,,rs1;anding of the development of leg:lslat;:lon C3:·ea:i;:i.ng 
At the turn of the t\rJentieth centm:oy, the p:c·edecessci' 
of the ]'ood and Drug Administration came into existence, 
~'he formation of the agency was prompted by the industriaJi ... 
zation of thi.s cotmtry, bringing with it the mass production 
of foods and drugs. Their wide distribution,_ coupled with 
the f'act that many people were moving from the farm to the 
.cities end becoming de1)endent upon processed foods, accen.,-
tuated the inadequacies in their formulation, production, 
and handling (~:). Much of the legislation concerning the 
-FDA was written in attempts to correct totally intolerable 
situations - even tragedies - exemplifying the lack {)f con-
cern for food and drug regulation in the past. 
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The d.l:'iving f'orce behind the legislation creating the 
agencJ's predecessor came from the chief of the Bureau of 
Chemistry in the U.S. Department of Agriculture at the time, 
Dr. Ha.rvey Wiley. Dr. viiley was an advocate of pure and 
wholesomf' food ;.md became ve:ey interested in the problems 
0 " fc>co' 011 t·tl', ·u"":.~, ... -e-~I'l~c • Tr1 19('J"- h·· 1: ~,:)···:t·n -·--1-~~~ 1-~+J. ':1'"--''t·-~·..-.a ,;.. , '1 '· . . "' 't .r.u.. ,\:'-_ lo .; .(.;4 E::;: ~ -- ·- • l:.. l \:,;: )l.:;.,~_,t.:..... .L!. 'f ,-_.~.--;. ~~ -t:_Jc~ •-l.l..to 
cer·tair.~. acldi ti:'ire.s in commo:n usC1 for food p:r-ese.r:vation to 
determine their ef'fects on humans. His group oi' young, 
heeJ.t;hy malo volunteers were fed a normal diet containi:ng 
the preservative 1.n question. Tho :press became int;erested 
in the experiment, labeling the group "The Poison Hquad", 
aiJd printing in.fo:rm;;rtion ~lhich, fo:P the most: ptou:t, had little 
basis :in f'act;. This created problems bet1·1een Wiley and the 
Secretary of Ag:ricul twre, J"ameH \vilscm, who ordered the 
projec.-t; to be discont:inued. The Congress and PreB:i.den-G TheodorE' 
Hoosevelt; also 11e.re concerned over the publicity and fel-~ t;he 
e:>..'1Jeriments should be discontinued. Dr. Wiley, ho~Tevex-, still 
very much concerned over the health hazard, continued the 
studies. He took the press into his confidence, releal>ing 
reports as they became available (3). 
In 1906, Congress developed stronger interest in Wiley's 
experiments and held_hearings on the subject. The hea~ings 
revealed that many foods and drugs were misbranded ~~d 
adulterated. Additionally, the hearings revealed that many 
of the chemical preservatives used were unnecessary, except 
in the transportation of perishable foods. This information 
prompted the introduction of the Pure Food and Drug Act of 
1906, one of the earliest measures by the Federal government 
to regulate interstate and foreign commerce for the specific 
purpose of the protecting the consumer's health. There was 
some question as to whether the approach was constitutional 
since it did not attempt to regulate .commercE> ~ri thin the 
proper definition, that is to protect the economic rights 
of the consumer. However, it was argued that Congress, fer 
consumers, should "not only protect their pocket books, but 
protect their lives (4)." 
The Pur.e Food and Drug Act o.f 1906 provided jurisdiction 
over foods and drugs and although this jurisdiction was rather 
limited, it provided a basis for the regulation of foods and 
drugs. The 1906 Act defined the terms "drug", "food", 
"adulteration", ·and "misb~·anding", thus establishing minimum 
standards for quality. The term "drug" included all medicines 
recognized by.the .United States Pharmacopeia and National 
Formulary, and any.subs.tance intended for the "cure, mitiga-
tion, or prevention, .. of disease in either man or other ani-
mals". An . adulterated d-"Ug was one which, if marketed by a 
name recognized in the official eompendia, did not meet the 
official standard. However, an exception was allowed in 
5 
that the official standards \-.rould not have to be met ii' the 
drug met its own purity, quality, and strength specifications 
which were clearly marked on the label. Drugs were considered 
misbranded if the label bore false and misleading statements; 
the drug offered for sale was an imitation of another article 
(false name), or contents had been deleted, added or changed 
(false contents); or the label did not bear the quantity of 
alcohol, narcotics, and certain other specified ingredients. 
Food was defined as all articles used for food, drink, con-
fectionary or condiment by man or other animals. Food was 
considered adulterated if any substance 'tras mixed \'lith it 
to lower quality or strength, was substituted wholly or inpart 
for the article, or if the food was treated in such a way as to 
conceal damage. Additionally, if the food contained poisonous 
ingredients or contained filthy or decomposed animal or vege-
table material, it ~ras adulterated. Misbranding of .food 
included any imitation of the food that ~ms not labeled as 
such; misleading labels or packaging; replacement of contents 
with other than the indicated ingredients; and the failure to 
include certain ingredients on the label (5). 
The authority for enforcement of the Act was delegated 
to the Bureau of Chemistry of .the. Department of Agriculture. 
The formation of regulations was assign.ed to the Secretaries 
of Agriculture, Commerce, and.Treasury. Dr. Wiley headed the 
enforcement of the regulations,· appoint.ing Mr. Walter Campbell 
6 
as his chief inspector, a man who would later be a prominent 
figure in the agency's development (6). The jurisdiction of 
the 1906 Act enabled the Bureau to upgra.de the quality of 
foods and drugs to some extent. Additional pieces of legis-
lation such as the Sherley Amendment of 1912, banning thera-
peutic claims which were false and fraudulent, the Filled 
Milk Act of 1923, and Caustic Poison Act of 1927 increased 
the scope of their regulatory powers (7). 
In 1927, the Bureau of Chemistry was replaced by the 
Food, Drug and Insecticide Administration. Then, in 1931, 
the name was changed to its current one, the Food and Drug 
Administration. Walter Campbell became the first head of 
the agency (8). About that time, the inadequacies in the 
1906 Act were evidenced by the prevalence of unsafe medicines 
sold with false claims. Mr. Campbell began to push for 
stronger legislation. The battle was not eas~ly won. Opposi-
tion arose to the agency's setting tolerance limits for pes"t;i-
c.ide.s on fruits.. Some .members .from Congre.s.s fe.lt the burden 
of proof that large levels were dangerous should be placed 
on the agency (9). However, other influences worked to out-
weigh the opposition. Books such as 100 Million Guinea Pigs, a 
Buyer 1 s Beware, b and The Tragedy of \vaste, c along with Franklin 
a- Kallet, A., and Schlink, F. J., "100 Million Guinea Pigs," 
Vanguard Press, New York, 1933. 
b - Lamb, Beatrice.,· "Buyer's Beware," The National League of 
Women Voters, Washington, D. c., 1935. 
c- Chase, Stuart, "Tragedy of Waste," Finch Press, Ann Arbor, 
f.'Iichigan, 1929. 
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Roosevelt's wish to surpass Theodore Roosevelt's legislation, 
created a favorable atmosphere in the early 1930's to push 
for a new food and drug act. Hov1ever, the sponsorship of 
the bill, coupled with additional opposition to the FDA's 
activities in the regulation of foods, caused it to be delayed 
for several years (10). 
In 1937 1 a tragedy occurred that gave the needed impetus 
to get the new legislation passed. A cbemist, in trying to 
find an adequate solvent for sulfanilamide, used diethylene 
glycol without testing the chemical for human toxicity. As 
a result, there were 107 deaths from the Elixir Sulfanilamide. 
This episode convinced Congress of the need for-stronger legis-
lation and, in 1938, the Federal Food, Drug and Cosmetic Act 
(F.D.&C. Act) was passed{ll). The new 1938 Act was of vital 
significance. As stated by Franklin Depew, it "can be ranked 
as the commercial law of greatest social and economic impor-
tance in the land because it regulated food and drugs- our 
two most vital consumer products (12). 11 The 1938 Food, Drug 
and Cosmetic Act, although it has been amended many times, 
still serves as the basis for the regulatory action of today's 
Food and Drug Administration. 
The Act is composed of a series of compromises that had 
developed in five years of hearings and four major revisions. 
The main provision is to "prohibit the introduction or delivery 
for introduction across state lines of· any food, drug, device, 
or cosmetic which is adulterated or misbranded (13),"·and is 
similar to the main provision of the 1906 Act. The basic 
8 
principles that guided the development of. the new legislation 
were that it must not. we ?-ken existing la11s, but rather 
strengthen and extend the law's .p1:·otection of the consumer, 
ru1d that it must impose no unnecessac·y or unjustified hard··· 
ship on. honest. industrial enterprise (14). · The Act streugt;h-. 
ened the lm11 by (15): 
1. requiring premarket clearance fol' the safety 
of drugs; 
2. covering cosmetics and devices. 
3. requiring the labeling of drugs to have: 
adequate direct:i.ons for use, wru:'nings against 
unsafe use or habit formation; the official 
drugs packaged and labeled according to the 
official compendia. 
lf.. providing for the esta.blishment of food 
stBndar·ds for identity, qual:\.tyr or con-· 
· t,ainer fill. 
5. prohibiting the addition of poisonous .S\ub-
stences to fQod. · 
6. authorizing factory insvections and injnrw-
tions to restrain violations. · 
In 1940, the FDA was transferred out of the Department 
of .Agriculture into the ]'ederal Security Agency which, in 
1953, became the Department of Health, Education, and Welfare 
(HEW). 'l'he agency is, today, a part of EEW (8). As the 
years passed, the legislation tightening controls on the 
food, drug, cosmetic, and device indust'l'ies inereaBed. 
In l9LJ-l, legislation required all insulin products to 
be batch certified, as the dose of the drug is critical. At 
the same time, antibiotics (i.e., the penicillins) had just 
been developed and were coming into more frequent use. 
9 
Variations in potency of these. life-saving natural products · 
became a pro'blem. CongreSl:1 enacted several laws during 
those years to require that each batch qf penicillin, 
streptomycin, chlortetracycline, bacitracin, chloramphenicol, 
and their derivatives be batch tested and certified by the 
agency. Subsequently, the 1962 Drug Amendments added a.ll 
other antibiotics to the list (16). 
Tighter control over potent medications was obtained 
in 1951. The HUmphrey-Durham Amendment divided drugs into 
two categories: Prescription, those drugs restricted to use 
on the physician's recommendation only; and Over-the-Counter 
(OTC), those drugs '<JMch can be purchased without a physi-
cian 1 s r~u.thorizat:i.on. The prescription drugse.were further 
subdivided into three groups: hypnotic or habi.t·-forming; 
were limited to prescription use by the Nev1 Drug Applieation 
(NDA) which contained information on the safety of the drug, . 
and was approved by the agency. T'ne amendment also provided 
for improved labeling of OTC drugs requiring adequate direc-
tions for s€:.fe. use (17). 
Under the 1938 Act, questions on the agency's authority 
to inspect manufacturers arose. A 1952 Supreme Court ruling 
stated that the Act did I).ot clearly permit mandatory facto.ry 
inspections. Congress alleviated the problem by passing .the 
1953 Factory Inspection Amendments allowing the agency, ei'ter 
written notice to the owner, to inspect the place of manu-
facture without warrant or permission (18). 
10 
Two other sets of amendments to the Act, the Food 
Additives Amendments of 1958 and the Color Additives 
Amendments of 1960 gave the agency additional power by 
requiring premarket clearance of chemical additives whose 
safety was not generally recognized and by allowing for the 
conditions for the safe use of a co.lor additive to be estab-
lished by regulation (19). 
In the late 1950's and early 1960's, Congressional 
committees began to study the excess cost of the drug indus-
try. The studies also reviewed inadequate competition, price 
controls, and patent protection, thought to be inherent in 
the business. The Kefauver hearings of 1962 were intended 
to· study just that, the business aspects of the drug indus-
try, until another tragedy occurred that changed their empha-
sis. Thalidomide, an investigational ne\'r drug being tested 
in clinical trials as a sedative for pregnant women, \~as 
found to cause phocomelia, a birth defect in which the limbs 
do not develop in their offspring. The hearings then became 
more concerned with new drug requirements: the animal toxicity 
tests; c.linical trials .and the distribution and use of the 
investigational drugs; removal· of drugs of questionable safety 
from the market; and prescripti.on drug advertising. The 
changes brought about by the Kefauver-Harris Drug Amendments 
of 1962 expanded the agency's regulatory authority, and estab-
lished (20) : 
1. current good manufacturing practices (QG~W's) • 
. 2. yearly manufacturer registration. 
;. drug factory inspections at least once 
every two years. 
4. marketing of new drugs only after approval 
for safety ~nd efficacy.· 
5. control over labeling suc)l that it could 
not be false or misleading in a:n.y \my. 
6. suspension of new drug approval by the 
Secretary of Health, Education a:n.d Welfare 
if. a hazard ~as suspected. 
7. ·. Yiolations for \vhich the a.pproval of a new 
d.ru.g could be withdra\m: 
a. false or misleading labeling. 
b. new eYidence showed satet7 and · 
efficacy not supported. 
11 
c. CGJVJP's not adhered to in production. 
d. inadequate records or reporting to 
the ]'DA. ,. 
8. adverse reactions o:r: other ini'orrnatio11 relat-
ing to the safety and efficacy o:f' the drug 
must be reported promptl;>' to FDA by the 
ruanufacturer. 
9< specified safety conditions to be met bef'ore . 
human trials. 
10~ informed consent of patients required in clini-
cal trials. 
11. all human antibiotics to be batch tested an.d 
certified. 
12. labeling requirements which·listed the qurocitti t:y 
of active ingredien'bn ru1d some, specified 
inactives. 
prescription drug advertising must sb.mv the 
established name along with the trade ne.m~;. 
'rhe efficacy requirement greatly increased the revi.e\v work 
required for the approval of nev1 drugs for marketing. :c;•:w 
manufacturers were required to submit "substanti.al evidence" 
12 
o:f . . the efficacy of the new drug through clinical trials ·on 
the drug. These clinical trials sometimes involve thousands 
of patients; thus creating many case reports for the agency 
to evaluate. The efficacy requirement not only affected 
new drugG, but extended to those drugs thatwe:r:e on the 
marketprior to 1962. Determination.of whether these drugs 
were effective presented. special problems to the agency, both 
·.in the system of evaluation and the manpower required to carry 
out a program. The decisj_on 1t1as made by the agency to contract 
the work; and the National Academy of Sciences (NAS)/the 
National Research Council (NRC) was chosen in 1966 to evalu.s:te 
the 1938~1962 drugs for efficacy. When the reviews were coru-
pl'Gted., the agency developed a prop;.ram to in.i tiatc action on 
tb.e e.:f.':tect:i.ve, probably eff'eoti ve, possibly ·1<ffective, <ll"!d 
:i.ncff'ElC"tivG recomm.endations .made by the· NAS/NRC revic>W cDm-
llli.ttees. The program, entit:led the Drug Effieacy Study 
Implementation (DESI) program, is still in progress. 
~'he agency's jurisdiction in the ea.rly 1960·'s covered 
foods, drugs,· devices, cosmetics, and product safety. In the 
late 1960's and early 1970's shifts in the responsibilities 
. crune abo·ut \d:trh the formation of the separate Product Safety 
Gommif;s:i.on, the passage of the Radiation Control for Health 
a:n.d. Sa.fei;y Act of 19'71 for FDA to protect the con;;umer against 
mmeeessary exposure to radiation, and the 1972 Public Health 
Service .Act. In the latter, the :I!"DA gained control over bio·· 
logical products which were previously held by the National 
Institutes of Health (NIH). Today, the agency's regulations 
13 
cover eli verse areas of. consmner protection to include: the 
use oi' impact--resistant lenses in eyeglasses· and sunglasses,· 
antibiotics in food producing animals, the interstate ship·• 
ment of pet tui·tles to reduce the incidence of salmonellosis, 
and performance standards of laser products. These regula-
tions are in Title 21 (l!'ood and Drugs) of the Code of Federal 
Regulations, with Chapter I being devoted entirely to the 
Food and Drug Administration. 
From its formation as the Bureau of Chemistry in 1906, 
the. FDA has undergone multiple restructu:t:ings due to emphasis 
shifts o:f the changing agency leadership, and to expansion 
of the agency's functions-through legislation. Today, the 
agency is subdivided into eight major m•ea£: .. Bureau of Foods, 
Bureau of Itrugs, Bureau of Veterinary ·Med:Lcine, Bux·Erau of 
Biologics, Bu:r:eau of Radiological Health, Bureau of l'1edica1 
Devices and Diagnostic Products, National Genter for 
Tox:Lcolog:ical Research, and the Executive JJirector for 
Regional Operations (Figure 1). Each of those areas has 
its own defined functions and structure that contribute to 
the implementation of the legislation passed by the Congress 
:i.11 the a:reao of foods, drugs, cosmetics, devices, diae,nostic 
products, biologicals, and radiologieal product;s. 
Bm·eau of Foods 
The Bureau of J!'oods plays a major role in the protect~_on 
·of the consumer \~ith its responsibility for the assurance of' 
safety, quali t;y, and proper labeling of foods., food and color 
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additives, and cosmetics. The Bureau adminis·ters its 
. prograrus and regulations through standards development, 
good manu_facturing practices (GMP's), review of food add.:i-
tive petitions, analysis of' I·Ggulatory samples, and strr~­
veillance through inspections of the industry (21). 
Three major areas are focal points for the Bureau of 
Foods activities: ]'ood Safety, Food Economics, ar1d Cosmetics. 
Food Safety, utilizing about 90% of the Bureau 1 s men power and 
budget, includes a number of programs to assure safety, 
quality, nutritional adequacy, and integrity of the nation's 
food through programs in such areas as: .food sanitation con-
·trol, chemical contaminants, mycotoxins and other natural 
poisons, shellfish safet;')', and the generally recognh;ed az 
sai'e ·(GRAS) food additive list; revim~. Food Economics 
i\mctions to protect ·the consurner from economic I·isk that 
could be incurred ~>Ji th lov: fill containers, . substandax·d ·. 
foods, and packaging and labelin.g violations. Cosmetics 
assures the sai'ety of cosmetic products (22). 
Bureau of Drugs 
A major sector of the FDA, the Bureau of Drugs aims 
to assl.Lt'e that d.:;:·ugs are both safe and effective, and of 
good quality. This is accomplished through the :Peview and 
evaluation of investigational ne'll drugs (IND 1 s), new drug 
applica·t;ions (N.DA's), and labeling, as well as the develop-
ment of good manufacturing practices (Gl'lP's) in indus·i;ry 
with surveillance to check compliance. The Bureau operates 
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a nUJilber of progr~ms to accomplish its mission. The ad.verse 
drug reaction reporting system a.ssetn'bles data concerning 
adveJ.•se reactio.ns that occur with marketed drugs to detect 
side. effects not seen :i.n the clinical trials on the drug. 
The drug product defect reporting system receives reports · 
from practicing pharmacists concerning problems they have 
had with the produc.ts they dispense,· thus aiding the agency 
to identify manufacturing problems. The Bureau also handles 
all of. the antio'biotic .and insulin certification, as \~ell as 
the monitoring of' all·methadone that is dispensed through 
its methadone monitoring program (23). 
As the principle content of this study was accomplished 
·Within thEl B1:.reau of Drugs., a more comprehensive d:l.scuss:i.on 
of the Bureau follows in Chapter III. 
Bureau of Veterinary Medicine 
The tvm major concerns of the Bureau of Veterinary 
Medicine are the. assm'rulce . that veterinary medications a:re 
se.fe and effective for their intended use, and that the 
refd.dues in food-producing animals clo not cause harm to 
humans. \Vorldng closely 1~i th t)le Bureau of l!'oods, Bureau. 
o:f Dru.gs, m.1d the Department of Agt·icul tu.re, Vete:t·imn"Y 
Hedicine coordinates inspection and investiga.tional programs. 
It plans, directs, and evaluates the areas of animal drug 
safety, antibiotics in animal feed, drugs residues, and 
animal feed safety (24). 
Bureau of Biologics 
The regulation of biologicals and blood products to 
provide protection to the consumer was transferred to FDA 
from the National Institutes of Health in 1972, and falls 
Uilder the jurisdiction of the newly created Bureau of 
Biologics. The major source of legislative authorit;y for 
this bureau is Section 351 of the Public Health Service .. 
Act rather than the 1938 Federal Food, Drug, and Cosmetic 
Act. Through registration and inspection of blood banks 
and firms colJ.ecting source plasma (human); testing of 
blood and blood products; review of bacterial, viral, and 
rickettsial vaccines; development of compliance prograrns 
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fol' biologie.s; and revie~rl of lice11.sing and control of c<J.r~ 
rent good ma."lu.facturing practices (CGMP 1 s), the B'tll'eau 8.ims 
to assure that biologics are pure, safe, effe cti v.e 1 a:nd of 
the proper potency (25). 
Bureau of Radiological Health 
Various aspects of radiation are controlled by the 
Bureau of Radiological Health. Controlling unnecessary 
radi.a:t~i.on exposure of man, coupled tvith the srJ.fe and ef:fec-
tive use c,f potentially hazardous ionizing and noionizing 
radiation constitutes a majority of the Bureau's frmctions. 
The major legislative base for this bureau is the Radia·Gion 
Control for Health and Safety Act of 1968. The control of 
radiation exposure by the Bureau involves the following: 
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surveillance and compliance to limits, reeeare;h into health 
effects,. and. development of· perfo:rmance standards of radi.a .. 
tion emissions from electronic prorltlctn (26). 
Bureau of Medical Devices and Diagnostic Products 
~'he Bureau of Medica1 Devices and Diagnostic Products, 
"lhose a(Jtions were previously delegated to the Bureau of 
Drugs, was created in ]'ebruary, 197L~, as the agency 1 s ne>vest 
Bureau d1.1e to the increased workload in this s.rea. The 
safety, efficacy and proper labeling of medical devices and 
in vi.EQ diagnostic products, along with the er;tablishment 
of standards for these procl.ucts is the responsibility of ·!;his 
bureau~ Surveillance of the industry to assu.re compliance 
\'lith the regulations and the collection arFl evaluation of 
datil on hazards of medical devices ancl di.r ... grwstics adds to 
the nev1ly created Bureau's respon.sib:Ui ties (27). I"sgis1a-
tion d.ee.ling '~ith medical devices is found in the adultera-
. tion ancl. misbJ.•anding sections of the Federal Food, Drug, and 
Cosmetic Act; hO\vever, there is no premarke·!;ing cll3arance 
provi~.i.on. .New legislation to provide for prema:eket clearance 
of diagnostic products and medical devices is r.mrrently. "()end-
ing in the Congress. 
:National Center of Toxicological Research 
In Pine Bluff, Arkansas, what once \vas a part o.f the 
Army's biological warfare production complex, is now the 
J!';DA' s National C~nter of Toxicological Research. The 
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laboratories .have been established to determine the health 
effects of chemicals and toxins, in both E!CUte studies and 
long-term low-level exposure (i.e. small quantities of 
chemical toxins in the environment). The P:in.e Bluff facility 
is the largest of the FDA laboratories (28). 
Executive Director for Regional Operations 
The "front-line" FDA employees, the investigators or 
': .. 
consumer safety officers, are scattered throughottt the Ii~tion 
in district offices and resident posts within the ten Department 
of Health, Education, and Welfare regions. They are coordi-
nated through the Executive Director for Regional Operations 
(EDRO). EDRO has authority over all FDA field operations and 
directs the Regional and District Food and Drug Directors. 
In addition, EDRO coordinates the FDA ~lith state and local 
agencies 1 policies and programs in the food. and drug· areas· 
to assure that the pure food and drug effort is not being 
duplicated or ignored in any way. EDRO provides each of the 
FDA Bureaus with field support for the Bureaus' compliance 
programs (29). 
As part of the study of FDA, a 111eek was spent in this 
area to determine EDRO's relation to the programs of the 
Bureau of Drugs. A more detailed discussion of EDRO is con-
tained in Chapter III. 
Development of' Pharmaceutical Education 
Around the turn of the t~entieth century, when the 
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problems with .the nation'~~ food and drugs. reached such 
proportions as to generate the 1906 Pure Ji'ood and Drug Act, 
pharmacy education commenced some of' its most rapid and 
significant changes. From its begirmtng e.i; the Ph:i.ladelphia 
College of Pharmacy in 1821, formal fJd.uc:ation in pharmacy 
served merely as an optional; and not too frequently 
utilized, supplement to the informal and unorga."lized 
apprenticeship systenJ of learning the trade. However, in 
1900, although apprenticeship i·las· still the most coril.1non 
method used to train the pharmacist, advances were made in 
pharmacy education which included: ai:t elementary school 
education requirement for entrance into pharmacy school, a 
t1~o yeru:· course of study (although some forty".week program3 
were iJt:i.ll offered), e.nd a new four year cou:rse offered by 
· tl1e Un:i.vsrsi ty of l'iichigan (30). A grm•ling <Jmph(ls:i.s o:n the 
value of the basic science.s in pharmacy, in the late 1800's,· 
established the trend towards increased college traini:ngas 
opposed to appren·t:iceship (31). 
The fifty-three colleges or depa:r.'tments of pharmacy 
. that 1:1ere in existence in 1900 were of highly va:dable 
quality. This problem disturbed many pha"Cma.cy educators 
enci prompted the formation of a group, the American Confer0mee 
of Phe_rmaceu.ticc.l ]'a01.1l ties (ACP:I'!') • which has effected gre<J.t 
changes in pharmacy education. In 1925, the name of thiEl 
organization was chru1ged to the presen'l; American Association 
of Colleges of Pharmacy (AACP). Through the establishment 
of minimum national standards for admission to the schools, 
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length of s-tudy, and .type of degree conferred, the AACP was 
effective in elevating the quality of pharmacy education (32). 
The standards for entrance into pharmacy· school and the 
length of study set by the AACP increased rapidJ.y from 1900 
to 1925. Fromvirtl.ially no admission prerequisites in 1900, 
i;he organization was successful in the.establishment of a 
minimum of a grammar school education in 1904, one year of 
high school in 1908, two years in 1918, end finally in 1923, 
only high school graduates could be admitted to the colleges 
of pharmacy.· Due·to the desire to incorporate ever-increasing 
amounts of material into the curriculum, the required length 
of study increased from forty weeks in 1904 to· tv1o years i:r1 
1907, three years in 1925, i'ow: yea:Nl in 1932'; and to five 
years in 1960 (32). Currently, some schools off'er a six yea~' 
program. 
In 1906, representatives from the AACP, Nat·ionnl 
Association of Boards of Pharmacy (N.A:i3P), and the American 
Pha't'macent:i.cal Association (A.PhA), joined to form the 
Pharmaceutical Syllabus Corumi ttee to provide some standardi·· 
zation t:o the curricula in pharmacy schools. The group pub-
lished !flf2l~€.C1:.m.g,£s:u~J-El S;z:J),~, which contained rec~lnunen,­
dations ±'or subjects to be includeQ. \'li thin the pharmacy cur-
ricuhllll, from 1910 ur1til 19'-~6, t~hen the task ~Ja.s taken over 
by the Committee on Curriculum o:f AACP. The recommendations 
in the §;ylla1?.l:!.§. during that time period for subjects to be 
contained in the pharmacy curriculum were: 
theoretic and applied pharmacy, biological 
sciences (including bacteriology, botany, 
pharmacognosy, pharmac.olo[;y, pb;ysiology, 
zoology, public health, and first aid), basic 
and applied chemistr;r,. physics, commercial 
subjects, English, :modern :for.eign languages, 
mathematics, and ot:her eultural subjects, 
particularly th<:; hhd;o:qr of civilization and 
history of pharmacy (33). 
Through the encouragement of the same· organizat5.or,, 
i.e. AACP, NABP, and .APhA, the states began to require 
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pharmacy education as a prerequisite to licensure. In 1904, 
the state of New Yoi•k became the first to pass a law that 
all applicants for regist;ration as licensed pharmacists 
should be graduated in pharmacy. Pennsylvania followed this 
precedent in 1906. By January 1, 1921, seventeen states had 
passed such legislation, providing the pharmacy schools vlith 
a solid fo•-lndation for existence (34-). 
In the eady 1900 1 .s, the compoundj.ng a,rld dispensing of 
pharmaceuticals \1as, .fox·. the most part, the basis for the 
pharmacist' .s education. About that time, when the trend 
developed towards incorporating the private schools of phar-
macy into colleges and. universities, pharmacy \~as frequently 
associated with the chemistry departments (Arts and Sciences), 
rather than the .medical departments. T.hus the pharmacist 
received no clinical practice.· The manipulative skills of 
the pharmacist, his expertise in the preparation aJ1d dis-
pensing of pharmaceuticals, were considered hls prima:r•y role 
as a professional (35). 
The change in the direction of pharmacy from the rnsld.ng 
of drug products to therapeutic ·counseling of patients about 
their drug therapy began. in the early 191!.0' s, as the 
manipulative skills of the pharll!aci.st were .used less 
frequently due to the growing number of nm~, pre made 
pharmaceuticals (36). However, the:ce •vas the feeling 
in some schools that the four year program was too short 
for students to learn the aspects of therapel.J_tic counsel-
ing and, at the same time, to have a sound scientifi·c 
knowledge of drugs. Therefore, the cotmseling was deem-
. phasized. This \1as .partially becam;e it was considered 
unethical as it was thought to·be solely the physician's 
duty. · 'l'he physical-chemical aspect of assuring a quality 
drug product was held to be the main consideration (35). 
Just si·tei· World \Var II, the objectives of pharmacy 
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were studied by a corumi ttee composed cf specialists in ea.ch 
of the various aspects of pharmacy. Their report, published 
i.n 19'J-8, ~~'1LRe~:L.Q! the PharmacELgtical fur£ve;y.,, 
contained fundamental statements about pharmacy practice, 
objectives of pharmacy education, and specific recommenda-
tions for the pharmacy curriculum. The objeetives that were 
established by the Survey were (37): 
1. Selecting, .screening, a..r1d g'eaduating those 
students possessing t:b.e technical abilities, 
persona~ character, and social outlook 
required .for the practit::e of the profession 
of pharmacy. 
2. Preparing student:s to procure, develop, pre-
pare, preserve, standardize, test, and dis-
pense substances and articles used in the 
diagnosis, treatment, and prevention of 
disease. 
4. Grounding students in the principles and. 
·practices of organizing end administering 
a pharmacy.; 
5. Making students fully conscious of the . 
ethical standards to be met by the pharmacist. 
6. Qualifying students to cooperate with members 
of the othe:r• health professions a.n.d to consult 
with them; to furnish accurate, objective, and 
scientii'ic information to physicians and mem-
bers of other health professions concerning 
drugs and the_ir action. 
'1· Preparing students to provide professional 
services to the public appropriate to the 
basic functions of ph<u•macy in its role as 
a health profession. 
8. Equ::i.ppin;:; and stimulating students to con-
t·ribute to -the profession by .}!B.:Ctic:1-pating 
in its various organizatione.l, literary, 
teaching, resoarch, and other activities. 
9,. Providing students >1ith an adequai;e founda-
tion for graduat~J WJrk in the various subjects 
of the curriculum. 
10. Preparing students to· assume the resporwi"oili-
ties of citizenship befitting profess:i.onals. 
:n. Enriching the life of the students through 
greater understanding and. appl'eciation of the 
culture; values, and problems of our civili-
zation. 
'l!o achieve these objectives, ge11eral and spec:ific curriculum 
reqnh:ements 11ere outlined. A strong foundation in the basic 
sciences of chemistry, physics, and biology was recommended. 
~'he technical skills of the pharmacist were to be included 
with emphasis on the qualitative accuracy and consultation 
aspects :rather than manipulative skills, and the economics 
of the operation of a phax·macy was to be explained. '!!he 
importance of the :phc;:rma.cist as a consultant to other 
-health professions.ls and _the psychological and sociologi-
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cal understanding of the patient v;as to. be stres8ed. Addi-
tionally, a broad, general education to provide an assortment 
of general ideas and aesthetic appreciation completed the 
education of the well-rounded pharmacist (38). Tho specifics 
of' the curricula \vere recommended in the 191~8 Survey as 
follows (39): 
l. Pharmacy (22 hours): orientation cour·se 
and courses in calculations, general 
pharmacy, . dispensing pharmacy, and manu-
facturing pharmacy. 
2. Physical sciences and math (57 hours): 
general chemiabry, inorganic pha:emaceutical 
chemistry, organic chemj_st:ry, :i.ni::rodx.ct:.:i.on 
to colloids, qumrt:Ltati ve ana1ys:Lc, 'oio·-" 
chemistry, chemistry and pharmacy in mea.:\-· 
,cinals, mathematics (algebra <m.d td.gnometry), 
and physics. 
3. Pharmacology _and related (2lJ· Jwurs); general 
biology, vertebrate anatomy, histology, physi.:.. 
ology, pha:emacology. 
4. Hicrobiology and public health (9 hours). 
5. Pharmacognosy (8 hours). 
6. Pharmacy administration (15 hours): 
pha:emacy accounting, drug marketing, 
mmlag,ement, ru1d phs.rm.acy law. 
economics, 
pha.rmacy 
Following the 1948 Pharmaceutical Survey, pharmacy 
education \-las headed in the direction of today with emph<,sis 
in education on the therapeutic care of the patient and m0.di-
cation counseling by the pharmacist. With the new social 
health legislation and increased concern for the quality of 
. 
health care, coupled with the laxge number of new drugs 
developed, it 'lias felt that the pharmacist should be 
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relied upon for his knowledge of the action of drugs, in 
addition to his dispensing sltills. Pharmacy education was 
then adjusted to .fit this new role. According to Swintosky 
(35) in the early 1970's, Brodie stunmarized that the phar-
macist should be trained to be: 
1. A manager of all drug-related resoux·ces •• 
2. A professional responsible for drug 
counseling and adv-ising persons 11i thin 
the community, 
:?. A drug consultant; this means tha\~ the 
pharmacist needs to be kno\vledgeable of 
di.seaso procesBes and the appro:priate 
treatment, e.d.minif;i;ra:tion, b:i.oayailabili ty, 
interactions, s:1.de effects &nd p:r·oper dose 
adjustment oi' dr-ugs. 
4. (,'hi·ef responsibility for maint:emmc.;, care 
·o:r chronically ill patients i'.fhose medical 
condition if.> stabilized but whcs!3 welfare 
is dependent upon conti:::med proper use eli' 
medication. 
5. Primary health care: intermediary between 
the patient BJJ.d ph,ysieian vn outpatiEm·t; 
situations. 
In the past decade, this new concept of the role of the 
pharmacist has been dubbed as clinical pharmacy. 
The incro.asing number of n<:M ·drugs on the market, . the 
incidence of hos:pi tal admission:3 duo to ·adverse drug reac--
tions, and the decreased amount of pharmacology taught in 
medical schools will necessi tc,te the pharmacist's becoming 
increasingly involved in the patient's therapy as the drug 
expert on the health care team (40). There have been numerous 
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definitions of clinical pha:rm.<Jcy. The Advisory Commission 
on Pharmacy to the Cal.:i.i'ornia State Legislature chose the 
following for its report;: 
A pharmacis1; who has received advanced training 
in the application of' drug therapy in a clinical 
environment (hospital wards, outpatient or com-
munity clinics, etc.) or who, by actual practice 
in a clinical environment, has mastered the con-
cepts of drug therapy and who applies them (or 
advises in their application) to the drug .therapy 
of·patients (41). · · 
The Committee on Cut'riculuro of the AACJP chose its official 
definition to be: 
Clinical pharmacy is that area within the phar-
macy curric:ulum which. cleaTs with emphasis on 
drug therapy. Clinical Pharmacy seeks to 
develop a patient-oriented attitude. The acqui-
sition of new knm•rledge is secondary to the 
attainment; of skills in :i.nterprcfessional a:nd 
pC\t:i.(mi; co!llllluni cations ( lJ-2) • 
:f.lhe goal of training pharmacists in a clin:Lcal setting 1dtb. 
emphasis on patient C!il'e Err1d drug therapy is where pb.armacy 
education stand.B today. In order to achieve this goal, i.:he 
AllCP Corm:r,:i.ttee on CurriculuJ11 ch!ll'8.(~ter:i.zed the educational 
objectives. Tl1ese objectives are ('J.2): 
1. To acquaint the student \d·l;h cJ.in:i.ca.l appli-
cations of pharmacologic and pharmaceutical 
principles; 
2.. ~'o help· make the stt1dent more avmre of the 
general methods of dias~:1osis Emd pat:i.E';nt Cc{I'<l 
sped.fically as they x·eJ.ate to drug therapy; 
3. To develop in the student; a facility for 
eff'ecti ve interaction with the patient <cnd 
w:i. th practitioners of' other health professions; 
4. To help the student; develop a patient awa:ceness 
in providing pharmaceutical services; 
5. '.l!o enable the stud.ent tc jntegrate the 
knowledge acquired. in preclinical yea.rs 
and·to apply it to the solution of real 
problems; end 
6. To develop in the stu.dent an a1rmreness of 
his responsibility in monitoring drug 
utilization. 
It is remarkable that, even at this point in time, 
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no mention of FDA drug regulation responsibilities is made. 
~g_rfacing of Pharmaceutical Education and the Food and 
P-~1g Admin~ptration 
Throughout the development of pharmacy education, there 
\'las little mention of inclusion within the curricula of some 
information on FDA drug regulatory procedures.; The system 
developed from teaching the basic sciences wi'ch emphasis on 
the physice.l-chemical characteristics of drugs, to the 
therapeutic nature and consulta.tion about drttgs. IJi ttle 
attention \vas given to the governmental agency \'Those respon-
sibility it is to regulate the drugs pharmacists dispense. 
The common goal of both the FDA and pharmacy of achieving 
safe and effective drug therapy has, \vi.th the increased 
ree;ulatory po\vers of the agency, created sit-uations where 
the FDA is having significe..nt effect on the practicing phar-
macist. Some of the regulations v1ritten by the agency that 
direci;ly affect the pra.ct:i.tioner include those requiring 
that nitroglycerine be dispensed in its original container, 
and. methadone may be dispensed only in specially licensed 
facilities. Additionally, the agency controls the labeling 
of drugs which has a direct effect upon the pharmacist in 
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both dispensing and therapeutic counseling functions. As 
the i.nteractions increase, there exists a need. for the. FDA 
.and pharmacy educ.ation to open lines of communication to 
avoid situations of misinterpretating one another's actions. 
The understanding of the mutual goal will aid in assuring 
that drugs are safe, effective, and used properly. 
The agency, in the past few years, has.become aware 
of the pharmacist and his value to its mission;. Several 
programs have been conducted by the FDA that have been both 
educational to the pharmacist .and benefiCial to the agency. 
Two such programs are the Commissioned Officer Student 
Training and ~~ternship Program (COSTEP} offered through 
the Commissioned Corps of the Public. Health Se;r.'vice, end. 
the Drug Product Defect Reporting System offered in con-
junction vri.th.the U.S.P. 
The COBTEP's were utilized i'irstin 1966. As the agency 
was in need. of additional professionals to execute the efficacy 
requirements or the 1962 Drug Amendments, Dr. Goddard, the 
Commissioner of FDA at the time, arranged to have approxi-
mately 20 COSTEP':s work for 2 years in the Bureau of Drugs. 
Many o! these CO:STEP' s were graduate pharmacists, and assisted. 
· the agency in its review oi' nevl d:rugs :for e!!icacy, and the 
iru:plementat.i.on oi" the NAS/NRC review panel recommendations. 
After this, C'.OSTEP within FDA remained dormant. Early in 
1974, the Bureau of Drugs of the FDA became interested in 
participating in the COSTEP again. Although most assignments 
within COSi'EP are to government hospitals or clinics oi' the 
Public Health Service, 17 students from 13 colleges of 
pharmacy were selected to work.in various areas within 
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.the Bureau of Drugs. Their assignments included: Drug 
Listing, Drug Product Surveillance, Drug Information 
Services, Over-the-counter Drug ReviEn~, Ne~; Drug Evaluation, 
and Biopharraaceutics~ Assignment to the program was for a 
period of time not to exceed 120 days. ~he students took 
part in a variety-of FDA activities that not only aided 
their understanding the f1.mctions of the agency, but did an 
excellent· job in providi.ng the FDA with the additional man-
po\~er needed for some of its projects. 
The types of activities in which the COSTEP'S'tookpart 
included review of investigational new drug applications to 
determine i:f the information includedmet the requirements 
prior to assignment· to a revie\qer. 'I'hey ansv1erecl consumer 
inquiries abm<t drugs and researched records to prepare_ 
memoranda :for Senate drug investigations. Further, they 
1r1ere involved in evaluation and coding of· information for 
the computer follo"1-up sys.tem of the d:r11g product defect 
reports. In addition they were given responsibility for· 
catego:rizing the ing-redients in the over-the-counter drugs, 
so as to identify what ingredients were being studied by the· 
_. variou.s panels, and for obtaining reference material from 
the library for use by the over-the-counter drug review 
panels. ~lost significantly, in response to Congressional 
inquiries, the COS'l'EP's researched and collected data on the 
so-called "drug lag" problem to determine if the FDA was 
·indeed hindering the introde1ction of useful, possibly 
life-saving drugs to the American marketplace through 
·its lengthy new drug approval procedures. 
ll. second program, bringing pharmacists in closer com-
munication \'lith the FDA, is the Drug Product Defect Reporting 
System. Through a contract VIi th the u.s.P.' the FDA has 
initiated a system whereby pharmacists can report any defects 
o~ problems they have found \vith products on the market. The 
Drug Product Defect Reporting System, initiated in 1972 by a 
pharmacist \forking in the FJJll., has served as an invaluable 
source of information for the agency in the detection of· 
problems occurring with marketed drugs. This interaction 
oi' the pharmacist, the dru:g dispenser, '-'lith the FDA, the 
drug regulator, has done a great deal to strengthen the ties 
between the tt•o and the reccgni tion that they are inter-
dependent.· 
· It appears evident, hO\~ever, that colleges of pharmacy 
must estp.blish some major: course of study in the area of 
governmental drug regulatory procedures if they !ll'e to sup-
port the needs of the health professions and, ultimately, a: 
ful~er responsibility :for the health care-of the nation. ·rt 
· :i.s sad to note that, from the inception of the l<,DA, pha:rma-
·Ceutical education has given only token attention to this 
agency \vhich is .responsible for the approval and regulation 
of' those substances, the principal raison ~~ for the 
prof'ession. This allegation can be supported by a perusal 
of the catalogues from the schools of pharmacy. At best, 
there are only a few whi::h lh:t minOJ' survey courses in the 
.7. ") 
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cl.esign and functions of the ]'J)A but these are usually incor-
porated into the pharmacy la.vl courses. Also, one might 
suspect that tho lack of advancement; possibilities for the 
pharmacist classificatj_on within the agency, so as to force 
pharmacists to seek other titles such as Consumer Safety 
Officer, reflects the absence of any :real pha"C'maceutical 
cla:i.m for responsibility within FDA. Therefore, if the 
pharmacy profession is to contribute to the contl~ol and 
rational use of its basic materials, drugs, it must begin 
to assume responsibility for educatinf; its practitioners 
appropriately to maximize the benefits of mutual support 
of the professions and the Food and Dl'ug Administration. 
'l'he J!'DA has alr,~ady acknowledged the value of ed.uca:t:ional 
programs in ·t;ho agency for students of the b.ealth professions 
through the graduate studies and the Commissioned. Officer 
Student 'l'raining and E'A:ternship Program (COSTEP). 
It is, therefore, the objective of this study to expand 
cooperative ecluca·l;ional programs for pharmacy students thx·ough 
the development of a course of stu.dy in FDA dxug regulatory 
procedures for schools of pha:r•macy,. JVJore specifically 9 :i.t is 
the intent of this project to design e. formal course or 
courses which may be offered for on-campus study and, because 
it is preclic-tecl to be a necessity for comprehensive un.derBi;and·· 
ing of FDA drug regulatory procedures and their application and 
:i.mpl:Lcat:ions, to make recommendations for a peri.od of :::·eside!J.cy 
within the l'DA. 
CHAPTER II 
EXPERIMENTAL METHOD 
Early in the fall of 1972, representatives of the 
University of the Pacific School of Pharmacy met with 
representatives of the Food ru1d Drug Administration, 
expressly the Bureau of Drugs, to discuss the feasibility 
of establishing a cooperative experimental program designed 
to provide training for graduate pharmacists in governmental 
drug regulatory procedures. The proposed program was to .. 
utilize the '\•;ork,;,study technique and to be j,ri partial ful:-
f:i.llment of the require!Jlents for .i;he Master of Science degree 
in Pharmaceutical Scien.ces. 
Based on the interest e:x"Jlressed by the agency, a sylla-
bus (Appendix A) was prepared. The syllabus contained the 
School 1 s projected representation of a basic framevrork which 
would provide a broad experience within the agency and allow 
the student to learn its functions. The goals; as set forth 




to provide background research material 
as part of a graduate degree program. 
to develop an efficient and meaningful 
program which may be utilized on a con-
tinuing basis for senior or graduate 
pharmacy students. 
3. to create a resource pool of professionals 




To accomplish these goals, the st)ldent would rotate 
through the several Offices of the Bureau of Drugs to gain 
a first-hand working imowledge of the structure . and f.unc-
tions of each. aud ho1r1 these interrelate to accomplish the 
Bureau's mission. Although the duration of each rotation 
. - . . 
\'/aS established rather arbitrarily, they 'tlere thought to 
be reasonable estimates. Modification of the syllabus would 
1;ake place, with regard to time frames, assignments, metho-' 
dology, and even·objectivesas the student began to gain 
experience• Continuous input from the student, preceptors 
\'lithin the agency, and supervising faculty were·encouraged 
to provide for revisions of the original document that would 
. .~ . 
put it into a final form >vhich would be suitable for subse..o. 
quent students. 
The syllabus described the duration of the residency 
within the agency as being from 4-6 months. It was divided 
into six units which included rotations to various areas 
\'li thin the Bureau of Drugs. Each of the unit descriptions 
was composed of objective, methodology, a..Tld assignment sec-
tions to give the student and the supervisor some guidelines 
on the purpose of the progr~~. The schedule of rotations 
included: 
I. FDA: Organization and F1mctions (1 week) 
II. Bureau of Drugs: Organization (l week) 
and Functions 
III. O:rfice of Compliance (1 ~;eek) 
IV. Office of Pharmaceutical Research (TBA) 
and Testing 
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v. Office of Scientific Coordination (1-2 
~reeks) 
VI. Office of Scientific Evaluation (4 months.) 
The syllabus was viewed as a flexible document and 
it served its purpose well for this program in that it 
was used as an introductory piece of information for those 
·in FDAwho became involved in the program's implementation: 
Although most of the methodology and the series of rota-
tions were adjusted to accommodate some practical concerns 
of the student and her supervisor (e.g. extra time in the 
division for adjustment to the agency's routine and allow-
ance for contribution to the workload, and changing the 
areas of rotation to parallel the Rureau's reorganization 
in September 1974), the objectives delineated~in the intro-
duction a11d under each of the unit headings were achieved. 
The student assigned to this project was expected 
to submit periodic reports to the faculty advisor and 
agency preceptors. These were to describe in some detail 
the functions of the division& and the experiences gained . 
within each; to recommend improved syllabus content; and 
to serve as a record f.rom which this thesis \vould be 
prepared. 
It \>/as in August 1974, that arrangements were finalized 
· for the author to be appointed to the FDA as a temporary 
employee for a period not to exceed one year· (Appendix B). 
Specific assignment vlas within the Bureau of Drugs, Office 
of. Scientific Evaluation,'" the area. of the agency 
corresponding to the student's main interests. Assigned. 
as the Assistant to the Assistfmt Director for Ohemical 
Review, Dr. Charles KumkUJJiian, the student was charged 
with the responsibility of "providing him with scientific 
and technical•expert:i:£e in the pharmacy area necessary to 
accomplish the program's mission" (Appendix C). The student 
\vas directed by Dr. Kurnkumian to a specific area i1ithin the 
Office, the Divisionof Surgical-·Dental Drug Products. 
Under the guidance of Dr.· Robert Jerussi, . supervisory 
chemist in the Division, the student was provided with a· 
working knowledge of the organization, functions, and regu-
lations of the agency through participation in the Division's 
responsibility for reviewing data submitted on ne-...; •::l.rugs to 
substantiate their safety and efficacy· and. special asGign-
ments pertaining. to the drugs handled by tile division. In 
addition, Dr. Jerussi arranged the rotations to other areas 
within the Bureau of Drugs and the Executive Director of 
Regional Operations. Memos with a syllabus attached were 
sent to the various directors of. other areas ~1i thin the 
agency. The memos contained a brief summary of the purpose· 
of the program, the need for rotations to their area, and a 
--·--
*The organizational title in effect at the initiation of this 
program is used here. After the reorganization in the fall of 
1974, the Office of Scientific Evaluation became the Associate 
Director for New Drug Evaluation and the Office of Scientific 
Coordination became the Associate Director for Biometrics ~md· 
Epidemiology. The other areas.headed by Associate Directors 
include Compliance, Information Systems, Drug Monographs, fu~d 
Pharmaceutical Research and Testing (Figure 2). · 
request that the student be allowed to work in their at'ea 
for a limited amount of time. These were sufficient to 
introduce the student to the other area directors, ru1d a 
rotation schedule was established. 
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September 30-0ctober 4, 1974 Office of Scientific 
Coordination* 
October 29-November 4 
November 18-22 
February 3-7, 10-14, 1975 
March 10-14 
May 21, 22, and 26 










'!'he com:prehensi ve understanding of each rotational area's 
drug regulatory functions \<Ias acquired ,through a series of 
discussions Hith the officials in eao.h of the divisions. 
In the morning of the first day of the rotation, the director 
of the area questioned the student to identif'y what aspects 
of the area's f'unctions would be of' most interest. The 
plromed rotational experiences then were directed towards 
providing information within the scope of this expressed 
interest. 
-------~--------
*See f'ootnote, p. 36. 
CHAPTER III 
RESULTS: REVIEW OF RESIDENCY 
Followin~ the approach outlined; the \vork-study residency 
. experience, ;from vlhich recommendations for curriculum were to 
be designed, was comprised of several rotations through 
various units of the agency. Although principal assignment 
and service responsibilities were in the area of New Drug 
Evaluation, the inclusion of short term experience in several 
other areas permitted.gaining a comprehensive understanding 
of the l'esponsibilities and functions· of the 1lureau as a 
whole.· An in-depth ~Jerking 1Gl.owledge of New Drug Evaluation, 
t.he author's chief interest:, was provj_ded by. responsibi1i ties 
assigned in. that unit and complr,ted under the guidance of that 
staff • 
. The. presentation which follov!S describes in some detail 
the functions of the several units included, the regulations 
under which they operate, and ho~1 they articulate in a total 
mission. These descriptions a;t'e inte11ded to serve as part of ·I 
the textual me.terial for the curriculum recommended in 
Chapter·IV of this report. The sequence of presentation 
here is not int:ended to suggest a chronologie approach to 
the topic, but starts, logically, with a brief description 
of the Bureau of Drugs as a whole, followed by a lengthy 
exploration of New Drug Evaluation. Those units iri which 
38 
39 
shorter rotations were completed follow in random order. 
Bureau of DrU5£ 
The Bureau of Drugs is responsible for the enforcement 
of those sections of the Federal Food, Drug, and Cosmetic 
Act which pertain to old, new, and investigational drugs; 
antibiotics, insulin and ho.rmones; prescription, non-
prescr·iption, and habit-forming drugs; as well a.s those 
which may be misbranded or adulterated. The definitions 
of these are.contained in Chapters II and V of the Act. 
Overall, the Bureau's. functions within the FDA include 
the development of policy with regard to the safety, effec-
tiveness, labeling and quality of all drugs for human use. 
:I:t is responsi.ble for reviewing and evaluating ne'IJ drug 
. 
applications U!'"ld claimed exemptions for imrestigational new 
drugs, as well as operating. drug experience and poison con;.. 
trol monitoring and reporting systems. In addition, it plans, 
coordinates, al'ld evaluates FDA surveillance and compliance 
programs relating to drugs. The provision of scientific and 
technical support for regulatory work in drug biology and 
drug chemistry are also within its functions, as is develop-
ment of regulations covering drug-industry .practices·(current 
good manufacturing practices). Finally, the Bureau ha.s 
responsibility for coordinating, directing, and reviewing 
the FDA antibiotic and insulin certification program (L~3). 
To accomplish these functions effectively, the Bureau 
is organized into a number of Divisions, as indicated in 
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Figure 2. ~Che grouping of the Divisions is by functional 
relationship. Each of the Divisions in an area has a leader 
reporting to an Associate Director in the Office of the 
Bure.au Director. In addition to the delegation of respon-
sibilities of the Bureau according to the divisions, the 
agency utilizes the Program l'ianagement System (PM.S). ·The 
system was introduced around 1969-1970 to provide for an 
interface between the agency's responsibilities and the 
agency's budget. It describes the objectives of.the agency 
in terms of projects to be accomplished for the year rather 
than through func.tional descriptions of organizational units •. 
This allows. for more effective planning from budget category 
to program to project to compliance progrrun, and provides an 
interface between the Bureau and the E'xecutive Director for 
Regional Operations (tho field force). The Bureau's programs 
include: Drug Quality Assurance, Over-the-Counter Dn1g 
Evaluation, Drug Application .Evaluation, Clinical Investigation 
Evaluation,Biopharmaceutics, Drug Efficacy Study Implementation, 
Drug Experience and Trends Analysis, Mathadone Honi to ring, Drug 
Listing, Poison Control, and Prescription Drug Advertising. 
Ne,..; Drug l!.'valuation 
Introduct:i.on - r---
The Associate Director for New Drug Evaluation has the 
responsibility of enforcing those sections of the Federal 
Food,. Drug and Cosmetic Act pertaining to new drugs. The 
Act defines a "ne~l drug" in Section 201 (p) to be: (44.) 
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1. any drug the composition of which i.s such 
tb.at such drug i.s not generally recognized, 
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among experts qualified by scientific·train-
ing and experience to evaluate the safety 
and effectiveness o.f drugs, as safe and 
effective for use under the conditions pre-
scribed, recommended, or suggested in the 
labeling thereof, except that such a drug 
not so recognized shall not be deemed to be 
a "new drug" if a·!; any time prior to the 
enactment of this Act it ~las subject to the 
Food and Drugs Act of ,Tune 30, 1906, as 
amended, <md if at such time its labeling; 
contained the same representations concern~ 
ing the conditions of its use; or 
2. any drug the composition of which is fmch 
that such drug, as a result of investiga-
tions to determine its satety and effective-
ness for use under such conditions, has 
become so recognized, but ~lhich has not, 
otherwise that in such investiga.tions, been.·. 
used to a material extent or for a matei';Lal 
time under such conditions. 
Several points in this definition have required clari-· 
fication through court decisions. !'lost specifically, the 
decisions have dealt wi-t;h the. app1ication of the "grandfather 
clause", which pertains to those drugs subject to the Food, 
and Drugs Act of 1906. In a 1972 case, United States vs. 
An article of drug, "Bentex Ulcerine", the claimant contended 
that because the drug had previous1y been marketed, from 
1958-1963, it fell under the provisions of the· grandfather 
clause Hnd therefore 111as uot co:lsidered to be a "ne\'i drug". 
FDA, however, made the decision that Ulcerine did not meet: 
the requirement of being "generally recognized as safe and 
effective" and was to be considered a new drug. This decision 
was supported in the court decision (45). The generally 
recognized as safe and effective statement leaves the new 
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drug definition open to the FDA's own interpretation. Based 
upon this court decision and others, the FDA has been given 
·broad authority over what constitutes a new drug. Thus 
through FDA's interpretation, the definition can include an 
added indication in the labeling, change in dosage, or a 
new combination of old drugs. The decision is primarily 
admin:i.strati ve. 
When a drug is considered to be a "new" drug, the 
Associate Director for New Drug Evaluation has the respon-
sibility over itslicensing as dei'ined in Section 5.05(a) of' 
the Federal Food, Drug and Cosmetic Act. This section 
states that no person shall enter a new drug into interstate 
commerce unless an approved application is in"· effect for th0 
drug. For a new drug application to be approved, according 
to Section 505 (b), it is required to conte.in: (46) 
L clinical data showing the ne~l drug is safe 
and effective. 
2. components of the drug. 
:;. composition of the drug. 
4. methods, facilities, and controls for manu-
facturing, processing and packing oi' the drug. 
5· samples of the drug. 
6. labeling for the drug. 
This requirement for the filing of a nm; drug application 
for approval '>las initially introduced in the 1938 Act. At 
this time, the application dealt primarily with the safety 
testing towhich the drug had been subjected. The 1962 Drug 
Amendments greatly increased the requirements for the approval 
of the application by the addition tb.at the ne•v -drug must 
be proven to be efficacious. The efficacy requirement 
·substantially increased the workload of the agency. 
To define the. new drug application requirements better, 
regulations which at•e included in Title 21 Code of Federal 
Regulations (21 CFR) have been promulgated. Two sections, 
21 CFR 312 and 21 CFR 314 are the most direct interpreta-
tions of the Section 505(b) statements. These sections 
describe the two principle application forms listing the 
requirements to be completed for the approval of a new drug: 
Form 1571 Notice of Claimed Exemption for an Investigational 
Ne\v Drug (INTI) and Form 356H New Drug Application (NDA) 
.(Appendixes D and E). 
The ·responsibility for the evaluatior, and approval of 
the Itm 1 s ·and -~mA 's submitted to the agency resides in the 
six drug rev'iev: divisions 1r1hich report to the Associate 
Director for New Drug Evaluation. The revie\-1 divisiol1s have 
responsibility over the c.ategories of drugs as follows: 
I. Division of Cardio-Renal Drug Products: 
cardiac, antihypertensive and gastro-
intestinal drugs. 
II. Division of Neuropharmacologic Drug Products: 
ne11rology-ana,lgesic ·and psychopharmacologic 
drugs, and the drug abuse staff. 
III. Division· of JVJetabolic and Endocrine Drug 
Products: fertility, anti··fertili ty, 
metabolic, and endocrine drugs. 
IV. Division of Al1tiinfecti ve Drug Products.: 
antiinfective systemic and vagina,l, derma-
tologic, opthalmologic, and otologic drugs. 
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V. Division of Oncology and Radiopharmaceutical 
Drug Products: oncologic, radiopharmaceuti-
cal, and antiinflammatory drugs • 
. VI. Division of Surgical-Dental Drug Products: 
respiratory, surgical and dental drugs. 
Although the primary function of these divisions is 
the revie~r of IND 1 s and NDA 1 s, there are additional respon-
sibilities which each accepts for its particular drug 
·products. ·These include the assurance that the drugs with 
approved NDA 1 s have the proper labeling. The continued 
surveillance of annual reports to pick up trends in adverse 
drug effects which could lead to changes in the labeling or 
possible withdrawal of the approval of the NDA is an impor-
tant function of the divisions over marketed drugs. Further, 
divisions supply all information to other areas of ·the agency 
for each of their respective drug classes to inclt1de the 
statns of NDJ,' s, policy, regulatory actions, freedom of· 
in:formation req·C~ests, and prOduct development (43). 
A seventh division in New Drug Evaluation is Drug 
Advertising. This division does review work, but not that 
of IND's or NDA 1s. Instead, it evaluates pr~scription drug 
promotional material, advertisements, and other labeling. 
The Division establishes policy and regulations· on prescrip-
tion drug advertising for the agency, and recommends action 
. 
to be taken when viGlations have been fom1d (43). 
The Process of New Drug Evaluation 
The FDA is intimately involved in the process of new 
drug development. Through the provisions of the Act, it has 
the power to license nev1 drugs by approving new drug 
applications thus influencing what drugs will be marketed. 
This important function of the agency greatly affects the· 
pharmaceutical industry. 
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Typically, new drugs are generated in one of two ways. 
A need for the treatment of a certain disease may be identi-
fied, causing a firm to instruct its synthetic chemists to 
construct a molecule to meet the need. Or, through basic 
research, a new chemical entity with potential pharmacologic 
activity is discovered. The new molecule is then patented 
with the u.s. Patent Office for seventeen yea-rs, after which 
others may test, use, or market the chemical. Firms generally 
patent many more compounds that will ever been seen bythe 
]'DA. As examples, it ~ras reported that, in 1974, :S:oe(!hst-
Dynachem filed for 101 patents, !'lerck for 66, Sandoz for 61, 
Squibb for 56, Ciba.,-Geigy for 52, Bayer for 49 and Hoffnian-
La Roche for tJ:5 (47), however, the .number of applications 
submitted to the agency \vas well below these· figures. 
The compound goes through initial pharmacological screen-
ing for activity and, if found to be active, will be subjected 
to further animal and chemical testing for refinemE!nts in the 
characterization of the molecule. The testing includes: 
toxicology·--subacute and chronic; pharmacology--absorption, 
metabolism, distribution, excretion, and specific activity; 
and chemistry--synthesis, identification, purity, and stability. 
If the chemical is thought to have potential for use in man, 
the firm must do the necessary tests, e.g. safety in animals, 
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\'lhich are required by· the FDA in their Notice of Claimed 
Exemption for an Investigational New Drug (IND). The firm 
is required to file an IND for the interstate shipment of 
any new drug without an approved new drug application and 
provide information which ;justifies the use of the drug in 
man. The data that are required in the IND to fulfill its 
requirements includes (48): 
1. descriptive name, chemical name, and 
structure {if kn01-m). 
2. complete list of components, including 
·reasonable alternatives .for the inactives. 
3. complete statement of the quantitative 
composition. 
4. description of the source and preparation 
of the ne;.1 drug substance. 
5. statement of the methods, fa.cilities, and 
. controls used for the manufacturing, · 
processing, and packing of the nz:·lr{ d1,ug ·to 
establish e.nd maintain appropriate stande.:erls 
of identity, strength, q1.tality, and pu.ri ty 
as needed for safety and to gi'IJe signifi-
cance to clinical. investigations made 1vith 
the drug. 
6. statement coveringall information available 
to the sponsor from preclinical investiga~ . 
tions and any clinical studies ru1d experience 
t'li th the drug: 
a. studies on laboratory animals 
b.; if marketed commercially or investi-
gated outside the United States, 
complete information about such dis-
tribution or investigatio:;l . 
c. if the drug is a combination of 
previously investigated or marketed 
drugs, a summary of preexisting 
information 
7• a copy of all informational material, includ-
ing label and labeling which is to be supplied 
to the investigator. 
8. scient:\.f:i.c training end experience that 
the sponsor considers to qualify the 
investigators as suitable experts to 
investigate the safety of the drug. 
9. names· allCl. a summary of the training and 
experience of each investigator and monitor. 
10. outline of the phase or phases of planned 
investigations and a description of the 
institutional review committee as follows: 
a. clinical pharmacology 
b. clinical trial 
c. institutional review committee. 
11. statement that the sponsor wiH. notify the 
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. l!'DA if the investigation is to be discontinued. 
12. · statement that the sponsor will notify each 
investigator if a new drug application is 
approved, or if the·investigation is discontinued. 
13. if the drug is to be sold, a fulJ. explanation 
why sale is required and sl:iould not be regarded 
as commercialization of a nevi drug for 1·1hi.ch an 
NDA is not approved •. 
. 14. . statement that the· sponsor 1vill not i.niti£-te 
clinical studies until 30 days after the date 
of receipt of the notice by the FDA·and he will 
withhold studies ii' requested by the :b'DA, · . 
~/herein information on the deficiencies in the 
IND willbe provided and a conference between· 
the FDA and the sponsor will be held on request. 
Additions are made to the IND throughout the investigation of 
the drug as it proceeds through the three phases which describe 
the stages of investigations in general terms. Phase I 
involves the use of healthy human volunteers for purposes 
of characterizing the absorption, distribution, metabolism, 
excretion, and toxicity of the new drug in man. In Phase II, 
a small population of diseased patients is selected upon which 
the new drug is used to determine efficacy. Phase III is a 
widespread study on diseased patients in order to charac-
terize the safety and efficacy on a large number of patients. 
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Triplicates of the si~1ed Form 1571 and the data generated 
to fulfill the requirement.s are sent to the :I!'DA' s offices in 
Rockville, Maryland. l'ihen the IND arrives at the agency, a 
receipt date is assigned. From the,t date, the 30 day wait 
for the firm, described in #14 of the Form 1571, begins. The 
document is routed through the Central Documents and Records 
room where it is assigned a number (IND's and NDA's are num-
bered consecutively according to the receipt date), and to 
Index and Aostracting for the coding of some of the. included 
information. It is then sent to the reviewing division 
responsible for the therapeutic class of drugs to '1-!hich this 
new chemical entity belongs. The incoming INTI's are classified 
by the divisions according .. to chemical type, therapeutic poten-
t;ial, and sponsorship. The chemieal types include:. ne.w. entity,. 
nevi salt, ne·w ·formulation, new combination, one already ma~r­
keted by another firm, and one already marketed by the same 
firm. The th<;rapeutic potential gain is classified as: impor-
tant, modest, little or none, significant for pediatrics use, 
~d DESI/OTC. The sponsorship is either noncommercial 
(individual or ins·!;:i..tute) or commercial. The commercial 
IND's are more lik:ely to give rise to NDA's. 
The FDA, as its first effect on the sponsor of the ne1v · 
d:rug in its protection of the consumer hA.s kept the new dx•ug 
off the market and prohibited its use in man prior to the 
submitting evidence of its safety in the IND. The agency's 
second major impact·comes with.the 30 day safety review done 
by the professional staff in the divisions of New Drug 
Evaluation. The r·eviewerB, generally the chemist, the 
pharmacologist, and the medical officer (the principle 
members of the review team) survey the submitted data for 
safety. 
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~'he chemist must make certain that the sponsor has 
properly identified the structure of thenew'chemical and 
that the formulations listed in the manufacturing and con-
trol sections are logical and agree with those submitted in 
the protocols for use in the clinical trials. Further, he 
checks that adequate quality control procedures are utilized 
·to assure the proper strength, purity, and identify of the 
molecule; and that the labeling contains the proper informa-
tia. " 
The ph?.xmacologist revievn1 the data ou the safety of 
the mo1ecu.le in the aTJimal toxicity tests. The dm'ation .of 
the studies and the animal species in which these tests·are 
to be performed varies 'tli th the route and duration of 
administration of the drug anticipated for human administra'-
tion. The firm must present adequate data that characterizes 
the saf<,ty in animals of the drug before its use in hum:m 
subjects. 
The medical officer confers with the pharmacologist on 
the an.imal data, and its relation to the dose that is to be 
used initially in man. The protocol, i.e. design of the 
clinical trial, for Phase I, the initial studies of the mole-
cule in man, is carefully evaluated so as to allow for the 
greatest margin of safety possible.· The choice of the initial 
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dose is a critical one, and is dependent upon the information 
generated from the animal toxicity studies and possible 
structural activit-y· relationships of the new compound tli th 
known drugs. It is a difficult decision, as the relationship 
·of .. animal data to man is not direct. 
Together, the 30 day reviews are scrutinized and the 
decision is made for human trials. The protection of the 
hu~an research subject is the most important consideration 
in making this decisi.on. To achieve this, the adequacy of 
the animal studies already completed and analyzed is ascer-
tained. The scientific merits of the research plan in addi·· 
tion to the qualifications of the investigator are determined. 
Fu1?-ther, the proper. characterization of the. new drug ohenlically 
is checked so that the investigator knows exactly what the new 
compound is a..'ld thus the clinical tests vtill yield meaningful 
data., (49). If any question as to t;he· safety of the drug 
arises, the division director can put a "clinical hold" on 
the IND to prevent the proposed study ~rom commencing until 
the matter has been cleared. Assuming no problem has arisen, 
the firm ente:c's into the phases of clinical trials. 
In testj_ng the new drug, the ~irm must .keep in mind that 
adequate, well-controlled· studies are required in order to 
determine the safety and efficacy of the new drug. Under the 
provisions of Form 1571 lO(c), a reasonable clinical trial 
shall contain (48): 
l. more than one independent competent 
investigator to maintain adequatecase 
histories of an adequate number of subjects. 
2. observations and evaluations of ro.1y and 
all discernable effects attributable to 
the drug in each indj_v.idual with com-
parable records of' patients used a controls. 
3. records of adequate information pertaining 
52 
to each: age, sex, conditions treated, 
dosage, frequency of adrn:i.nistrationof the 
drug, results of all releve:J.lt elinical 
observations and lab examinations made, 
adequate information concerning ony other · 
treatment given, full statement of adverse 
effects e:J.lrl useful results observed, ro.1d 
whether such results or effects are attribut--
able to the drug. 
Phase I is ·the preliminary stage in the use of the ne~; 
drug in human beings, and involves a small number of healthy 
volunteers. It is conducted to determine such parameters as 
toxid.ty, metabolism, absorption, elimination, prefe=ed 
. route of administration, and safe dosage range (50). The 
FDA monitors the firm's use of the drug through periodic and 
adverse reaction reports which are submitted to·tb.e IND~ ·The 
idea of using normal human vol<mteers'who will derive no 
benefit from the new drug has been criticized as introducing·. 
an unnecessary risk, and leading to inaccu:rate results, as 
some disease states could alter the pharmacological parallleters. 
This criticism has some validity, but on the other hand, people 
in diseased states are more difficult to control e:J.ld the 
Phase I absorption, metabolism, excretion,·. and dose ranging 
studies are critical. In most disease states, there are 
"normal" periods. Because the diseased person is more debili-
tated, trueing him off medication in order to develop the 
pharmacologic profile would not be advisable. A second dead-
line for review is at 60 days. This is an in-house deadline 
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for the reviewers in which a detailed notation of the initial 
deficiencies, not serious enough to ~mrrru1t a cli.nical hold, 
are cited. The firm is sent a letter containing this ini'orma·-
tion so as to aid them i~1 the development of the IND. 
If the Phase I studies prove the new drug to be rela-
tively safe, the clinical trials·enter into Phase II. Some 
additional animal data on the subacute and chronic toxicity 
may be required, depending upon the duration of administra·· 
tion. Additionally, some manufacturing and control data will 
be added if i;he firm has altered the :f'ormulation. A limited 
number of patients with the disease state the molecule has 
been designed to treat are utilized in Phase II, after pre-
liminary data on the efficacy of the molecule,.has peen 
generated.~ As in Phase I, the sponsor sends all protocols 
of the Phase II sh1.d:i.e:a to 1i'JlA for approval. In general, a 
good protocol should contain (51): 
1. clear statement of objectives. 
2. m~?thod of selection of subjects. 
a. suitable for purposes of study. 
b. assigned to test groups in a way 
to minimize bias. 
c. assure comparability in test and 
control groups (age, sex, severity, 
or duration of disease, use of other 
drugs). ~ 
3. explanation of the methods of observation and 
recording of results. 
4. comparison of results of treatment with a 
control to permit quantitative evaluation; 
four types of comparison are recognized; 
a. no treatment: where objective 
measurements available and placebo 
effect is negligible. 
b. placebo control: compare results 
of new drug with those of inactive 
preparnt:i.on. 
c. active treatme11t control: compare 
to an effectiv.;) regimen. 
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d. histol'ical control: in certain cir-· 
cumsta:nces, sueh as withdiseases of 
a high a11d predictable mortality with 
signs and symptoms of predictable 
duration, or in prophylaxis where 
morbidity is predictable; new drug 
may be compared with prior experience 
derived from adequately documented 
natural history of the disease. 
5. summa.-ry .of methods of analysis and an evalua-
tion · of' data. 
At the end of Phase II, the molecule has been charac-
terized for safety and efficacy.· T'ne extensive Phase III 
c~linical trials are then con.templated. Consultations \vith 
FDA perEJonnel sometimes termed pre-NDA confer13nces, are made 
by the .firm concerning the :protocol .for the H1ane III studies. 
These st-udies utilize a large number of patie:ni;s ·,rith the 
disease t:he drug is designed tq treat. The large numbers 
a.':'e needed for statistical support in the determination of 
the safety, efficacy, desired·dosage range, and side effects 
of the drug. 'l'his is generally by comparison to a group of 
patients treated with a placebo. The studies in Phase III 
are generally of ·1;he double-blind and double-blind cross-over 
tJ']?e. T'ne "double··blind" refers to the fact that neither the 
inve:::tigat<:•r nor the patient know v;hether active drug or 
placebo is being administered. Patients entered into the 
studies are numbered, an.d then randomly assigned either the 
active or the placebo. If the study is of the cross-over 
type, then the patient receives .the active drug for a period 
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of time and switches over to the placebo for an equal amount 
of tj_me. The controls aid in the meaningful statistical 
analyses by supplying data on some of the variables inherent 
in most studies. The spontaneous remission of .the disease 
can occur and thus distort the results on efficacy. The 
"placebo effect", a phrase defining the amelioration of a 
disease merely by the administration of an inactive dosage 
. form to a patient can be significant in any patient popula-
ti.on, and thus the reason .for the widespread use of the 
double-blind and double-blind cross-over studies. Similarly, 
with the "Hawthorne effect", patients may become better solely· 
due to the special interest taken in their particular disease 
state by entry into a clinical trial. This effect is diffi-
cult to eliminate. 
Thousands of patients are generall;y util:i.z,ed in these 
trials. The investigators use the drug similar to the wc.y 
it would be used if marketed, which reguire·s extensive c:oordi-' 
nation and inoni taring on the part of the sponsor. . As required 
by the regulations, each study has a clinical monitor ;~ho is 
well-qualified (s1..\bmi ttcd curriculum vitae is reviewed by the 
med:i.co.l or dental officer along with tllose of all investiga-
tors). 'I·he purpose of t:he clinical monitor is to assure that 
an. investigators are actually doing the study and are follow-
ing the \~ritten protoc:ol. In addition, the clinical monitor 
makes certain that the reports of the investigator are returned 
according to schedule. 
Additionally, the drug product formulation used in the 
Phase III trials should be the snme as that to be used on 
the market. Stability data on the formulation in its con-
tainer f~r marketing should be generated. 
If all has prog-.cessed well, and the firm feels the 
results of its studies provide substantial evidence to 
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support the claims for safety and effectiveness from the 
data in the various phases, the firm prepares to file a New 
Drug Application. The application, J!'orm 356H, by regulation 
must contain (52): 
1. · Table of Contents. 
2. Summary of all the data on the drug which 
presents a sound basis for approval. 
3. Evaluation of safety and effectiveness. 
4. Copies of label and labeling. 
5. . Whether the drug is limited to use :.tnd.oP 
professional supervision.· 
6. Full list of components. 
7• ]ull statement of the composition. 
8. l!'ull description of the methods used in, 
and the facilities and controls used fOJ:·, 
themanufacture, processing, a.nd packing 
of tb.e drug. 
9. Se.mples of the drug. 
10. J!'ull reports of preclinical investigations . 
that have been made to show if the drug is 
safe and effective for use. 
11. List of investigators. 
12. Full reports of clinical investigations that 
have been made to show if the drug is safe 
and effective for use. 
13. If this is a supplemental application, full 
information on each proposed change concern-
ing any statement made in the approved application. 
14. Environmenta.l Impact Statemen·t;. 
The Form 356H and the data generated to fulfill the 
requirements are submitted in triplicate by the method 
described specially in 21 CFR 314.1 (3). The NDA is sent 
through Central Documents and Records room for numbering 
and routing, to Indexing and Abstracting for coding and 
abstracting, and then to the appropriate revie1~ division. 
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The 180 day revie~l time allowed the agency begins when the . 
document is received. The team of reviewers: the Chemist, 
the Pharmacologist, and the ~1edical or Dental Officer~ ~1ith 
the possible addition of the Consumer Safety Officer, the 
Microbiologist, the Statistician, and the Biopharmaceutics 
specialist, now begin the. scrutiny of the submitted data in 
their area of expertise and responsibility in order to deter-
mine if the drug .is indeed safe m1d ef:t:ective. To prove 
·efficacy, the sponsor must submit"substantial evidence" in 
the application. "Substantial evidence" is defined in 
Section 505{d) as " ••• evidence consisting of adeque.te and 
well-controlled investigations, including clinical investi-
_gations, by experts qualified by scientific training and 
experience to evaluate the effectiveness of the drug involved, 
on the basis of which it would fairly ar.td responsibly be con-
cluded by such experts "!;hat the drug will have the effect_it 
purports or is represented to have under the conditions of 
use prescribed, recommended, or suggested in the labeling or 
proposed labeling thereof (53)." 
Within substantial evidence,- there are several specific 
parameters which are examined. The number and t7Pe of 
patients enrolled in the studies to test the drug are 
checked for applicability to the questions about safety 
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and efi'icacy.. The measurements utilized to signal toxicity 
are scrutinized for their adequacy to signal the reactiops. 
Any adverse drug reactions are carefully studied. to note 
their significance. The long-term animal studies for 
carcinogenicity at this point are complete and problems in 
this area are noted. The stability studies for the drug 
product are now complete and any problems in this area which. 
might invalidate some of the clinical studies due to an 
unstable product are noted. If all appears to be adequate 
. with respect to the above, the ultimate decision as to whether 
the drug is safe and effective involves the ·weighing of the.· 
benefit'-t.:)-risk ratio.· ·The ratio is individualized for each 
N:UA. Drugs \'lhich cure some life· threatening disea!".e, but not 
without a severe sj_de-effect may be approved, whereas the same 
side effect in another drug treating a milder condition would 
be considered too seYere to all.0\'1 its approval. The balance 
is delicate and, -~i th the massi Ye amounts of data to be 
studied, can be a difficult one about which to. make a decision 
in 180 days. 
The reviewers are not entirely alone in the.weighing 
of the benefit-to-risk ratio. Since 1972, in response to the 
increase in scientific knowledge and the complexity of new 
drug development, the use of advisory committees in the 
Bureau of Drugs has greatly increased. The committees provide 
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high levels of input from scientists outstanding in their 
field, allowing the agency to make reg;ulatory decisions \~ith. 
advice and to open up the agency's decision-making. The 
Bureau now has 17 scientific advisory committees to aid in 
the review of IND's and NDA's that need some special con-
sideration, in the areas of: antiinfective, arthritis, 
.cardiovascular-renal, controlled substances, dental, drug 
abuse, endocrine-metabolic, gastrointestinal, neurology, 
obstetrics-gynecology, oncology, opthamology, psychophaTina-
cology, pulmonary-allergy, radioactive·pharmaceuticals, 
respirato~·y-anesthesia, and surgical. The criteria for 
IND's to be considered by the committee includes those 
representing important therapeutic advances, n.t:>vel and 
improved methods of drug administration, or have a poten-
tially significant hazard, as well as those \'lith safety 
problems or any other in which the committee .m11y be inter~ 
ested. For NDA's to be considered, the criteria include 
those with important therapeutic advances or important ne\v 
uses \~i th narrow benefit-to-risk or those representing drugs 
of controversial efficacy. In addition, those which may 
need post marketing studies .and others representing drugs 
being considered for Vlithdrawal from the market because of 
safety or efficacy problems may be considered by-the committee. 
Any others in ~1hich the committee may be interested may· b1.3 · 
brought for examination (49). 
Once the reviews have been compiled and the. decision 
has been made as to whether the NDA is to be approved, the 
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letter is drafted. If the application fails to meet one or 
more of the requirements of Section 505(b) of the Act, the 
sections are .cited as reasons for its nonapproval. If all 
of the following conditions have been met, the application 
is approvable (46). 
l. Full reports of investigations which have 
been made to show whether or not such drug 
is safe for use and whether such drug is 
effective in use. 
2~ A full list of the articles used as·com-
ponents of such drug. 
3. ·. A full statement of the composition of 
such drug. 
4. A full description of the methods used in, 
and the facilities and controls used for 
the manufacture, processing, and packing 
of such drug. 
5. Such salilples. of such drug and of the arti-· 
cles used as components ther.sof as the . 
Secreta~; may require; and 
· 6~ Specimens of the labeling proposed to be 
used for such drug. 
The firm submits the final printed labeling for review, 
and an inspection of the facilities that 1t1ill be producing 
the drug product is made by the field personnel to determine 
the firm's ability to manufacture the drug, and their.com-
pliance with the Current Good Manufacturing Practice regula-
tions. lffien the final printed labeling has been reviewed m1d 
approved and a satisfactory inspection report has been received, 
the drug product iS allowed to be marketed. 
The Reviewers 
'l'he review and evaluation. of IND 1 s and UDA 1 s at the FDA 
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:i.s probably one of the most scrutinized, r•er5rganized, debated, 
and criticized functions of the agency. Congressional hear-
ings hav-.e brought many attacks on the process. On one hand, 
the agency is accused of taking an inordinate amount of time 
in the approv:Lng new drugs thus creating a "drug lag" between 
their marketing in the United States. and the Europeru1 coun-
tries (54). On the other hand, the opposite viewpoint was 
presentedin the August 16, 1974 hearings before the Senate 
Health Subcommittee by some agency employees who felt the 
agency '\'Ja.s allowing unsafe drugs on the market (55). 
What is the purpose of the review process and 'I'Jhy has 
it been so heavily criticized? The history of reviewing 
dates back to the safety question ra;Lsed by the Sulfru:1ilamide 
Eli:x::lr Tragedy oi· 1937, and the more recent Thalidomide 
Tragedy of 1962. The passage· of the Federal J!'ood, Drug, 
and Cosmetic Act in 1938 and the Drug Amendmeuts of 1962, 
gave the FDA the responsibilityto assure that new drugs 
are safe a.11d effective. To control effec.tively these new 
drugs coming onto the market, certain parameters abou·t; their · 
safety and e.fficacy must be knovm, and the information 
included in the IND's and NDA's must be complete, accurate, 
scientifically competent, and substantial. ~1he trained· 
scientists must make these decisions. 
The reviewer 1 s job has a variety of descriptions. ~'o 
begin, reviewing is a difficult job, an intricate operation 
'~ith many different facets. It is a "general" job. Although 
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the revie•11ers are assigned drugs in some specific drug 
category, they must be capable of handling a variety of 
different kinds of inform.o,tion on new techniques for animal 
testing, drug m~~ufacturing, or clinical procedures from 
experts in those fields in industry. .The reviewer must, 
therefore, be flexible and have the ability to educate 
himself in new areas. As the FDA's kno\vledge of problem 
areas increases, then the agency tightens up. its require-
ments and demands more of the industry, thus increasing 
the amount of general "specific" knowledge required by 
the revie'\ver. This "tightening" has been very evident 
since 1962, with the quality and quantity of the submis-
sions increasing every year. 
It is a denia.'1ding a.-'"ld pressu..--:-j_ng ;job. l'he respo.n-
sibili ties of· the revie'l'rer are gre:at. Although the dead-
lines for revievl work a.ppear to be adequate to be met 
easily (e.g. 180 days for the. ~IDA), one must remember that 
the reviewer does not handle just one nm or NDA, but many. 
Thus his time must: be organized adequately to allow for 
thorough coverage. Some clinical data fill over 400 volumes 
or jackets and. t:tms the medical officer vwuld be required 
to review IJ. j aclmts of over 1200 pages per day! The work-
load never decreases, it either remains relative;Ly constant 
or increases. The number of applications received (56) 
depends upon the timing of the firms, and for the past 
years has been: 
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127.2. 122!± .12.22. 
IND's 913 842 818 
NDA's (original and 
resubmissions) 
332 333 338 
Supplements 2447 2461 2705 
(original and 
resubmissions) 
It is a lonely job. Although the reviewer can utilize 
advisory panels, consultants, and colleagues, he alone is 
faced with making a decision or evaluation about the adequacy 
of the data to assure safety and efficacy, and must be pre-
pared to defend his-decision. It must be remembered, too, 
that drugs are toxic substances and are intended for "the 
diagnosis, cure, mitigation, treatment, or prevention of. ,, 
disease" or "intended to affect the structlu'e or fu.'1.ction. 
of the body" (57). 'l'lhen one begins to alter the body's 
physiological 1Jalances, or the imbalances which occur in 
certain disease states, it i.s both dangerous and difficult 
to preQ_ict all of the possible reactior1s. 
Wno are the reviewers? As mentioned previously, the 
review work is done utilizing the team approach with the 
pha.rmacologist, chemist, and medical or dental officer 1tlork-
ing together to review the data that have been submitted• 
Additionally, to aid the primary team of reviev1ers, the 
consuraer safety officer, microbiologist, statistician, and 
biopharmaceutics specialist are utilized. Each member takes 
a different look at the application in his area of expertise. 
The Pharmacologist. 'l.'he primary concerns for the 
pharmacologist as a member of the review team are the safety 
of the drugs and their pharmacological activity. In the IND 
and NDA regulations, the information on safety of the drug 
as cl.etermined in animal studies includes (48) & (52): 
IND: Statement covering all information 
available to the sponsor derived from 
preclinical investigations and any 
clinical studies and experience with 
the ~~gs as follows: 
adequate.information about.p:re-
.clinical investiga.tions, including 
studies on laboratory animals on 
the basis of which the sponsor has 
concluded that it is reasonably safe 
.to initiate clinical investigations 
with the drug: identity of person 
· conducting the study; identity and 
qualifications of the individuals 
who evaluated the results and con-
cluded it is reasonably safe to 
initiate clinical investig,?otions. 
NDA: Fu11 reports of preclinical investigations 
that have been made to shcM whether or not: 
the drug ie safe for USE' end e:ff'ectiYe in 
use\10 
The pharmacologis·~ thus concentrates on these· sections of 
the regulations. The first big review is the 30 day safet-y 
review. '!!he pharmacologist hasthe crucial responsibility 
of determining, whether the submitted data a:r:e adequate ·and 
justify the use of the drug in humans. The studies that 
will generally be accep·table for the Phase I trials are out-
lined in an artic,le appearing in the FDA publication, I•'DA 
;t>a·£>~:1:.§. entitled "Current Views on Safety Evaluation of Drugs", 
by Edwin Goldenthal (58). The types of animal studies 
required for the phases of drug investigation are outlined 
in this article, and vary with the route of administration, 
the duration of human administration, the phase of study, 
and the type of patient in which it '<lill be used for each 
individual drug (Table I). 
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After the 30 day safety evaluation has been made, and 
the initial dose has been determined to be relatively safe 
to begin the Phase I studies, the pharmacologist must then 
begin the task of monitoring the additional, chronic animal 
studies that are submitted to support the extended use o·f 
the drug in humans.· This \vork continues throughout the IND 
phases, as many of the chronic toxicity or carcinogenicity 
studies can take several years to complete. The.se tests 
can also be both difficult and costly a.s many animals must 
be used for the. long-term .studies to assure an adequate num··· 
her at the end of the trial for significant .data. 
In the lWA, the pharmacologist's work has been mostly 
completed, because -if the animal studies >vere inadequate in 
any phase of the IND, the NDA would probably not be submitted. 
The work that does remain involves the review of some of the 
most extensive chronic toxicity and the carcinogenicity 
studies. In addition, the pharmacologist makes comments on 
the labeling for the product in the areas of his review work. 
This could include eomments onthe description, actions, 
indications, ~mrnings, animal phm·macology, ·and adverse 
reactions sections that reference animal data as justifica-
tion for inclusion. 
The Chemist. The chemist is responsible for the review of 
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information pertaining to the chemistry and manufacturing 
and controls of the drug. In the review, the individual 
review topics include: components, composition, facilities, 
personnel, synthesis, raw material controls, other firms, 
manufacturing and processing, container, packaging and 
labeling, laboratory controls--finished dosage form, control 
numbers, stability, samples and results~-methods validation, 
labeling, establishment inspection--CGI1P 1 s, registration, and 
environmental impact statement. 
The time frames for the review of the documents are the 
same for all of the disciplines: IND·-;...30 dey safety and 60 
day for initial deficiencies, and NDA-··180 days. The chemist 
concentrates upon his portion of the documents <<ith some 
checking into. the clinical section to make certain that the 
formu.lation. that was or j_s tO be used i_n clinical -'cx·ials is· 
the same as the one submitted in the composition section, and 
that there are no additional drugs being used about which the 
..firm has submitted no manufacturing m1d controls data. 
To further define the types of manufacturing and control 
informa.tion the IND or NDA should contain, the Pharmaceutical 
Manuf·a.cturers Association (PMA) and the FDA met to develop 
criteria. The product, Qu}~.=kn.~?D'lli!.l~g.i\f£.il:flL@lSUJ.2~§. 
!.2Vl.ill..:.IL2ll(LliPn. prqvides the specif'ic information to be 
submitted that will adequately meet the requirements in the 
regulations. These guidelines were very helpful for the 
chemistry reviews done by the author. 
In the 30 dey safety review,· as stated earlier, the 
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chemist is responsible for the assurance tha.t the firm has 
properly cha'T.'acterized the new d.:cu~, the formulations listed 
in the manufacturing and control section agree with those 
listed in the protocols, adequate quality control procedures 
are utilized to assure the proper strength, pw:•ity, and 
identity of the drug, a~d the labeling has the required 
information. 
In checking the proper characterizations of the new com-
pound (in addition to structural determination from the 
synthesis), there are several steps (59): 
1. gross examination: pbysica.l state, color, 
odor. 
2. determination of purity and physical 
characteristics: 
a. purity: although used, the mel;:;.-
ing point, boiling point, refrs.e-
tive index are generally not the 
bes>c tests for purity; but l'B.ther 
gas,· liquid, or thin layer chroruo-
tography should be used. 
b. physical characteristics: melting 
point, boiling point, density, 
refractive index, empirieal formula 
(from elemental analysis), molecula:r 
. \veight;, solubility, opt:i..cal rotation, 
spectral properties. · 
3. classification by function g.roup: acid, .base, 
soluoili ty, .element?-1 analysis. · 
4. final identification: absorption spectroscopy, 
nuclear nagnetic resonance, inf'rlli~ed and ultra-· 
violet spectrometry. 
The quality control procedures generally use a reference 
standard which has been completely characterized for compari-
son of the results of certain tests, for example, gas 
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chromotography, with the sample batch. An assay of the 
sample batch is also included. ]'or a clinical hold to be 
placed on the Phase I studies due to deficiencies in the 
chemistry, the:re must be evidence of inadequate controls 
over the ne\•1 drug, i.e. the sponsor does not kno\•1 what is 
being given to the patient, whether due to stability prob-
lems, impuri.ties, or lack of proper characterization of the 
compound. 
The 60 day review·of' the IND involves more thorough 
scrutinization of the information, \"lith the minor deficien-
cies in the application being noted to the sponsor in a 
letter. The nm does not need to contain as much informa-
tion as the 1--TDA, and the sponsor can have some flexibility 
in the pr·ocedures while l:te is deciding ho'rl and i£ they \oJill 
market their new drug. As the drug approaches the Phase III 
clinical trials; however, the sponsor should ha.ve a. defi11ite 
formule.tion that he will propose for marketing, complete vd th 
on-going stability st-udies in the container to be .used, the 
purity of the reference compound should be at a high level, 
and the sponsor should l1e developing more detailed manufac-
turing and control data .• 
The chemist'B review of the NDA is lengthy and involved, 
and generally the application is not approvable on. the first 
submission, due to the fact that many fail to J:espond ade-
quately to the requirements directly stated in the Form 356H. 
In the past few years, the chemists (as with the other dis-
ciplines) have become much more stringent in their reviews, 
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requiring much more information about,. for example, 
packaging and stability, as more knowledge is gained 
about the problems that ca:n occu:r·. The area of mett,:red 
aerosols is one in which the requirements for information 
to be submitted has increased considerably. Over the past 
few years, interest has developed in the difference between 
the types of valves; good, indicative function tests for 
the metered aerosols; and the possible effects of the change 
in a mouthpiece on particle size. Stability data on these 
dosage forms includes not only the potency of the active 
ingredients as with most dosage forms, but the. \'Thole unit, 
i.e. the stability of the mouthpiece, valve, actuator, bottle, 
and the contents (mostly freons) within. Addit:ionaJ.ly, 
packaging materials are being checked more thoroughly today 
for poten".;ially hazardous leaehables, for exa;ople 2·· 
mercaptoimidazoli.ne in gaskets and vinyl chloride from 
polyvinyl chloride con_tainers. As kl1o\vledge about the 
hazards of leachables and the ability to detect small amounts 
(parts per billion) of the chemicals is gained, more work in 
tracking these down in the NDA will be made for the chemist. 
The chemist reviews several sections of the package 
insert, and has the responsibility over the package labeL 
In the insert, the chem:i.st reviews the description, .structural 
formula, and ho'\'1 supplied sections for accuracy. In addition, 
the chemist generally skims the remainder of the labeling 'to 
see if the firm is in compliance with the regulations as far 
as the number of times the trade name can be mentioned on a 
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page and the height and prominence of the lettering. On 
the package label, the chemist niu.st review the entire docu-
ment fo~ the required information, 1.e. the statement of 
the ingredients, the declaration of the quantity of con-
tents, and the form for making and the adequacy of the 
required statements. Most ot these ·labeling regulations are 
included in 21 CJ!'R sections 1.100-1.115. 
The chemist generally must revie\<r the drug master file · 
(Dl"'F) as many IND 's and NDA' s refer to one. The drug master 
file is. a document submitted by a firm to either avoid dupli-
cating information that'is submitted to the firm's several 
IND' s or NDA' s or from a supplier that \vi shes to maintain 
tr·ade secrets and not divulge the information··on components, 
manufacturing and controls, etc. that is r·equ:Lred_ by FDA for 
an nm or NDA to its customer. The Di'IF can contain most ru1y· 
aspect of the manufacturing and controls information~ facili··-· 
ties, personnel, composition, ra'tl material description, 
specification and controls, synthesis, general manufactur·ing 
and procession or packaging ~md labeling. · 
Hedical Officer o,., Dental Officer. The l-'ledical Officer or 
---~----'""""" - u-
the Dental Officer is the team leader in the Review Process. 
After all disciplines have made their respective reviews, it 
is the- team lee:der that pieces them together to make a final 
decision. As a member of the team, it is his responsibility 
to determine the efficacy and safety of a new drug from the 
clinical trial results, 8lld to weigh the benefit-to-risk ratio 
in making that judgment. He is generally faced with a 
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voluminous amount of data. to sort through .and evaluate, as 
most NDA submissions contain several hundred jackets, most 
of which contain clinical data. 
In the 30 day review, the Medical or Dental Officer, 
together with the Pharmacologist, determine whether the 
animal data are adequate to support the proposed use and 
the initial dose for the Phase I trials. Along l'lith the 
initial dose to be used, the protocol that accompanies the 
IND must also be approved. It must include adequate pre-
cautions to be taken that '\'Jill detect any toxic effect 
readily so as to minimize the risk involved to the volun-· 
teers. In addition, Phase I dose ranging studies will be 
perforrn0d to determine the best dose to use in the Phase II 
studies, and generally contain tests which '.vill be indicative 
of the tolerance and toxicity of the drug as it is used ir1 
man from a very low dose to higher doses E.;;em'lrally oYer 'I'Ieekly 
time periods. The tests may include blood pressure, pulse, 
.ECG, and laboratory (urinalysis, total protein, albumin, 
globulin, uric acid, glucose, BUN, SOOT, alkaline phosphatase, 
total bilirubin, and CBC), •ri th side effects monitored care-
fully. If the Pharmac.ologist and the ~1edical or Dental Officer 
agree that the initial dose is sufficiently low to begin the 
trials, an.d that the protocol is adequate, the 30 day safety 
release slip is signed and the firm will be .allowed to begin 
the studies. (In actuality, if the firm has not heard from 
the FDA within the 30 day \~aiting period, they are allo~md to 
begin the studies.) 
The Medical or Dental Office:r· rwu o.ssumes the 
responsibility for reviewingall information that comes 
in on the IND concE:rning additional protocols, data from 
the studies, adverse reactions, and additional investiga-
tors. The first two phases must be watched carefully to 
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see that the patients are not subjected.to unnecessary risk. 
In Phase III, the drug has been fairly well characterized, 
and the protocols are reviewed. The results are generally 
not submitted to the IND from this phase, but are rather 
included as part of the NDA. 
In revie\ving the NDA data, the t1edical or Dental Officer 
is faced 'Vl:i.th a great volume of !naterial. Fii·st, the total 
docUJne;:J.t is ZCJ.rveyed to determine the types of ... studieE: that 
have" been submitted to prove the drug is safe a11d. effective. 
Any cor:r·espondence either from the firm or the FDA is revievled 
so as to obtain a total picture. The submitted labeling J.s 
scrutinized for the claims of efficacy made by the firm 
a).ong with the adverse reactions and contraindications found. 
After this overall picture of the NDA is obtained, the review 
of the individual studies begins 1t1ith notes made on the study 
design, the rating system (subjective vs. objective), the 
adherence to the protocol by the investigators, and the 
adverso rea·;)tions. To characterize the drug, clinical, 
labora.tory, and observation data of the effect of the drug 
in n::an are submitted. The clinical data include information 
on the patients physical examination, vital signs, and 
possibly a chest x-ray. Laboratory data on the urinalysis, 
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clinical chemistry, and hematolog-<J aid in the determination 
of the ~~ug's effect on the va~ious body systems. Addi-
tionally, the investigator must make clinical observations, 
noting any adverse or toxic effects the drug may have on the 
patient. This monitoring of the drug must be consistent in 
each of the studies to yield meaningful results and thus 
requires strict adherence to the protocol. A variety of 
studies all have their place in the evaluation of the drug. 
These studies include dose ranging, metabolism, pharma- . 
cokinetics, detoxification, enzyme induction, bioavailability, 
and efficacy with each requiring different measurements. The. 
results of the evaluation of each of these studies are pteced 
together to obtain an overall picture of the safety and 
.efficacy of the drug. 
i',JJ:1en all 'the reviews hav-e been.. completed, the team Jea.der 
then coordinates them into a final evalu.ation of the drug. 
All aspects of ·the labeling. are scrutinized for adequate 
substantiation by the submitted data. The recommendation 
for either approval or disapproval of the NDA is made based 
upon the v1eighing of the benfi t-to-risk ratio. 
'l'o aid the principle revie\~ers, the consumer safety 
officer, microbiologist, statistic:ta.'1, and biopharmaceutics 
specialist are utilized. Each of these members has a specific 
area of the review process in \vhich he can add his expertise 
in order to add thoroughness and depth to the revie\v. 
Consumer Safety Officer. The administrative member for the 
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team of revie;o;ers is the consum0r safety officer (CSO) • 
.As a trained scientist (requirement for employment is a. 
Bachelor of Science), many of '-'lhom are pharmacists, the 
consumer safety officer is responsible for the classifying 
of doc.uments and insuring their smooth :flmv th1.•ough the 
division. Additionally, the CSO coordinates the work of 
.the reviewing disciplines and handles the division's respon-
sibilities on the regulatory actions taken on IND' s and HDA' s. 
Further, he must answer the inquiries that come into the 
division on its drug products. Many of the CS0 1 s come from 
the field offices of the agency and thus have a good back-
ground in drug regulatory procedures and can answer questions 
in the division about the regu.lations. 
After a document has been pl'Op.erly logged into the. 
division's doc.uments room, the CSO 2'eviews it for complote-
negs. At times, an HID or HDA may be r!>~jected prior to revievl 
if there are omissions of parts of the regulations. The cso: 
has th:i.s :t·espons:ibility. This procedure saves reviewer time 
by eliminating an unnecessary review, as the document is 
deemed nonspprovable on its face. Other administrative 
functions for the IND ar1d NDA process ru.'e ;numerous. · 'These 
functions are basically regulatory and include the drafting 
of letters to firms stating the. agency's decision on the 
application, ~Ihether deficiency, comment, or request. 
Due to the number of reviewers: pharmacologist, chemist, 
microbiologist, statistician, medical officer, bioavailability 
analyst, advisory committees, and consultants, involved in the 
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review of an IND or NDA, there is a definite need to 
coordinate their activities. The CSO is responsible for 
this coordination, keeping in mind the various time limita-
tions to assure .that the decisions \vill be made within the 
statutory limit. After all reviews are gathered together, 
the CSO extracts the conclusions, recommendations, and 
requests made by the reviewers and includes them in a letter 
to the sponsor of the document~ In addition, the CSO keeps 
track of any document going to another division for a con-
sultative review. 
Mi~.~-oJ .. qgj..&!i_. Although most microbiologists are located· 
in the Division of Antiinfective Drug Products to revie\1 
IND's ana, NDA.ts for antibiotics and sterile pi'•oducts (i.e. 
optha1mic5), the Surgical-Dental Division has one reviewing 
microbiolngist-. The microbiologist in the division handles 
those. sections of the documentE which include microbiological 
informat':i.on on its drug products: sterilization, pasteuri-
zation, tmd microbial studies done on antimicrobial products. 
ThEo introduction of the polyvinyl chloride, flexible 
b2gs usecl :for blood and la.rge volume pa.renterals, has created 
a considerable amount of work for the division, ·and in par·· 
ticularly, the mic:robiologist. The sterilization of these 
products ~:;liffers from· the moist heat steriliza-tion described 
in the U.H.P., thus each submission needs a separate review. 
The development of the good manufac-turing practice reg\1lations 
for large volume parenterals will set more definite standards 
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for sterilization and will alleviate some of the review work 
that must be done on these products, although all deviations 
will have to be approved on an individual basis •. 
The types of data to be reviewed in this area include 
the method of sterilization, the physical and microbial 
methods used to develop and quantify the cycle's efficacy 
and to validate the sterilization of the entire product, and 
checking the controls of the firm over the microbiological 
environment of the process. The pasteurization of these 
products is also important to prevent mold contamination of 
sterile blood bags that have an overwrap or cover. 
Some drug products in the division not only have the 
requirement to. be. sterile,. but. are designed to prevent infec-
tion as vrith the sm'gical, 'tlound, ~mel. burn d::.•essings. The 
P.nimal studies designed to test~ the ef:!'icacy of' si.1ch products 
are reviewed by the.microbiologist from the protocol and 
methods, through the submitted data.. These studies generally 
include both qualitative andquantitative assays of the micro-
bial populations that are present in the wound site. 
Those products which contain chemical ~timicrobial 
agents must also be reviewed by the microbiologist for 
efficacy. The review criteria for both the .ULYJ-..t!:£ ~d 
·clinical studies of these products must· be set up by t:he 
division. The evaluation concentrates upon certain criteria: 
reduction in microbial counts, development of resistant strains, 
~d the identification of the microorg~isms to note shifts in 
the populations. 
Statistician. Due to the volume of data submitted by the 
manufacturers in their ,justification of the . safety and 
efficacy, the primary revie~l team frequently request 
statistical analyses. The sta.tisticians are not part of 
New Drug Evaluation, but rather in Biometrics and 
Epidemiology. The requests for statistical analyses are 
sent from the revimrle!' through the division director to 
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the Division of Biometrics. A statistician is then assigned 
to do the review. 
l"leetings are held bet•reen the statistician and the 
reviewer in which the types of analyses are discussed. 
·Depending upon the types of information to ·be.· extr·acted 
i'rom the studies, different reviews are done., ... These reviews 
can cover the design of the study; the ir> .. fluence of va.r·iailces, 
for example ~Ieight, height, age, sex, ~eve:C'i ty of disease and 
the condition of the patient; the significance of the improve-
m.ent; and the comparability of the drug with the placebo. The 
information. from these revie\vs aids the reviewer in his deter-
mination of the safety and efficacy of the drug • 
.!li~.!>l£.ceutics Snec:i.ali.§.i. With the increased interest in 
the bioavailabiJ.i·i:;y of drug products, many of the revievm:rs 
are requiring this kind of information to be. included in the 
NDA. The agency's expertise in this area of bioavailability 
is in Drug l'lonographs. Documents are routed from the reviewer 
(generally tlrrough. the Medical Officer), through the division 
director to the biopharmaceutics specialist in the Division of 
Biopharmaceutics. Here, the clinical studies on· the 
absorption.,. distribution, metabolism, and e:Kcretion of 
the new drug are reviewed. Determinations of the amount 
of drug which the patient is actually receivingaids in 
dose determination. Recommendations based upon these 
revie~/S are returned to the New Drug Evaluation reviewer 
for use by the Medical Officer in determining the safety 
and efficacy· of the drug product. 
Assignment<! in the Division 
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As part of the work-study program, the author was 
expected to participate in the execution of the Division of 
Surgical-Dental Drug Products' responsibilities, ru1d was 
assigned various projects that met a specific"·need in the 
division. The bulk of the work was the review of the 
chemistry portion of many IND's and NDA's. Additionally, 
the analysis and evaluation of data submitted pursuant to a 
l!'ederal RegifJter notice on vinyl chloride and polyvinyl 
chloride, 2.11 investigation of problems which had occurred 
with the metered aerosol dosage form, and the organization 
of clinical data in preparation for a medical officer's review 
provided \'Vork for the student. These projects not only met a 
need .for the Division; but simultaneously provided the student 
\'Ti th a working knowledge of Ne~v Drug Evaluation, the agency, 
and the contents and flow of docUlllents. 
Polyvinyl chloride, a resin used as a major component 
for a \~ide variety of plastic products, received its sanction 
by FDA in 1956, in that it was listed in Lehman 1 s "Food 
Packaging". Its acceptance was based upon its lack of 
mig.-ration into foods when tested in the early 1950's (60). 
However, in January 1973, the FDA received reports from 
the Department of Treasury's Bureau of Alcohol, Tobacco, 
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and Jl'irearms that stability problems \'lere experienced in 
those distilled spirits packaged in polyvinyl chloride (PVC). 
As vinyl chloride is considered to be a poisonous substance, 
the Bureau of Alcohol, Tobacco, and Firearms banned the use 
of PVC containers for distilled spirits, and the FDA became 
concerned about its use in food packaging. 
A new development, a year later, caused the concern to 
become more intense. On January 22, 197L1., the Or:.cupatidnal 
Safety and Health Administration received word that E. F. 
Goodrich Chemical Company had. reported .several deaths of its 
1.1orkers from a rare form .of liver cancer, angiosarcoma, and 
. that these deaths may have been related to their '<Jork wi.th 
vinyl chloride. In addition, Professor Cesare !1altoni of 
Bologna, Italy \vas conducting studies of the effect· of vinyl 
chloride inhalation on rats, mice, and hamsters and found 
tumors at 250 pa:r·ts per million (ppm) which were histiologi·· 
cally similar to those or the Goodrich workers. 
As the FDA was concerned about what drugs might c.ontain 
vinyl chlor·ide or were packaged in PVC with the potential oJ 
the leaching or extracting of vinyl chloride from the PVC, a 
Federal Register Notice was published on April 22, 1974, 
detailing information the agency required to understand the 
extent of the use of vinyl chloride and polyvinyl chloride 
in drugs and drug packaging. The request was authorized 
ttnder Sections 201, 510, and 70l(a) of the FDC Act, and 
required each manufacturer registered under Section 510 to 
submit (60): 
1 •. reporting firm name, address and 
registration number. 
2. list of drugs containing vinyl chloride 
and a list of drug products for which 
polyvinyl chloride is used as a container 
or container liner. 
In addition, the following information was requested, but 
not required: 
3. National Drug Code number, if one' had , 
been assigned. 
4. statement if drug is OTC or prescription. 
5. route of administration. 
6. amount of vinyl chloride in average daily 
dose. 
7• quantity of drug distributed in the past 
twelve months. 
B. copy of label and labeling. 
9. vinyl chloride content of the polyvinyl 
chloride used for manufacture of container 
·or .liner. 
10. rate and level of extraction of the vinyl 
chloride from the polyvinyl cnloride. 
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11. rate and level of absorption of vinyl chloride 
.as an ingredient or of vinyl chloride extracted 
from polyvinyl chloride liner or container by 
the drug as an average daily dose. 
12. name and address of the manufacturer of the 
polyvinyl chloride resin. 
These data were sent to Drug Listing for coding, then to a 
member of the Bureau's vinyl chloride committee. The 
responsibility of the analysis and evaluation of the 146 
polyvinyl chloride reports, ranging from a single page to 
over 100, was delegated to the author. The points felt 
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to be pertinent for initial use were investigated: drugs 
containing vinyl chloride as an ingredient, amount of vinyl 
chloride in an average daily dose, vinyl chloride content of 
the polyvinyl chloride used for manufacture of container or 
liner, rate and level of extraction of vinyl chloride from 
polyvinyl chloride, and the rate and level of absorption of 
vinyl chloride.· Upon completion of the initial analysis, a 
report "'as written to the Bureau of Drugs representative on 
the vinyl chloride committee, indicating the ;results of the 
pertinent pOints.: 
1. Nanufacture Compl:i3l1Ce 
a. list of the firms that responded. 
b. completeness of the reports. 
2. Results 
a. drugs containing vinyl chloride as 
an ingredient. 
b. vinyl chloride content of polyvinyl 
chloride used to manufacture con-
tainers ru1d liners. 
c. rate and level of extraction of 
vinyl chloride from polyvinyl 
chloride. 
d. rate and level of absorption of vinyl 
chloride. 
3. Potential Problem Areas 
A second analysis required some quantification of the 
data from the reports, to determine the impact certain 
regulatory actions would have. The first fifty polyvinyl 
.chloride reports were examined for information on the num~ 
ber of cap liners, containers, and blister material used 
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in drugs with approved NDA's vs. drugs which did not require 
NDA's. The second analysis included all 146 reports to 
determine t;he number of cap liners, containers, and blister 
material of all drugs vs. solids made of polyvinyl chloride. · 
These results 111ere submitted to the Office of Regulatory 
Affairs to aid in the drafting of ~deral Register proposed 
rules on drugs packaged in polyvinyl chloride. Additional 
sem•ches o.f ·the data '<'ere made upon request. The names of 
some Bolid d·osage forms in blister packages \'lere sent to the 
Bureau o£ Drugs l'harmaceutical Research and 'I'esting Labs so 
they could be ro:1alyzed for PVC content and those tirms which 
included b:i•c1.ogic.al products in their reports were sent to 
the Bureau of Biologics. 
Interb:u:reau ro.eetings on \vhat action the l!'DA should take 
on PVC used in all of the products were held and the student 
v1as HllovFed to attend these discussions. They provided 
insight into the interrelationship of the various Bureaus of 
the agency, and the procedures involved in the development 
of FederaJ:...B.'?:E}S.!fl:_ rules and ref!,'Ulations. 
In thee pulmonary drug products, a fed.rly unique dosage 
form has, in the recent years been under close scrutin;r by 
the FDA. The metered aerosol has a valve that delivers a 
measu:c-ed dose to the patient. The proper metering of the 
valve is especially important as some of the more potent 
pulmonary drugs are administered via this route. 
Two recalls of metered aerosols ea~·ly in 1974, due 
to leaking propellents from the valve which led to a c.on-
centration of the active ingredients and subsequent over-
dose of the drug through the valve, caused concern with the 
supervisory chemist as to the adequacy of the function of 
all other metered aerosol drug products. The author was 
requested to compile information from IND's and NDA's about 
the metered aerosols which included: IND/1TDA number, trade 
name, sponsor, valve type, container, manufacturer, gasket, 
seal, diaphragm, material supplier, composition, dosage form, 
expiration date, if any, and ioihether the drug".was OTC or 
:prescrigtion. To obtain the information, over 60 HTD' s and · 
NDA' s were surveyed. T\vo memos were i1ri tten •·ri. th the in.forma-. 
tion. The first i'laS for the. information of the revievrer on 
the type of problem that had occurred warranting the recall. 
T'ne second covered the results of the search: discontinued 
or vii thdravm IND 1 s or NDA' s, the background of' the valve 
problem, the types of valves used by the firms with metered 
aprosols, and the problems \1hich occ'\.UTed in obtaining this 
information. 
The assignment familiarized the author with DTD/NDA 
contents, the Indexing and Abstracting service, documents 
control, m1d the importance of valve and mouthpiece in 
obtaining proper dose. Additionally, processes involved 
in the manufacture of aerosols which included stability of 
I 
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the entire unit, quality control testing done on metered 
valv-es, cold fill (one stage) vs. ~~o stage fill, suspension 
vs. solution, control of parts or components, spray tests, 
particle size distribution, was presented. 
In addition to problems with the valves of metered 
aerosols, the gaskets in some of them contained small 
amounts of the potential carcinogen, 2-mercaptoimidazoline. 
A Federal Register notice of May2, 19?4, stated that the 
possibility of 2-mercaptoimidazoline rearranging to form 
ethylenethiourea, a known carcinogen, existed. The notice 
proposed that the use of the chemical as a stabilizer in the 
neoprene rubber parts would be prohibited. The task was to 
locate those firms >1Tith metered aerosols that"·use gaskets 
;;i tb. the compound. The search '11Tas incorporated into the 
seeking of inf·ormation on metered aerosols. Once this 
irlformation vla.s obtained, two memos were written. The fh'st 
was to the master files of those firms which had 2-
mercaptoimidazoline in their gasket formulation to po:i.nt 
this out to reviewers. The second memo was·sent to the 
supervisory chemist ar1d listed which metered aerosols had 
the stabilizer in their gasket formulations. 
Following the work on the special projects assigned, 
the author began revie~ling the chemist 1 s portion of many 
IND's and NDA's. The types of IND's included one new chemical 
entity, two new dosage forms, seven individually sponsored 
(noncommercial~·marketed), and one IND amendment.· One 
original NDA was reviewedin its entirity. Several 
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supplements and an amendment which included information on 
stability, particle size distribution, labeling, overfill, 
manufacturing changes, container changes, additional quality 
control procedures, and annual reports 'ITere also reviewed. 
Additionally, the student worked with a medical officer on 
the organization of one of the agency's most lengthy NDA's. 
The chemist's review of the NDA required careful 
examination of techniques, calculations, drug master files, 
and data to evaluate its adequacy. ·The review process is 
very individualized and each reviewer develops his own pro-
cedure from experience with the documents and consultations 
with fellow revie'llers. The student developed her O"!ll pro-






Scan. Brief survey of the document to 
beCOme familiar with its contents. Note 
deletions of any sections of the regulations. 
Background. Check documents room for cur-
rent correspondence, amendments, related 
documents, and other action taken relating 
to the drug. 
Guidelines. Review the requirements in 
~orms 1571 or 356H. Study Guidelines: 
Manufacturing and Controls for IND'"'S"a:nd 
NDA 1s written by ~~A and Pf~. 
Gross Review. Reread the submission again 
tak~ng note of \vhat is or is not included. 
Resears~· Utilize reference texts, articles, 
and other sotu-ces to gain familiarity with 
any areas that are unknown. 
Revie\•1. Close scrutiny of the document. 
Take one requirement at a time using the 
PMA-FDA Guidelines and other sources. 
Consultation. Possible conferences with 
surei~or, colleagues, team members, 
advisory committees, the Associate Director. 
for New Drug Eval.uatL:m, and the Director 
of the Bureau of Drugs. 
B. Write Review. Include summary under each 
heading of' i'he information submitted 1Hith 
explanations as to its adequacy. 
9. Decisions and Recommendations. From the 
notes and review, determine the comments to 
be included in the chemist's portion of the 
letter to the sponsor. 
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10. Draft letter. The chemist's portion of the 
letter to the sponsor of an IWD includes the 
listing of the deficiencies and asks for 
additional information. \'lith the NDA, the 
application is either approvable or non-
approvable. The decisions must be supported 
by citing sections of the Act, and making 
statements that explain the types of def'icien·-
cies and V<hy. In supplements to NDA' s, · the 
chemist writes the letter to th~. firm stat:i.:ng 
the decision and the reasons- · 
The contents of a drug master file were also presented 
to the author in that several of the mahuf'acturing and coll-
trols sections reviewed referred to a drug masterfile. The· 
drug master file is a document which is submitted by a 
supplier or manufacturer separate from the IND or NDA, and 
contains manufacturing and controls illformation which is 
pertinent to the document review. 'I'here are basically two 
reasons for the submission of a drug master file. The firm 
may either refer to their ovm drug master file 1.<1hich contains 
information c:ommon to several of their IND's or NDA's and 
thus decrease the amount of paper that must be submitted with 
each application; or they may refer to one of their suppliers' 
drug master files which possibly contains trade secret 
information the supplier does not went to disclose to·the 
new drug sponsor. 
Compliance 
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To obtain an indepth knowledge of the way in which 
Compliance acts to assu:re ·that drugs are safe, effective, 
of acceptable quality, and properly labeled, three weeks 
~;ere spent in the various divisions. Compliance has the 
responsibility of the establishment and enforcement of drug 
standards based upon the sections of the U.S. Food, Drug, 
and Cosmetic (F .D.&C.) Act pertaining to drugs. The perti-
nent sections include: 50l(a)(2)(B) Good Manufacturing· 
Practices, 501(b,c,d) Adulteration, 502 Hisbr~ding, 20l(p) 
and 505 Ne<r Drugs, and 506 and 507 Certification of Insulin 
and Antibiotics. 'l'he establishment of standards j_nvolves 
the development of regulations through the interpretation 
of these sections of the F.D.&C. Act. Although this process 
is considered interpretive, the regulations can and do become 
substantive through due process in the courts. Thus, the FDA 
goes into court with strong cases, for if the agency loses a 
case, the effect of regulation can be lessened. 
~'he enforcement of the st.andards set in the F .D.&C. Act 
and in the regule.tions can be either volunte.ry or involuntary. 
Voluntary means are reg;ulatory letters and recalls, and are 
not directly defined in the F.D.&C. Act, but are rather 
administrative methods utilized to curb violations before 
court proceedings are warranted •.. However, the F.D.&C. Act 
I 
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does provide for three legal mechanisms for its enforc.eme!lt, 
to include seizures, injunctions, and prosecutions. The 
regulatory letters and recalls have provided more efficient 
and sometimes more effective methods of insuring conformance 
to the F.D.&C. Act and its reB~lations. The regulatory 
letters have just recently been incorporated as the procedure 
used to deal with most first time offenses, and have reduced 
the number of seizure, injunction, and prosecution actions 
taken by the BQ~eau. This procedure carries with it a change 
in philosophy, that is, solutions to problems are sought in 
an administrative. \~ay which saves time through the encourage-
ment of voluntary corrective action. This is not to imply, 
however, that Compliance is being "less tough" on the 
. e• 
offenders. The letters cr.n•ry a good deal of weight in that · 
. the violations of' the F .D.&C. Act are cited, and the firm is 
requested to respond llithin 10 days or less conce1~ning the 
corrective action to be taken, or regulatory action (i.e. 
seizure, injunction, or prosecution) will follow. 
The fastest, most efficient method of removing products 
which are a potential hazard to health from the market is the· 
secondvoluntary compliance action, the recall. The recall 
involves the volrmtary action by a firm to remove its product 
from th(~ mar1cet t:hrough the notification of distribution 
centers, retailers, practitioners, and consumers about the 
hazards involved, and urging them to return all stocks. 
There are several types of recalls, depending upon FDA's 
involvement: 
l. FDA Initiated. 'l'he l!'DA requests tha:t the 
firm recall its product from the market. 
Although compliance is not mandatory, the 
firms generally .::omply, so as to avoid bad 
publicity. Only the Commissioner of FDA 
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and the Associate Commissioner for.Compliance 
may request such action. 
2. Vol1mtary: FDA Advised. The firm volun-
tarily recalls their product and notifies 
the FDA either before or after the recall. 
3 •. Voluntary: FDA Not Advised. The firm volun-
tarily recalls their product, and doesnot 
notify the FDA. There is no.requirement for 
the firms to notify the FDA about their recalls. 
The recommendation for an FDA initiated recall generally comes 
from a field report. If the firm does not agree, and a 
health hazard exists, then FDA can seize the product and/or 
"advert5.se" the problem, leading to bad publicity fer the .. . 
firm. So, although volunta:I?y, it is in the firm's best 
interest to :Lni tiate the recall vihen VJarranted. 
In addition to the types of ~·ecalls, there are classes 
of recalls which categorize the medical significance of the 
health hazard involved with the p~·oblem product. The class 
of recall is determined by a medical officer in the Office 
of the Associate Director for Compliance. These include: 
I. Emergency situation with imminent danger: 
the. cor1sequences are immedia.te or long rRnge 
and life threatening, and 100% effectiveness 
checks are done to individual pharmacies, 
ma.rkets, hospi -Gals, and possibly consumer·s. 
Examples include botulism, label mix-up on 
potent drugs, defective heart valves, excess 
radiation exposure, sub or super potent life-
saving drug. 
II. Priority situation: may be immediate or long 
range, not quite as life threatening as Class I, 
publicity given. Examples include sub or super 
potent drug (not life saving) or DESI violations. 
III. Routine: remote possibility of a threat 
to life. Examples include label error, 
mislabeling, subpotency, and leaking 
capsules. 
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The depth of the recall is determined by the severity 
of the problem and the distribution system of the product. 
It can go to the distributor (wholesaler), the pharmacy 
(retail), or to the consumer. The effectiveness and depth 
are monitored by the various district offices, mainly 
through telephone contact with the distributor and pharmacy 
(90%) with some visits (10%). The levels for the effective-
ness checks include: 
Level I: 100% effectiveness. Check all 
distribution, retail and possible 
consumers; e.g. Class I"recall. 
Level II: "intensive" eztensi v·e coverage (not 
100%). "normal" 1096 of the direct 
(distribution) accounts per district 
with two customers per direct account. 
Level III: 2% direct accounts and one customer 
per direct account. 
F'or the Class III recalls, the effectiveness checks are the 
exception rather than the rule, howev·er, in a case of a 
Class I recall for botulism, the whole district office con-
tributes t:i.me to the effectiveness checks to make certain 
that all of the adulterated product is removed from the 
m=ket. 
Under the authority of Chapter III of the :B'.D,&C. Act, 
several legal actions can be taken fo:v violations. 'l'hese 
actions include seizures, injunctions, and prosecutions. 
Generally the initiation of one of these actions is made by 
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the district offices. The cases are prepared by the district 
compliance branches and sent to Compliance, Bureau of Drugs 
for evaluation, development, and coordination through to the 
General Cotmsel of Health, Education, and Welfare, the group 
that will generally try the case. (The U.S. District 
attorneys will at times handle the cases.) 
A seizure is a civil action taken against the "goods" 
(i.e. violative product). An example of such acti.onis FDA 
vs. Amygdalin Injectable. and Yellow tablets which is a new 
drug on the market without an approved NDA, and was seized 
to prevent its sale or distribution. The process for a 
seizure action is described as follows. The drug is suspected 
as being misbranded or adulterated. The investigator (FDA 
field personnel) collects an official samplE>. 'rhe sample 
is submitted to a district lab for analysis. The lab work-
sheets, coupled \;lith the inspection report are sent to the 
district's Compliance branch where a summary and recommenda-
tions for seizure is developed according to guidelines which 
define those violations which warrant seizure. If the vio-
lation is not d.e.fined in the guidelines, the district confers 
with Compliance, Bureau of Drugs, for approval of the seizure 
action. ~~he seizure notice is then sent to the u.s. District 
Attorney who, in turn, contacts the u.s. Marshal.. The u.s. 
Harshal puts a \vri t of Attachnrent on the goods for a set period 
of time, while a claim and answer to the violations are filed 
with the court by the offender. A bond, which is greater than 
the product worth, is put up while the product is being reworked. 
If, after reworking, the product does not comply, the 
offender can be held in contempt of court, and the product 
is destroyed. This action may lead to prosecution of the 
responsible individuals. 
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Injunction involves court action against a firm and/or 
responsible individuals to restrain violations of the pro-
visions of the F.D.&C. Act. The injunction prohibits the 
firm from producing its product(s) when inspectional reports 
indicate that the firm has a history of violations of the 
F.D.&C. Act and continues to do so, although responsible 
individuals have been notified about them, and warned to 
correct them. The injunction is filed thirty days after 
the last inspection with the following information: .firm 
officie.ls involved, investigation findings with citations of 
the sections o.f the F.D.&C. Act violated, recommendations 
based on the findings, and possible affidavits on CGMP's 
to document deviations. A requesi; for a temporary restrain• 
ing order (THO) may be obtained to prevent distribution of 
the products manufactured under poor conditions. The court 
then sets a brief hearing on the TRO and gives the defendent 
firm time to present its case. Several days later, a full-
fledged hearing on the injunction will be held, after which 
the court rules on the order. When appropriate, the injunc-
tion proceedings may also provide for a recall of all products 
manufactured during the violative period as noted in the 
injunction recommendations. 
The third legal mechanism is the prosecution. The 
prosecution taken against the firm and r·esponsible individuals 
based upon a history of problems and past regulatory actions. 
The action is based upon inspectional evidence that sho•tls 
the firm has not observed essential control elements and a 
record of faulty past performance, which might include 
several recalls, seizu:r.•es, an injunction, or a combination. 
As the prosecution is a lengthy procedure, these other actions 
are considered in advance. The defendents in a prosecution 
can include the firm's responsible individuals (e.g. presi-
dent, vice president, directors of qua.lity control and manu-
facturing), a corporation, or an association. Prior to 
prosecution, citations (provided for in Section 305 of the 
F.D.&C. Act) are given to the defendents which. state the 
cause for the contemplated criminal action. The legality 
for citing the firm's responsible individuals, e·v-en though 
they may have no knov1ledge of the wrongdoing, was tested in 
the famed u.s. vs. Dotterweich case in 1.943. The case 
involved the president and general manager of the Buffalo 
Pharmacal Company, Dotterweich, who was tried for violation 
on three counts of Section 30l(a) of the F.D.&C. Act which 
prohibits the introduction of misbranded or adulterated drugs 
into interstate commerce. He was four;d guilty on all three 
counts in the lower courts. The Circuit Court of Appeals 
reversed the conviction, hov:ever, on grounds that only the 
corporation was the "person" subjeet to prosecution. The FDA 
took the case further, and in a landmark decision, the con-
viction was upheld in the Supreme Court due to a unique 
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interpretation of the F.D.&C. Act, which dispensed with the 
conventional requirement for criminal wrongdoing: "the aware-
ness of .some wrongdoing" (61). 
This, then, makes the top officials of a firm (i.e. 
those who can control what happens in the firm, for example 
extra moneys for quality control on the products) responsible 
for all of its activities. Prosecution is a lengthy court 
procedure, and :i.t generally takes many months to prepare. 
~'he charge may be either a misdemean.or or a felony depending 
upon the incidence of bodily harm from the violative act. 
This decision is not made within FDA, b1,1t rather by the 
prosecuting attorney. The penalties, as defined in the 
F.D.&C. Act, for the first. conviction can include imprison-· 
ment fer orie year or less and/or $1000 fine; a:nd for any 
additional convictions, imprisonment for three years or less 
and/or $10,000 fine (62) ~ 
To carry out its responsibility of the establishment 
and enforcement of the drug lm~ of the F.D.&C. Act, Compliance 
is divided into four divisions: Drug Nanufacturing, Drug 
Product Quality, Drug TJabeling Compliance, and IvJethadone 
Nonitoring. The divisions become involved in most phases 
of compliance from the establishment of standards and the 
development o.f programs designed to insure conformance to 
these standards to the final handling of cases recommended 
by the districts for violations. The concerns of the divisions 
frequently overlap with respect to the regulation of drugs as 
misbranding, adulteration, and poor manufacturing practices 
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are violations are difficult to separate. 
Drug Manufacturing 
The Division of Drug Manufacturing, under the provisions 
of Section 50l(a)(2)(B) of the F.D.&C. Act, establishes and 
enforces current good manufacturing practices (CGMP's) through 
its two branches: lVJanufacturing Standards and Standards 
Assurance. Thus the division.concentrates on the adherence 
of the firms to CGMP's through the development and direction• 
of compliance programs designed to police the drug industry 
through field inspections of the manufacturing in-·process, 
and the recommendation and coordination of the cases involving 
compliance actions taken regarding violationr; of CGl'lP 's. 
These functions overlap with those of the Divisions of Drug· 
Labeling Compliance and Drug Quality Assurance, as in most 
cases, viola.tions of CGJ.V'"JP' s lead to misbranding and adul tera-
tion. 
As of late, the division 1 s functions have te.ken on 
increased importance. The Department of Defense's cha.c'1ge 
in the method of drug selection for purchasing, the ma.'l:imum 
allowable cost regulations (MAC) for the reimbursement by 
the Depar·tment of Health, Eciucation, and Welfare for drugs 
purchased under the Nedicaid and Medice.re programs, and the 
approach of some form of National Health Insurance have at 
least one view in common: all assume that the FDA assures 
the quality of all drugs. In order to assure the quality of 
drugs, the way in which they are manufactured must be ade-
quately controlled. The realization that one cannot "test" 
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quality into drugs, but must rather "build" it into them has 
taken on increased significance, especially in this division. 
The responsibility for the development of the CGMP 
regulations resides in the Manufacturing Standards Branch 
of the division. The regulations are included in 21 CFR 
Part 133, and discuss, in general terms (using such \'lOrds 
as "adequate" and "sufficient") what s:nould be done in the 
~anufacture and control of good quality pharmaceuticals. 
Until this year, these general "tunbrella" CGMP • s \'lere all 
the agency had to enforce 50l(a)(2)(B); '1hich made court 
proceedings rather lengthy as these CG~W•s would have to 
be defined by lmown experts for such individual case. The 
· · conc.epts have changed, and with the reorganization of the 
Bureau of Drugs in October 1974- \'lhich led to the development 
of this branch, more specific regulations will be pu.bli~Jhed. 
The new approach to CG1·W' s is th:!:-ough its manufe.ctu.":ing 
process. The first of these specific CGMP's to be published 
will be those for the manufacture of large volume parenterals. 
Problems that have oc.curred, most evidently and dramatically 
since 1956, identified this area of' need for stanclards in 
menufacturing practice. The production of sterile, pyrogen-
free large volume pa~enterals is a good case where it is 
essential (potentially life saving) that qua1ity ·be built 
into the products. The. United States Pharmacopeia XIX in 
its definition of Sterility Tests reenforces this thought 
by stating that "·t;he significance to be attached to a demon-
stration by test that a drug or device has been rendered 
sterile is determined largely by the extent of the control 
exerted during the manufacturing an.d sterilization pro-
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cesses" (63). The proposed regulations for large volume 
parenteral good manufacturing practices were a compilation 
of expertise from industry and li'IJA. . They provide detailed 
information about those areas considered to be critical in 
assuring a good, sterile large volume parenteral. These 
areas include: water and air quality, sterilization equip-
ment, sanitation, sterility and pyrogen testing, and stability. 
The CG!1l?'s, with the pooled knowledge from the manufacturer 
and re~~latory agency, will improve processing techniques ro~d 
will·hopefully avoid recurrence of the problems that have been 
plaguing the large volume parenteral industry;· 
Another example of some proposed. work would be specific 
CC'rl1l?' s on tableting. The tableting process could be broken 
down into t'••o categories: the types of tablets to be made 
(coated, time release, uncoated) and the amount of active 
ingredient included (low dose-high potency vs. high dose-low 
potency). These CGMP's would describe the various types of 
granulations or slugging, drying cor-trol (with its effect on 
stabilit-y), lubrication, grinding (size of. granules), mixing 
time, tableting (to maintain proper pressure), and coating 
(which can create a variety of problems if not done properly). 
The project of developing the specific CGf.'IP' s is sizeable, 
and will take many years to achieve. It will be a big step 
for\...-ard towards assuring that drugs on the market are of the 
highest quality. •ro assure that the drug industry is aware 
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of the development of CGMP's, so as to be able to conform 
to the standards, the br&~ch serves as an education coordi-
nator and liaison to the industry. 
r-~ 
~~e Standards Assurru1ce Branch has the responsibility 
of enforcing the CGMP's developed by the Manufacturing 
Standards Branch. Through the investigations, lab findings, 
and recommendations of the Compliance Branch of the FDA 
district offices, the Branch provides for uniform i.nter-
pretation of the firm's compliance with CGMP's. The field 
.reports are evaluated by the Branch where determinations are 
made as to whether regulatory actions based upon CGHP vio-
lations are v1arranted through checks for misapplication of 
policy or lack of evidence in the reCO!l';llJepdations. If the 
decision is made by the Branch to proceed t'fith complirulCe 
action, the case is developed further, and sent to the General. 
Counsel (DITElrJ) ¥There the proceedings e.re handled. 
Another responsibilityof the Branch is to provide 
information to New Drug Evaluation (NDE) concerning a com-
pany's adherence to CGMP's in connection -with the approval 
proce<;s of new drug applications,· abbrevj_ated new drug 
applications, supplements, and antibiotic or insulin certi-
fication. In the approval process associated with these 
documents, a statement is required about the Gl'lP 's of the 
firm. The divisions of NDE notify Standards Assurance that 
such a statement is required at any given time, the branch 
will send out a request for an inspection to the field, and 
will relay the results back to the appropriate NDE division. 
prug l':rodu.ct Qual).t;z: 
The Division of Drug Product (iua::Lity's name is 
descriptive of its function: to assure the quality of 
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drug products. This goal involves a variety of compliance 
programs vlhich are administered by. the division: drug 
quality assurance, antibiotic a.>J.d insulin certification, 
and drug product defect reporting. These progran1s are 
handled by the three branches of the division: Drug Product 
Quality, Antibiotic Certification, and Product Surveillance. 
The Drug Product Quality Branch directs the compliance 
prog:r.•an1s issued in the area of product quality .assurance by 
enforcing the adulteration sections of the Ji'.D.&C. Act.· The 
Branch differs :i.n jurisdiction from Standards ".Ass·t)_rance in 
the Division of Drug Nan1.l.f.s.ctur:i.ng in that its action stems 
from. laborato1~y findings of drugs already on the mark:et rather 
than from the in-process proceduras involved in the manufacture 
o:t the product. Again, the functions of the t1110 branches do 
overlap, but this is the definition given to separate them. 
The programs in the a-rea of drug quality assurance are 
the lm·gest in terms of the utilization of the field manpower 
for drugs. The programs involve th~ surveilla.nce of drugs 
on the market. This survey provides good data bs.se for the 
monitori!lg o:f the quality of drugs through the ce>llectionof 
random samples and subsequent laboratory analysis. In that 
there m·e many more drugs on the market that could possibly 
be tested, certain drugs are selected for inclusion in the 
compliance program. The selection is based loosely upon one 
of the following criteria: 
1. impact of' the drug: low dose-high 
potency medications. 
2. wide use: several chosen from the 
Gosselin "Top 200" drugs prescribed 
list. 
;s. therapeutic significance. 
4. documented production problem. 
Detailed information is sent to the district offices to 
implement the program. This includes the sampling plan, 
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the types of' lab tests to be done, and the drug products to 
be tested. The progra~ not only aids to identify possible 
industry-wide problems in production, but the use of several 
l!'DA laboratories in the analysis of the SB.'llples provides 
better coU.aberation of assay methods which lead to their 
improvement and. possible inclusion in the USP/r:.'F. If any 
drug product on the market is found to be in violation·of 
the F.D.&C. Act primarily through adulteration, the Branch 
will also develop and coordinate the cases utilizing the 
same tools (:regulatory letter, recall, seizure, inju..."lction, 
or prosecution) as the other divisions, depending upon the 
extent ct.'ld severity of the problem. 
The chief responsibility of the Product Surveillance 
Branch is to coordinate, evaluate, ·and monitor the . reports 
received from pharmaCists in the ·drug product defect report-
ing system (DPDRS). The system has been highly successful 
in providing a central location to \~hich the pharmacist can 
report defects in the products dispensed, thus adding an 
extra quality control check for FDA. DPDRS was initiated 
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through the combined. efforts of the United StatesPharmacopeia 
(USP) and the FDA to: 
·1. serve as a central location that would 
compile data on drug product defects. 
2. identify drug product defect areas and 
inform the drug manufacturers. 
~. follow-up on tho correction of the drug 
product defect. 
After two years in a pilot program status, the DPDRS has 
developed into a permanent, viable information source for 
drug product defects. It is cosponsored by the American 
Society of Hospital Pharmacists and many state and local 
pharmacy associations, and endorsed by the American 
Pharmaceutical Association and the National Association of 
Retail Druggists. The .USP and the FDA share the responsi-
bility for the .smooth flow of the 125 reports received weekly 
from pharmaci.sts nationwide. :!'he USP sends, receives, checks, 
and computerizes the DPDRS reports. The l<'DA Bureau of Drugs' 
Product Surveillance Branch reviews, evaluates, identifies, 
and follows.:..up on problems, in conjunction •"lith Compliance 
to aid in the maintenance of quality pharmaceutical products 
(Table II). 
The DPDRS is set in motion at USP, where periodic mail-· 
outs which include a cover letter, tvm DPDll.S forms (Appendix :!!'), 
and a po~1tage prepaid return envelope are sent to every ·pb.ar-
macy in the nation. In the letter, the program is ex1Jlained, 
and pharmacists encouraged to send in the reports to USP 








A.lerted to the 
problem. 
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1. InitiHtes drug product 
defect reports. 
2. ReceiVE:lS aclmo\vledgement 
from USP. 
3. May receive other "feed-
back". 
4. Provides valuable service 
tovmrd better quality · 
drugs. 
1. Assigns special number to 
each report. 
2. Immediate review :for 
health hazard. 
:;. Computerized drug defect 
report data. 
4. Provides liaison with 
pharmacists, sponsoring 
organizations, l!'DA, and 
ma.nu:facturers. 
5. Uses data base for setting 
drug stan.d;oJ.rds. 
1. Screens report. immediately 
for priority of action. 
2. Stores computerized data 
and makes '.;rend analysis. 
;. Pert·orms invest;igations, 
lab analyses, and sur-
veillance. 
4. Advises USP of .investi-
gational findings. 
5·· Uses data as bar•is for 
special programs or 
regulations. 
1. E"valuates report. 
2. May ccmmuni<~ate \vith 
pharmacist, :l"DA, or USP. 
:;. Corrects as necessary. 
T.Al3LE II 
Drug Product Defect Reporting System Flow of Documents 
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packaging, contents, or the drug itself, which could include: 
underfills or overfills,· foreign material in the prod.uct, 
broken tablets, mislabeling, or lealcing capsules. Upon 
receipt at USP, the DPDRS reports are dated, and checked 
twice by professionals for priori ties, i.e. imminen·!;ly 
hazardous situations, which are identified and relayed to 
the FDA by phone. Any samples submitted are bagged an.d sent 
to the FDA. The reports are then assigned an accession num-
ber (to be referred to in all communications), the daily 
log is typed, then checked by the pharmacist. A letter of 
acknowledgement is sent to the reporting phro.•macist along 
with two ne1-.r forms and a return ·envelope. Eight copies o.f 
the reports are xeroxed and distributed: six-·copics to tM 
:B'DA one COP"' to the product man'ltfactm•er, a.nd one copy i:o 
' ~· ~I 
USP's files. The forms are cod.Eld and l~;e;ypunched. for the 
comput.;:,r, both by the clerical and the pharmacy sta.ff, double-
checked along 1r1ith a check for the pharmacist on an off-·line 
printout. The keypunched data is then transmitted to magnetic 
tape and put into the Bureau of Drugs computer. 
On the same day as USP receives the·reports, the six 
xerox copies are sent~ to the Product Surveillance Sta.ff for 
evaluation, circulation, and :follow-up. Each report is 
evaluated individually ,md on a daily basis by the sta.f:f. 
From the review of both the reports and the USP phone calls, 
decisions are made concerning the potential problem, and 
those that could involve an imminent hazard to the patent 
are handled expediently. This immediate action could involve 
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phone calls to the pharmacist who sent the report, the 
pharmaceutical manufacturer who makes the product, or the 
FDA district office where the manufacturer is located. 
This is designed todetermine the exact cause of the 
problem, how widespread. it may be, and what measures need 
to be taken to correct it, i.e. inspection; sam~ling; and 
investigations leading to possible recalls, injunctions, 
or seizures. In the three years of existence, the DPDRS 
has been directly responsible for over 60 recalls. 
All reports are entered into the computer, and used 
in periodic trend analy·ses. The other copies of the reports 
are ciJ~culated to various I''DA offices to include the Bureau 
of :Biologics, Bureau of Diagnostics and Medical Devices, 
Ne'\OJ Drug :F;valuation and EDEO, depending u.pon their content. 
The follm·r-up on the DPDRS reports involves an inspec-
tion of the firm to determine 1t1hy the problem occurred So."'ld 
if any act on had been taken to alleYiate the situation. 
Thef'ollow-up inspection reports are receiYed by the staff, 
coded, and entered into the computer system against the DPDRS 
report accession number, to ascertain whether each report has 
been handled. This completes the cycle of the report from 
pharmacist to follow":'up. 
lin important aspect of the system is the.snalysis and 
interpretation of the computer printouts. These printouts 
are capable of listing defects by manufacturer, drug name, 
dosage form, defect type, accession number, and text from 
the pharmacist. 1Tend analyses ·Of these printouts can reveal 
certain classes of defects: 
.I. Defects in one product from one company. 
Indicates ei'!;her a breakdown of controls 
on the one product, or difficulty within 
the company to manufacture that product • 
. II. Defects in. several products in one com-
pany. Indicates a breakdown in the Good 
Manufacturing Practices of that company. 
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III. Defects in similar products on an industry-
wide basis. Indicates that the manufactt~­
ing technology has not been perfected on 
that kind of product. 
In the future, these printouts will provide an early detec-
tion mechanism, so as to catch a defect problem before it 
reaches recall proportions. 
Utilizing an untapped resource, the professional 
intimately involved >v:Lth the assurance that t};i,.;. patient' 
receives quality pharmaceutical products, the drug product 
defect reporting system fills a defil'li te need for the phe.rma-
·cist and the consumer. In the past year, the program has 
become highly successful and truly l!Jidespread, with a fifteen 
percent return on all mailouts, and with.one out o:f every 
three reports considered to be significant. It has increased 
the phac>macists 1 awareness of the services of' both the USP 
and the FDA, and has provided him with a mechanism through 
'1-lhich corrective measures can be ·taken. T'.ae early surveillance 
allows the agency to foresee and correct problems before they 
reach significantly detrimental proportions, thus increasing 
the agency's effectiveness as a consumer protection agency. 
Under the provisions of Sections 506 ond 507 of the 
F.D.&C. Act, the l!'DA has the responsibility to certify all 
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batches of antibiotics and insulin. The responsibility for 
the issuing the antibiotic and insulin. cer'cificates is in 
the Antibiotic Certification Branch of the Division of Drug 
Product Quality. The branch combines the information received 
from the Division of Antiinfective Drug Products of New Drug 
Evaluation where the IND's, Form 5's and Form 6's (NDA end 
ANDA for antibiotics) are reviewed and approved, with the 
laboratory results :from the National Center :for Antibiotic 
Analysis. A determination is made as to whether the batch 
can be certii'ied, and if so, issues the certificate. 
To better tmderstand the Branch's functions, a descrip-
tion of the· series oi' activities involved in antibiotic 
certification is needed. If a firm desires to market an 
"' 
antibiot:ic, the first procedures are similar to those used 
for any other new drug. An IND is filed with the Vi vision 
of Antiinfective Drug Products. M'ter the appropriate 
Phase I, II, and III testing is done, a l~'orm 5 is submitted. 
The Form 5 includes the same safety, ef:ficacy, manufacturing 
and controls data that are in a NDA •. The Divisiou reviews 
the application and mal~es a decision as to whether the 
application is approvable.· \Vhen it appears that the appH-
cation is likely to be approved; the analytical methodology-· 
included in the I•'orm 5 is sent to the National Center for 
Antibj.otic Analysis of Pharmaceutical Research and Testing, 
where the tests are run for validation. If the Form 5 is to 
be approved, methods to actually be used in the certification 
process are developed, validated, and published as regulations 
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in the ;F:,ederal Regis.E£. These published regulations are 
in.cluded in the 21 CFR Part 400,. and contain detailed 
.information about the types of tests (sterility, biological, 
chemical, and microbiological) to be run on the antibiotic 
and the procedures by ~lhich to perform them. 'I'he bulk of 
the approved antibiotic is sent in as the first step in 
pertification. All bulk antibiotics must be certified prior 
to the certification of the final <:lesage form. The results 
from the analysis, coupled ~lith those of the firm, are sent 
to.the Antibiotic Certification Branch of Compliance, for 
issuance of the certificate. After the final.dosage form 
has been prepared, an analysis is done and the results are 
sent to the B:ea.nch. Results from the 1ab, firm and the 
previously analyzed bulk are evaluated, compared, and checked 
for conformance t;o the regulations. If all is in order, the 
certificate is issued and the product may be marketed. About 
1% of the samples.submitted for certification per year are 
found to be below standards. The process for the certifica-
tion of insul:in is similar. 
The antibiotic and insulin certiHcation program is a 
unique regulatory tool for the agency, and. gives 1!"DA much 
tighter control over the quality of marketed B.J':ltibi.otics a.r:td 
insulins than any other of its reguJ.a1;ed commodities. . '.l'he. 
B~~anch, in addition to its power to prevent the marketing of 
drugs through noncertification, can also "decertify" a batch 
of antibiotic or insulin based upon post-certification data, 
and the drug then becomes misbranded under Section 502(1) of 
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the l!'.D.&C. Act. 
Dr-ug I;abeling Com.I!]i~ 
The Division of. Drug Labeling Compliance is concerned 
with a variety of regulatory activities which derive their 
authorit-y :from the sections of the l!'.D.&C. Act prohibiting 
the misbranding .of drugs. TI-ro branches: Prescription Drugs 
·and Over-the-C'..ounter Drugs handle the notification of the 
firms whose products are involved in the Drug Efficacy Study 
Implementation (DESI) program and the Over-the-Counter (OTC) 
drug ingredients reviews, about the ~.cJ.epal Rez~ state-
ments on those products, and implement the subsequent regu-
lations. These branches are responsible i'or the complim1ce 
actions (regulatory letters, seizures, in;jm:~ctions, prosecu-
tions) involving drugs >~hich require new drug appli(>ations 
(NDA) but are on the market without on<~. 'Ine third branch, 
JJrug Listing, has the responsibility for the direction of 
1.'he J!'DA Drug Product Listing and Establishment Registration 
Program. 
The Prescription Dr1.1g Branch handles DEBI, which is 
D(>aring completiot1. In addition, the Branc.h handl~s com~· 
pliance actions iz.wo.lving misbranding of prescription drugs, 
or violations of the new drug sections of the ]'.D.&C .. Act. 
The DESI program is one of' the more important projects ~;hich 
l!'DA has had to improve the quality of prescription drugs. 
The Kefauver-·Harris Drug Amendments of 1962 were respon-
sible for the existence of the DESI program in that the 
requirement that drugs be efficacious was added to the ne1rr 
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drug section. This implied that all dxugs that had NDA's 
from 1938-1962, which were reviewed for safety only, would 
have to be revie\~ed for efficacy. The task was an enormous 
one, as the FDA had to tackle over 8,000 drugs with its 
limited resources. To overcome the problem, a contract 
proposal was written. The National Acadenry of Sciences/ 
National Research Council (NAS/NRC) \~as designated to do 
. the revie"'· This body is composed of top scientists who 
have proven themselves in their respective fields prior to 
membership in the Academy, and seemed well suited for the 
job. The reviewers were divided into various panels, each 
covering a certa:in drug category with the drugs being revie'Ned 
individually by marketed product. T'.o.e data required \~a.s to 
be from \~<ell-controlled clinical studies on the effectiveness 
of each o:f the· drugs, along \-Jith other in:formation on the 
drugs to in<:lude the claims made for the product and a full 
l:l.st of its ingredients. The panels then revievmd the data, 
and came u,p with one of.the following conclusions (64): 
Effective: the evidence was adequate to support 
the claims. 
E.ffeetive with :reservations: the claim might be 
.effective, but some change. had to be made 
such as in labeling or in ingredients. 
P:ro'bably eff'ective.: more evidence was needed to 
support the claim, but likelihood was that 
the evidence 1·1ould be gathered. 
Possibly e.ffecti ve: the claim needed more study, 
but the chances that evidence could be 
.ga;thered to prove its effectiveness were 
· oit.ly moderate. 
Lacking substantial evidence of effectiveness: 
there was no scielitii'ic evidence to sup-
port the claim. 
Ineffective as a fixed combination: although 
each of several ingredients might be 
ef:fecti ve, combining them. did not mak.e · 
the drug any more useful than if one or 
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more of the ingredients were used separately. 
The reports from the NAS/NRC review on the effectiveness 
of the over 7,000 drugs (with many more claims, each claim 
being examined individually), vrere released from 1967-1'~69. 
It was then the FDA's responsibility to interpret them accord-
ing to agency policy, and implement them. In 1968, a task 
force vms formed \'lhich led to DESI. Timetables were estab-
lished fo:e manufacturers to meet requirements cf proving 
In addition, although the NAS/NRC panels reviev;ed each drug 
product separately, these M~!...B§~~iP~ not;ices contained 
statements that applied not only to that particular drug 
product, but to all identical, related or similar products. 
Thus, :i.n essence, all drugs ("me-too's", i.e. generics, 
included) that had not submitted evidence to the panels would 
be subject to the agency's rulings under DESI. This "class 
action" s.s it is termed, \<las no"!; without opposition, and was 
contested in the courts. The :B'DA, ho~mver, won its case, 
and the "class action'' 1r1as implemented. 'l'he timetables to 
allo\<l the firms to respond to a "less tha<'l effective" status 
as def'ined by the NAS/NRC have all been published in the 
Federal Registe~ using the guidelines of: one year with 
reasonable extensions for probably effective; six months for 
possibly effective; and sixty days for i.neffecti-ve. 
Allowances were made for the firms to have s.ut:ficient 
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time during which to set up adequate clinical studies, and 
in Some cases, reformulations of a drug product warrmited 
reclassification into another "less than effective" class, 
thus extending time. The related, similar, or identical 
products were identified by the districts. This information 
~ras sent to compliance so that all manufacturers could be 
notified of FDA's position on the NAS/NRC review of their 
product and of the timetables that had been se·i; up for 
supplying information as to the effectiveness of their 
product. The reformulations or changes in labeling of tb.e 
drug products required additional revie~; to d.etermi.n.;·, their 
status in light of the revisions. As most of the NAS./NRC 
panels ha.d finished th(~ir ,.;ork a.nd been disbanded, the 
assignment fell to the six revie~r divisions of :Ne\'1 Drug 
Evaluatj.on. The incoming data (clinical, pharmacological, 
manui'ac-turing and controls) 'I'Jas reviewed fol' safety and 
efficacy by the various disciplj_nes depending upon the 
nature o:f·the changes. The new status of the drug is then 
published in the ~·al_R~tElr.• and if it is less~tha.'l­
effective, the drug will be removed from the market. 
If the time runs out and no information has been 
received, or it is inadequate to substantiate effectiveness, 
letters are sent to manufacturers allowing 10-15 days to get 
the drug off the market. Most firms anticipate this type of 
action and deplete their stock so as not to necessitate a 
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recall. The district offices, then, in the DESI compliance 
programs, follow-up on the drugs to det;er:nine if the drug 
is indeed off the market. If the firms. have not complied, 
regulatory action "'ill be taken. 
To notify healtb.·practitioners about products which 
have been classified·as ine.ffective and are to be removed 
or have been removed from the market, a listing has been 
compiled by the Branch. This is to be directed to pro~· 
fessional organizations, state officials, and others, on 
request. This will aid the pharmacist in clearing the 
inventory o.f those products which are ineffect:i_ve and in 
explaining to the consumer the reason \~hy he can no longer 
purchase those particula.r items~ 
In addition to its DESI responsibiliti.es, the 
Prescription Drug Branch must make certa:i.l:. the "new :irJ,gs" 
are uot on the market vii thou-t; an approved nevi' drug appli-
cation, and. that prescription drug manufacturers are in 
compliance with the labeling of their products. 'rhese mis-
branding violations are generally received in reports from 
the field, and the cases are evaluated and·coordinated 
tbx·ougb. the Branch much the same as the other Compliance 
bra."lche s operate. 
The OveJ?-i;he-Counter Drug Branch 1 s responsibilities in 
the en.forcement of the OTC panel monographs are just begin-
ning as the Prescription Drug Branch i.s finishing DESI. The 
OTC panels have been meeting only since 1972 and have released 
the first 3 of 19 reports. They are conducting their review 
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in a manner that is a bit different from that of the NAS/NRC. 
There are over 26 drug ingredient categori<~S identified which 
.have been assigned to 17 panels. The drugs, instead of 
undergoing product by product evaluation, are being studied 
for safety and efficacy by ingredient. The operations of 
the OTC panels are much more open than those of the NAS/NRC. 
The FDA had received criticism for the secrecy in which 
decisions on drug products leading to DESI were made, and 
thus a.ttempts have been made to keep them as open as possible. 
The reports published vlill be incorporated into EQ.~.J'~. 
~f}:t;~~L monographs, and will contain the information about 
what ingredien·l;s products can contain and hovl these products 
may be labeled. The Division of OTC Drug Evaluat:ion in DI11g 
Monographs has the responsibi.li ty for ooo:t'd.:i.nating the panels 
and. the Branch has the responsibilit-y "to enforce the mono-
graphs from their reports and monitorj_ng their implementation.· 
For :fm•the.r discussion, see Drug Monographs., Division of OTC 
))rugs. 
Legislation which gave authority to the l!'DA in an area 
essential to the regulation of drugs was finally passed by 
Congress in 19'72. The Drug Listing Act authorized the FDA 
to obtain a cm·rent listing of every dru.g manufactured or 
processed. under the F.D.&C. Act. Thus, this much mleded 
in:forruation will soon be a reality. The Drug Listing Branch 
of the Division of Drug Labeling is responsible for assembling, 
evaluation, and coding this tremendous amounts of data on some 
167,000 human drug products, 5,000 veterinary products, 9,000 
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biological, blood and blood derivatives, and 13,000 i!L...Y.:[:ttQ. · 
diagnostics (65). The data to be accumulated will include: 
name of the drug, manufacturer, quantitative listing of the 
ingredients, classification according to any special 
authority of the F.D.&C. Act under which the drug is 
marketed (NDA, antibiotic, insulin, or animal drug), labeling 
and package insert, and for the non-NDA prescription drugs, 
copies of advertising. The information is being computer 
programmed and should be readily retreivable by 19?6. \'lith 
the advent of this new information, the regulation o~ drugs 
\'!ill become facilitated as FDA 1-1ill have a better knov;ledge 
oi" the products on the market. 
Metha.done l"ioni to:rirw: 
....,,_~...,...,.-~ ....... -~---
The primary responsibility of the Division of Methadone 
Non:ttoring is th>e control of the distl'ibution of methadone 
to ·nro:cotic addiction treatment centers a11d to hospital 
pharmacies for use as an analgesic. The Division works 
closely with the Drug Enforcement Agency (DEA) and helps 
coordinai;e the activities of other federal, state, and local 
methadone monitoring programs. 
Nethadone ha:s beenput under strict control only in the 
past decade. In the early 1960's, the d~'ug was on 'the market 
.for its ani;itussive and a.nalges.ic activity and was under 
invest:igation (IND) for use in narcotic addiction treatment. 
It was then limited to use as an analgesic in narcotic addic-
tion treatment by the Comprehensive Drug Abuse Prevention and 
.. 
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Control Act of 19'?0. A special IN.D form and DEA licensure 
were required for maintenance therapy. ]'rom 1970-1972, the 
P.rug was distributed through any pharmacy. Pro bleras with 
the control of methadone became evident to both FDA and DEA 
as physicians were. prescribing the drug wi thou1; regard for 
the special requireJJlf:'.nts. Jl decision was made to either 
limit the distribution or stop it altogether. In 1972, 
regulations were written which required a closed system of 
distribution of methadone. These regulations were not with-
out opposition. Methadone may now be dispensed only in 
narcotic addiction treatment centers which meet the FDA and 
DEA requirements and in a limited number of approved hospital 
pha:r.•macies j:'or use as an analgesic. 
The Narcotic Addict ~'rea·l;ment Act of 1974 defined the 
requirements :for the use of methadone 'in tne centers. These 
re qui.rement;s al:?e : 
1. registration with DEA of any treatmen·t program 
using any narcotic drug for treating addiction. 
2. adherence to the DEA security and record-
keeping regulations. 
3. adherence to the medical st&"l.dards of. narcotic 
. addiction treatment (rehabilitation) as set by 
the Secretary. ( 1'o dai;e, methHdone is the 
only drug with such standards, therefore 
ruling out the use of other narcotics.) 
· 4. file special IND form. 
~'he Federal Interagency Methadone Review Board shares the 
responsibilities for monitoring methadone and is made up o.f 
representatives from FDA, DEA, National Institute for Drug 
Abuse (NIDA), and the Special Action Office for Drug Abuse 
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Prevention. ·The. FDA has the responsibility of revie;dng 
the IND's and inspectj.ng the treatment centers using 
methadone (done by the field investigators). DEA licenses 
the programs. NIDA is concerned with the psychological 
rehabHi tation. of the addicts, . in that methadone is only 
used for maintenance, not for treatment of addiction, this 
aspect is very important. 
The use of methadone for analgesia in hospitals also 
carries a number oi' special requirements. Hospital pharma-
cies must be approved before they ean dispense the drug. 
In addition, the approval commits the pharmacist to maintain 
the s'>cm.•i ty of the drug and obtain a statement from the 
physician statiz.lg that: "Methadone is to be used for 
analgesia in patients with severe pain"; thus the physician 
cannot set up his own e.ddiction treatment program ~~i·thout 
the_ proper :forms. If not used properly according to the 
signed statement, the physician can be held liable for not 
adhering to it. (The drug is generally used :for analgesia 
in (\flllCer patie11ts, because il; has properties similar to 
morphine, but is longer acting.) 
Methadone is the first drug to have a limited NDA, that 
is, the ch'ug has speciaJ. controis ovel.' the conditions :for 
distribution and use. The authority for this action is 
stated. to stem from the safe and effective requirement in 
Section 505 of the F.D.&C. Act. If the FDA does not con-
sider the widespread distribution and use of a drug to be 
safe and efficacious, then it can impose a limit as 
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exemplified by the. methadone program. However, this 
approach has been contested in the courts in the case of 
·"~'he American Pharmaceutical Association (.APhA), three 
individual pharmacists, an~ a physician vs. the Secretary 
of HEW, Commissioner of FDA, Attorney General and the 
Acting Administrator of the DEA. The .APhA, et a.J .• , 
challenged the limited distribution of methadone in a suit 
brought against Casper Weinberger, ~h. in the u.s. 
District Court :for the District oi' Columbia in ~1ay, 1974·. 
The .lil"hA charged that the restrictions imposed on the dis-
t:ri bution of methadone exceeded the Ji'DA' s limits of authority, 
\vore discriminatory, and in violatim1 of due process !J!'Ovided 
for ill the Fifth Amendment. The chargefl 'de:ce c01mtered by 
ci'l;ing that the :l!'DA 1 s authority under the F .D.&C. Act allowed 
. the agency to control access to market of all ne\v cLcugs (21 
USC 371). In addition, the Drug Abuse Prevention and Control 
.Act o.f 1970 authorized the development of "appropriate methods 
of professional practice in the medical treatment of ••• 
narcotic addicts." The judge ruled in favor of the APhA 
(lowe~' court decjsion) and this decision is now in the process . -· . 
~'he outcome of the appeal will have an impact on the 
future of J!DA' s control over lim:i:l:;ing the distribution e.nd 
use o.f certain drugs. ~1ethadone is, at present, "in-behleen" 
the investigational and approved ne\v drug stages. If the 
limited. use concept is sanctioned by the courts,.then tho 
the approval of. drugs v;hich are considered to be 
inapproprj.ate for general use but rather for certain 
specialties, may come into existence. 
Biometrics and Epidemiology 
Biometrics and Epidemiology provides several valuable 
services to the other areas of the Bureau of Drugs. The 
DiYision of Biometrics works with Ne\'1 Drug Evaluation on 
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the review of IND 1 s and ND.A 1 s; ~~i th Pharmaceutical Research 
and Testing on the development of analytical methods; and 
\'lith Drug I1onographs on the analysis of bioavailabili ty data. 
The collection, evaluation, and dissemination of ii1formation. 
on the toxic ei":fects of drugs is provided by '!;he Division of 
Poison Control and the same functions in relation to adverse 
drug reactions are furnished by the Division of Drug; 
Biometrics 
.,_,_,.__..,..,.....~ 
Supporting the Bureau in its programs requiring statis-
tical or biomathematical services, the Division of Biometrics 
is relied uponheavily. The Division conducts research and 
development in methodology in statistical ·a.."'1d biomathemai.:ical 
services, and evaluates ne\1 statistical methodologies. Com-
puter programming for the statistical andbiomatb.ematical 
computations is also performed by the Division (1>3). 
New Drug Evaluation, with its responsibility to review 
IND's and NDA 1 s frequently requests a statistical review of 
data submitted.· 'l'he responsibility of the statistician 
reviewer is described in the section of this report on 
New Drug ~'valuation. In addition, the statistician may 
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be requested to revie'tl the bioequi valence data in an. llNDA 
£or Drug Monographs. He may become involved in the review 
o£ both the design and the evaluation of data in these 
studies. It is important that the design of the study be 
reviewed prior to its conduction because variables can be 
minimized, and statistically sound comparisons can be made. 
Once the studies have been completed, the statistician then 
analyzes the data for significant dif.ferences bet\~een the 
_ bioavailability of 'c;he generic drug product and the standard. 
In the Bureau of Drugs 1aboratories, the;·s·t;atj_sticia'l'ls· 
provide .input which will minim..i.ze variables' in the laboratory 
analysis and thus give more accurate results. 'fhe repro-
duc-ibib~ty of e:ny assay procedu.re is its n:ost important 
feature, for values that change due to the variances inherent 
in the assay invalidate it. An example of a projec·~ 1-1orked 
on cooperatively by this Division and PRT j,s the comparison 
of rad:i,oili1illtul0 vs. biological assay. 'fhe study is to ascer-
tain whether the radioimmune assay vJhich is much easier to 
do can be int,.;rchanged ~;i th the biological assa.y. Input 
fx•om the statistj_cian in both the design of the study and 
the analysis of' the results e:x:pediates the development of a 
useful procedure. 
A process through ~<hich the agency can solve a problem 
with limited manpower, is contracting. By contracting experts 
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in some field of study to work for a liroi tP.d time, resero:·ch 
is done on a particular problem. 'l"nroughout the chain of 
.events in contracting, the sta.tifr~ician 1 s input aids in the 
achievement of data .,.,hich are statistically valid. This 
chain of events can be described as follows. The agency 
recognized a problem for which additional data or a solution 
is sought •. The problem is thoroughly researched to determine 
its exact nature. Based upon the research, a memorandum of 
need is written which defines the problem a'ld the need for 
data to clarify or solve it. A projeGt officer and e.dvisor·y 
group are appointed to study the problem and to write a work 
statement. 'l'he problem mt1st be ;,rell understood at th:Ls po:Lnt, 
fmd the vrork statement should be. specific so· as not to obtain· 
superfluous information. Statistical input at this point is 
helpful in achieving specificity. :!!'rom the ~;ork st;a.tement, 
the cc>ntract officer dra\'lS up the contract which, after review, 
is announced in Commerce Busines£._])ailz. Proposals a't'e sub:'" 
sequently subnLi..tted, and _are reviewed by the. project advisory 
group and the contract officer, ~eading to the selection of 
a . qualifj.od contractor if one is available. .Du.:t"ing the co1:trse 
of thr; study, the contractor's 1t1ork is monitored closely by 
the project officer and contract officer "rlith the option of 
termination of the contract if the \'lark is unsatisfactory. 
If all proceeds well, the contract is completed and a report 
that aids in the solution of the problem is submitted. 
Poison Control 
The Poison Control Division works to support the 
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activities of the state and local governments in their 
poison contl'ol centers, by furnishing them. with information 
on the to:x:ic, hazardous, a.'ld caustic substances that may be 
:i.njested. The information includ.es clinical and statistical 
data on the toxic effects of drugs, chemicals, and household 
substances. Additionally, suggested educational programs 
.and. printed. material is supplied. The Division evaluates 
reports received on injuries and fatalities from the above 
mentioned substances, and through these evaluations, the 
determination of which substances require child-resistant 
packaging or special labeling is made with recommendation 
sent to the FDA and the Consumer Product Safety Commission. 
Furthermore 1 research on the treatment for persons \vho ·have 
injested toxic substances and on product modifications '.1hich 
are necessary to cut-doirm inj·uries is done (l~3). 
J!l'UiLl'~~-eE.,ee 
Although clinical trials are conducted prior to market-
ing of a drug to determine its. safety, adverse drug reac·tions 
with a 101~ incidence fail to be presented in these tests. The 
·function of the Division of Drug J<Jq>erience is to monitor drug 
experience reports on marketed drugs to serve as a warning for . 
any unforeseen adverse drug reactions. In this respect, the 
system works as a Phase IV follo\1-up program aiming to identify 
the adverse d:t'Ug reactions when a drug is used. on the general 
population. 
The adverse drug reaction data is obtained from physicians, 
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hospitals, and ~-ug manufacturers, and are reported on the 
Form FD-1639 (Appendix G). Copies of this form are sent to 
FDA and are numbered, card punched, and computerized using 
the Costart language for the reactions. The computerized 
printouts from the Form FD-1639 list drugs both by trade 
name and generic. The impossibility of delineating .the 
incidence of the adverse drug reaction in the absence of 
the number of exposures, leads the division to dependence 
upon two other surveys of adverse drug reactions, one in 
Boston and one in Florida for comparison. In Boston, 20-30 
hospitals participate in an intensive surveillance program 
and the incidenceo(reaction/exposure) of.the adverse drug 
reactions is obtained. The University of Florida conducts 
a surveillance of two hospitals to determine the number of 
adverse drug reactions. 'l'he comparison ·of the Drug Experience 
information tli th that. of the Boston and Florida studies is 
tabulated. If there are frequent occurrences of adverse drug 
reactions that are not listed in the drug labeling, .the dis-
crepancy is examined and evaluated with a possible labeling 
change being made. 
Pharmaceu:t;ical Research and Testing 
Pharmaceutical Research and Testing is the laboratory 
arm of the Bureau of Drugs. Located in downtown Washington 
D.C. (separate from the Bureau's main offices in Rockville), 
the laboratories develop methods of analysis for drug products 
and confirm these methods through collaberative studies in 
124· 
conjunction \dth the EDRO district labs. They work with the 
US:P/N.fi' Committee of Revision in the development of their drug 
monographs. All ani7ibiotics and insulin are test;ed in the 
labe as part of the certification process. Unb1own samples 
received from the field are analyzed. 'l'o accomplish these 
.functions, Pharmaceutical Research and Testing is divided 
into four areas: Division of Drug Biology, Division of Drug 
Chemistry, National Center for Antibiotic P~alysis, and the 
National Center for Drug l!nalysis. The National Center for 
Drug .Analysis is not pbysically located in Washington D.C., 
but is in St. Louis, Missouri, so that t;he author was unable 
to visit it. In addition to serving the Bureau of ~r-ugs, 
these l~tboratories support the efforts of the· district 
laboratories and aid other federal agencies ;vith drug analysis 
upon request. 
1kl.l6.J?io 1slliY., 
~~e Division of Drug Biology is predominantly rese~rrch 
oriented, studying the pharmacological and toxicological 
effects of drugs on biological and microbiological systems. 
The group aJ.,so develops bioassay a.'ld animal system utiliza-
tion techniques in the study of drugs. The four branches 
of the division include Drug Bioanalysis, Drug :Pharmacology, 
/' 
Drug JVii.crobiolog,y, and Drug 'l'oxicology. 
The JJrug Bioanalysis branch bioassays such fu'Ugs as 
digitalis, insulin, d-tubocurare, and some other endocrine 
drugs and develops new bioassay methods. ~·he amount of drug 
in the various organs is determined. Their bioanalytical 
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findings are correlated \1j_th the physiochemical methods of 
the division. Support and advice cu'e given to the field 
labs! USP/NF, and others on bioassays. The Branch is cur-
rently developing new radioiromune assays for various drugs. 
Drug Pharmacology is lnvolved with the development of 
animal models and the parameters to be measured for drug 
effects. The Branch supervises some extramural contracts, 
and does some studies which are on request from the New Drug 
Evaluation or Biometrics and Epidemiology sta.ffs ~;hich have 
detected problems not being researched by industry, academia 
or ·other government agencies. Some exmnples o.f the types of 
projects include the factors that influence the absorption 
of drugs into the brain and their seque1ae; i;he effects of 
nutritional deficiencies or enviro~~ental pollutants on drug 
absorpt:Lo::1; BJ."l.d behavioral teratology, drug interactions, 
and ei'.fects on the heart and respiration. 
Drug Htcrobiology has four areas of study: sterility, 
enzymology, taxonomy, and immunology. 'The· group· does pyrogen 
testing to deYelop better methods than the rabbit t0st; vlhich 
is time consuming ro1d expensive. These other methods include 
the lymulus lysaJGe and antisera, but false positives and false 
negatives have been a problem. Research into assays designed 
to determine microbial contaminants in drugs is on-going and 
the group warks with the official com~endia and other FDA 
units in their development. 
Drug Toxicology is similar in function to Drug Pharmacology, 
however, the studies deal with parameters used in testing 
•' 
toxicological effects of drugs and the manifestations of 
these toxic effects. The applicability to man of these 
toxic effects, i.e. animal models, is studied, along with 
the specific changes that o_ccur and their significance. 
!)rug Chemi~ 
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~~e Division of Drug Chemistry includes four brro1ches: 
General Methods Research Bra.."J.ch, Instrumental Analysis 
Research Brarwh, Drug Standards Research Branch, and the 
Natural Products Research Branch. . The General Methods 
Research Brro1ch updates and reviews the monographs in the 
official compendia and develops .methods for analysis. 'I'he 
Instrumental Analysis Resee.rch Brtmch handles the instru-
mentatim::, sn.pporting tb.e lli ;rision and intere.cts ~ii th all -!.;he 
ether bran.ches. The types of instrumentati.on available 
include: thi11 layer chromotography, infrared spectTornetry, 
gas ch-:•omotog.r·aphy-mass spectrometry, electron synthetic 
reactor, nucleal:' magnetic resonance, and liquid., .. liquid 
ohromotog:r.aplzy. ~'he brffilch, as an example, runs kno~m 
samples for drug stan.dards.. The Drug .Standards Research 
Br~.nc.h handles the IND/NDA methods validation requests 'tlhich 
come- i:n from Ne\·1 Drug E'valuation revie\<Jing chemists. The 
efforts of the districi; laboratory 'in thoir vJOrk on the 
valj_dation aTe coordinated. The bJ.'anch also does unknovm 
identification, with the help of the instrumental analysis 
brro1ch, receiving most of the samples from the field. Addi-
tionally, the group works with reference standards. The 
Natural Products Reseaxch Branch is responsible for methods 
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development and analysis of the hormones, and other natural 
products. 
National Center for Antibiotic Anallsis 
The National Center for Antibiotic Analysis is broken 
into five branches: Biology, Chemistry, Sterility Testing, 
Nicrobiologic.al Assay, and Antibiotic Residue. These 
branches share the Division's prime.ry responsibili.ty of' the 
analysis for certification of all batches of antibiotics. . 
The number of batches ranges from 20,000 to 21,000 per year. 
They reviev.•, validate, and develop the antibiotic cer•tifica-
tion tests to be published in the J!'ed§_ral Re_gi,ste:t;: and become 
part of the antibiotic.' s monograph. Problems dealj_ng with 
antibiotics a:t.oe investigated upon request .from other parts 
of the Bureau of other federal age.ncies. Consumer complaints, 
residues, and inspector samples that .need analysis fo:::> nn:t;i-
biotics i.!J.'e a.lso handled. 
The Biology Branch performs all animal testing i'or the 
antibiotics. This includes: pyrogen testing in rabbits, 
histamine testing .in cats, and toxicity and safet--y testing 
in mice. The Chemistry Branch certifies. and maintains the· 
official antibiotic standards. In addition, they perform all 
the chemical tests listed in the CFR which include: pH, 
moisture, identit--y, potency, and ash/heavy metal content. 
Sterility testing branch does its testing on all those samples 
required to be sterile. Tests using membra..11e filtration are 
the most common. 'rhe Microbiological Assay branch determines 
the potency of the antibiotic through microbiological means 
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either by cylinder plate or turbidome·t;ric assays. In 
addition, some work on official standards is done. The 
Antibiotic Residue group is divided beh1een regulatory work 
and research. The work consists of' testing official samples 
of foods for drugs (residues); certifying all antitumor 
agents (requires special precautions as they are potent 
drugs); and methods validation. This work involves inter-
action with the Bureau of l!'oods, u.s. Department of 
AgTiculture, Bureau of Veterinary l"Jedicine, Bureau of 
t·1edical Devices and Diagnostic Products, National Institute 
for Occupational Safety and Health and the Environmental 
Protection Agency. 
D.r-c'.g Monographs 
In the past fe\·J years, the FDA has pJ.accd increased 
err.phasis in c.<:l'taj_n problem areas of drug quality that either 
1rrere not recognized as such; or Ttlel?e identified, but manpower 
restric·!;ions prevented active pursuit for solutions. Que.s-
tions about the safety and ef'ficacy of over-the-counter (O'J:G) 
dr•;;g products, an ar·ea criticized, led to the development of 
the OTC drug ingredient review program. ~~e concern over the 
l):i.oequivalence of generic drug products he.s occurred in the 
last decade. The development of the digoxin bioequivalence 
problem emphasized the importance of the determination of 
the bioavailability of some drug products prior to the sub-
stitution of one for another. The coni'lict in the regulation 
of some drug products under the strict new drug applications 
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vs. the regulation of their generic equi.va.lent under the 
abbreviated new drug applications, and the lack of licensing 
procedures for others, has led to the discussion of a possible 
program to change the designation of some of the "new" drugs 
to "old" drugs, and to develop a monograph system to regu-
late the "old" drugs. The area of Drug Honographs is 
responsible for the implementation of these most recent 
agency policies through its three divisions: Over-the-
Counter Drug Evaluation, Biopharmaceutics, and Generic Drug 
Monographs. 
Ove:z.::::."!'he-,9ill]11ter Dr.)Jg EvaluFJ.tion 
The purpose of the Division of Over-the-Counter Drug 
Evalue:ti.o:n is the implementation of the p:r:·cgrruu desigllfJd to· 
eveluate for safety and ef'ficacy all ingredients included in 
over-the-counter (OTC) drug products. The division identifies, 
categori:<:ns, and gathers data on the ingredients in the O'rC 
drug products in preparation for their re·iTie\t for safety an<i 
eJ'ficacy by panels of experts. After panels are chosen, the 
division personnel serve to support and coordinate panel 
activities through research on the ingredients, re.c:ording of 
the minutes of the meetings, and the drafting of memos and 
reports. The informai;ion submitted by the drug product manu-
fact-urers on the drug ingredients is reviewed and coordinated 
by the division for use by the panel. ~'he division then 
recommends Bureau action based upon the panel reports &'1d 
assists in the preparation of the final drug monograph (43). 
The procedure involved in the review of the over-the-counter 
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cL."'"'Ug products differs from that USfld in the; N.AS/NRC review 
of all drugs with approved NDA's prior to 1962 that has been 
going on in this past d.ecade and is nea..r.ing completion. In 
lieu of reviewing each drug product individually as the NAS/ 
NRC project did, the OTC drug evaluation reviews each ingre-
dient in a given therapeutic class. No action is taken 
individually on any given drug product, but rather the use 
and labeling for the active ingredient are specified in a 
drug monograph to which the drug product must comply if it 
is not to be deemed adulterated or misbranded. 
The process began with the identification of all of the 
active ing.c·edie11ts (over 700) contaj.ned j_n the estimated 
100,000 to 500,000 .OTC drw5 prod.uci;s. These h1@,'2'ed.ients 
were placed i.n. cne or more of the 26 therapeutic categm::·ies 
esi;abJ.isb!i'ld., ~.'hese therapeutic categories were grouped into 
. 1? pano:i. topics for review. 
1. Antacids 
2. Antimicrobial I (antimicrobial soaps, scrubs, 
pre-op preparations, skin antiseptics, skin 
~mund cleansers and protectants, antimicrobials 
f.or continuous topical application) 
?). Ini;ernal AnaJ.gestcs (internal analgesics and 
internal antirheumatics) 
l~. Cough-Cold-Allergy-Bronkodilator-Antiasthmatic 
5. Sedatives-Sleep Aids-1'ranquilizer 
6. Topical Analgesic-Burn Treatment-Sunburn· 
Treatment and Preventative~·Antirheumatic 
(topical)-Otic 
?• Dental-Dentifrice (fluoride toothpastes) 
8. Antimicrobial II (antiseborrhea, ru1tiacne, 
topical antibiotics) 
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9. J,a.xati ves-Antidie.rrheals-Emetics-.Antiemetics 
10. Ophthalmic (eye washes, contact lense 
preparations) 
11. Contraceptive and other Vaginal drug products 
12. Hemorrhoidal 
13. Oral Cavity (mouthwashes, oral antiseptics) 
11-1.. Vi tamin-t1ineral-Hematinic 
15. .Antiperspirants 
16. Internal Miscellaneous (alcoholism cures, 
antiflatulents, digestive aids, 
hair gro11ers, impotency cures, OTC 
cancer cures, smoking deterrents, . 
weight control products, worm remedies) 
17. Ex·t;ernal Missc(i)llaneous (baby cream, bleaching 
preparations, boil ointment, bust 
developers, corn pads, depilatories, 
medicated bath prepare,t:!.ons, OTC cancer· 
cu.res, tattoo removers, wrinkle removers) 
Once the panel topics w-ere determined; the advisory review 
pro1el selection was initiated. The panel is composed of seven 
voting members (Chairman seleeted from ·this group), an Industry 
Liaison, a Consumer Liaison, an Executive Secretary, a Panel 
Administrator, and a Drug Information Analyst. The. seven voting 
members and two·non-voting liaisons are chosen :froll1 nominations 
made from a number of professional, trade, and consumer organi-
zs.tions.. The vo'Ging members are experts in the area of the 
panel review, a.11.d include physician· specialists, pharmacists, 
and Ph.D. toxicologists a:nd pharmacologists. ~)be consumer 
liaison is chosen by one of the eonsumer organizations. 1~1e 
industry liaison is chosen a.11.d supported by the Proprietary 
Association. He serves to answer questions the panel has w-ith 
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respect to industry and to keep the industry informed on 
any special needs the panel may have for information on the 
drug ingredients. These liaison members furnish the needed 
interaction between ·l;he panel, the consumer, and the industry 
so as to allow for the smooth development of the monographs. 
The Executive Secretary, Panel Administrator, ru1d the 
Drug Information Analyst are all employees of the agency. 
The Executive Secretary is familiar through his work at the 
agency with the drug categories that the panel is reviewing. 
He \'lrites the summary minutes, answers questions about agency 
policy, and compiles a complete file of information for the 
pa.nel. The Panel Administrator and the Drul?:~ Information 
A."l.alyst work in the OTC Drug Evaluation :Division. 2-'he Penel 
Administrator asmll:'es the smooth operation of the pa-c.el b;r 
ha11dling all administrative functions to iltclud.e meeting dates, 
circuJ.at:i.on of minutes, an~l distJ:·ibution of the :Lncom~cng de.ta,. 
The Drug Information .Analyst ser-ves as a resource person by 
a:i.ding the panel in the accumulation of needed information. 
Initially, the division sends out a request for data on 
the drug ingredients in the panel revie•T categories to be set 
up next. The data on the ingredients generally are provided 
by the firms \vhich have drug products containing ingredients 
to be revieoJed. and include animal and human .safety and efficacy 
data, labeling, and the quantity of the ingredient in the d~cug 
products, and can be submitted throughout the entire review 
process. The firms also have the opportunity to present their 
data to the pa.'lel at one of their meetings. In addition, the 
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research done by the staff of the OTC l'lrug JS"valuat:i.on Division 
supplements this information. 
The panels are charged. v1ith the responsibility to review 
the OTC Drug labeling and to establish monographs stating the 
safe and e:f.'fective conditions for use of the drug. ~'he panel 
makes its decisions based upon the. expertise of its members 
and the data presented. The standards for safety, effective-
ness fu~d labeling are defined in the 37 CFR 9464. They are 
allo~;ed to meet as often and as long as appropriate. lli.'})eri-
ence to date has shO\"I!l this to be biomonthly meetings for 
about; 2-3 years. The decisions made on each ingredient to 
define its proper category: 
1. GR~S (generally recognized as safe) and 
GRAJ<:; (generaliy recognized as eff'9ctive) 
and not misbranded 
2. Not GRAS an.d/or not GRJIJ!: and/or urisbranc1.ed 
:.;. Suf'f:icient data not available at time of 
judgment to decide status of a11 ingreclien·t 
Once the panel has made their decisions on all ingre-
dients, the panel report is v1ritten. The decisions included 
a:t.'e translated into the language of the ~§.eral Jl~ist.~JL by 
the OTC D:r-ug EvaJ.uat:i.on. Division as the drug monographs, and 
sent to the Commissioner for his approval.· The labeling is 
defi:Lled explicitly t~i th all indications not determined to be 
safe and efficacious excluded from the monograph. 1'he condi-
tions for marketing., conditions for exclusion, and the full 
report of the panel are published as the Proposed Nonograph. 
Sixty days are allowed for comments to be sent to the Hearing 
Clerk. The 'fentative Final monograph is published and an oral 
hearing is allo•,led, after w·hich the Final Monograph is 
printecl. The monograph regulations are enforced by the 
Division of Drug Labeling, OTC Branch of Compliance. .Arty 
changes desired are handled by appeal through the courts 
and could lead to amendment procedures. 
The OTC panels have been meeting since 1972, and to date 
have published 3 of the estimated 19 reports (some pro1els 
l'Iill be publishing more than one report): Antacids (l!'inal), 
Laxatives (~~oposed), and Antimicrobial I (Proposed). 
~ioph~~r~~ 
In the past decade, the bioequivalence of drugs has 
been a major issue especially with reference to the repeal 
of the antisubst:l.tution la1r;s which have prevented the pharma-
cist from substituting a less e)~ensive generic drug for its 
brand name counterpart. The t1~""imum Allowable Cost (r1IAC) 
regulations for reimbursement for drugs promulgated by the 
Ilepartmeni; of Health, Education, and Welfare for their health 
programs such as Nedicare ,and Medicaid, have increased the 
emphasis of FDA on assuring that substitutable drugs are 
b:i.cequivalent. The bioequivalence, bioavailability, and 
pharme.cokinetics questions in the FDA a:r·e handled by the 
Division of Biopharmaceutics. The Division is divided into 
three brane):les: Biopharmaceutics Labora'bory, Biopharmaceutics 
Review, and Pharmacokinetics Reviei"J. The branches i11terrelcd;e 
to perform these functions. 
The Division.has several major responsibilities. The 
data submitted to IND's, NDA's, ANDA's, Form 5's, ro1d Form 6 1 s 
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that contains information on the 'bi()availabili ty, 
bioequivalence, and pharmacokinetics is reviewed. The 
pharmacokinetics work most frequently involves Eltudies 
inPhase I of the investigation (IND). These studies 
include absorption, distribution, metabolism, blood level, 
~llld excretion information which are performed early in the 
investigative stage to characterize the drug, generally 
utilizing radioactively tagged material.. Bioequivalence 
studies are frequently included in the ANDA to demonstrate 
the equivalence of one formulation of a drug to a stru1dard 
(usually the formulation with the approved NDA). For a 
change in formulation in a drug v1ith an approved ND.II., bio-
equivalence studie.s may be required. Addi.tion,ally, drug 
disposition data, dosing regimen, and specialized drug 
delivery systE-ms are reviewed to assn.re bioavailabi1:\.t;y. 
~:'he divisions in New Drug Evaluation and· the Division 
of Generic Drug Honographs are responsible for the revieN of 
the above mentioned documents, and send requests \dth the 
appropriate jackets to the Division. The data are reviewed 
and recommendations for approval, disapproval, or additional 
information are retl.lrned to the appropriate division fm· 
incorporation into a letter to the firm. 
'l'he drugs that are already marlceted, such as those to 
be included in the MAC proposal, require surveillance by the 
Division for bioequivalence. On June 20, 1975, the proposed 
bioequivalencc/bioavailability regulations \vere published 
in the Federal Register. As the back-up to the MAC these 
regulations define terms relating to bioequivalence and 
bioavailability, and list 193 problem drugs and dosage 
forms.that require special testjng for bioequivalence/ 
bioavailability determination. The 193 problem drugs are 
separated into 4 groups (66): 
1. 47 drugs requiring }.,n vivo bioayailability 
testing to establish b~oequivalence. 
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2. 70 drugs requiring in vitro l1ioavailabili ty 
test~ng to determine dissolution rates. 
3. 62 products requiring special regulatory 
handling because of special dosage forms: 
aerosols, enteric coated tabs, controlled 
release, radiopharmaceuticals, supporsitories• 
4. 14 products requiring special regulatory 
handling because of menu£acturing problems: 
7 biological preparations and 7 intrathecal 
or intraventriculm' injection. 
The Division nm,1 has the added responsibility of revie\·ting 
all data that come :in in response to the ne~; regulations, 
thus inc~reasing its vlorkloe.d. 
Gen~<;<..Jl.£lli!> ... J;:Ionog,ra;g.h.a 
Generic drug monographs (or old drug monographs) is a 
concept being developed end v1ill be implemented by this 
division. T'ne inequitable method of regulating the drug 
proclucts wi·i:;h approved NDA' s by t:he strict NDA requirements 
\'lhile their generic equivalents are ma-cketed under the more 
lenient ANDA requirements has been criticized both inside 
and outside the agency. l!'u.rther, those drugs under the 
grandfather clause are regulated solely through the mis-
branding and adulteration sections of the F.D.&C. Act, thus 
adding to the inequitable approach to drug regulation.. The 
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new approach involved the classification of drugs into three 
categories: ·new, old, and banned. The ne~r drugs are those 
which will be regulat&d under the current NDA procedUre. 
Old drugs are those drugs which are generally recognized as 
safe and effective either under the grandfather clause, or 
through reclassification of neVI drugs VTith approved NDA's 
\'thich have been on the. market for an adequate length of time 
to prove they are safe and effective, the latter group having 
undergone the NAS/NRC revieVT. These old drugsVTill then be 
written up in a. mo:o.ograph which specifies labeling require-
menta for indications, side effects, contraindications, etc.; 
in-Pl'ocess specifications for the development of the dosage 
f ' th t 'h . ... 1' ty d · orm ~;o assure . , e proper s rengt: , PU-L'l.·~y, qus. l. , an 
identity; and bioavailabili.ty data. The Old Drug l·lon.ogra:pb.s · 
>-Jill eliminate the existing MIDA procedvre 1 with the enfo:cce-· 
ment being throush e2:isting means of CGHP inspectiol!s, 
ao.ulteration, and misbranding •. 
The process by \'Ihich the Old Drug r1onographs will be 
developed by first publishing proposed . rt<lemakings in tho 
;E'~£If'yal fuJJQ-§1£:£.• Hearings will be held 011 the rulemakings, 
after wh:i.ch the information from the hearings,. where applicable, 
will be incorporated into the drug monograph which is published 
right to petition for changes. For additions to the ind:i.ca-
tions for the drug, the sponsor will be required to file an 
NDA. 
In addition to the responsibility for the old drug 
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monographs, the division reviews the Abbreviated New Drug 
Applications (ANDA's), Abbreviated Antibiotic Applications 
(Form 6 1s), and their supplements, for approval, disapproval, 
or withdrmval. These applications contain similar information 
to that contained in the New Drug Applications (NDA) with the 
exception of the clinical data on the safety and efficacy 
of the drug. Instead, data on the bioequivalence of the 
generic with the original drug under the NDA must be proven. 
This data is sent to the Division of Biopharmaceutics for 
revie>'l. The remainder of the application, the labeling, 
inanutacturing, and cont-rols data, is reviewed by the chemista 
and·medicaJ. officers in the divicion. 
~'he Executive Director for Regional Operations (EDRO) 
has by :fa-r.• the largest unit in the Food and Drug Administration 
as it includea all of the agency's personnel in the field, or 
about 47% of the total FDA work force. These manpowe:r· reso.urces 
<Jre divided among the Bureaus: Foods, Drugs, Veterinary 
Jvledic:i.ne,. Radiological Health, and Biologics, and the National 
Oentel' i'or Toxicological Research according to their needs end 
to the priorities set by the leadersh:i.p of the agency. These 
needs and priorities are communicated to EDRO mainly in the 
form of Program Management System (Pli'JS) Oompli~.nce Programs, 
that have been developed within the individual bureaus. The 
basic Compliance programs for the Bureau of Drugs include: 
Drug Application Evaluation~ Drug Production Quality, Drug 
Efficacy Study Implementation, Drug Pharmaceutics and 
Methodology, Clinical Investigation Evaluation, end Drug 
Abuse and Methadone Honitoring. 
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In addition to its function·of implementing compliance 
programs .from the other areas in the agency, EDRO coordinates 
the work of the other .federal, state, and local regulatory 
agencies vlhich have jurisdiction over the same consumer 
products as the FDA. Through the cooperation of these agencies, 
greater assurance is provided that all areas·o.r regulatory 
activity are adequately enforced and there is no unnecessary 
duplication of effort. 
To coordinate the activities of the field personnel \'iith 
those of the bureaus, the main office of FJ)RO ;is divided into 
tt.1.l:'ee divisions: Planning and Analysis, Federo.l-State Relations, 
and :F'ield Operations. ·l'hese divisions ·not onl;r coordinate 
activities, but also se.rve as support to the ten regional 
offices. ·These regions are comprised ·Of nineteen district 
offices and are located in major cities.tbroughout the United 
States and Puerto Rico (Figure III). ·The functions of these 
divi!lions e.s they relate to the mission of the Bureau of Drugs 
wi11 be der~<;ribed. 
Planning and Analysis 
The Division of Planning and Analysis has a name descrip-' 
tive of its function: to create the EDRO workplan and to 
monitor manpN;er utilization and the progress of the compliance 
programs in the various districts. The EDRO workplan is 
created through the interfacing ~•i th the Bureau of Drugs' 
project officers and the .Associate Commissioner for 
Compliance, and the monitoring is done by a program oriented 
data system (PODS). The system aids in planning by giving 
out cost efficiency data on the compliance programs, track-
ing all compliance programs, giving monthly reports of what 
has been accomplished to that month, and comparing the results 
with the year's workplan~ The districts' operations are 
. quantified in categories such as the utilization of manpo\ver, 
quality indicators, plan the number of_hours, and staffing 
patterns. In addition, the Official Establishment Invento:ey 
is maintained.· This _provides information on the elli',psed time 
between firm inspections, giving 18 and 23 month alerts to the 
districts where the drug firms have not been inspected 'tlithin 
those time periods so that action can be taken. By lcM, drug 
firms must bfJ inspected every tvro yem•s • 
. .Another useful data source m.aintained by the agency is 
the mapping by computer of the number and types of firms 
located in each count-y of. the u.s. This tool allo\'JS the 
agency to better distribute and utilize its specialized man-
po~ter. A "sldlls bank" has also been developed and includes 
deta:l.led information :!.'.s to the skills of 't:he various in7esti-
gators so that they can be utilized in emergency si tv.at:i.ons. 
The benefit of lab automation vs. increase in personnel, 
technical training, and the value of special labs are also 
analyzed by the division's personnel. 
The three branches of the Division of Planning and Analysis: 
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Program Planning and Review, Systems Analysis, an9. Special 
Studies share the Division's respons:Lbilitiea. The branches' 
as well as the Division's functions relate directly to the 
Program J1ana.gernent System (PMS). As mentioned previously, 
the Pl"IS describes the objectives of the.agency in terms of 
proje•::ts for the year rather than through functional descrip-
tions of organizational units. This has allowed a more direct 
relationship from budget categoryto program to project to 
compliance program, and thus is easier to plan. 
Federal-State Relations 
The Division of Federal-Ste.te Hela·i;ions serves as the 
liaison between the FDA and the state and, ldcs,l cl.gencie.s co~l­
cm:ned with food and drug regulation in operations, training, 
and progra.'ll deveh>pment. T"nree e.rea.s: State Services, 
Program IJeveJ.opmeni;, and the Cincir ...l'lati T~'aining Fac:l.li:ty 
. assume these responsibilities •. 
State SerYi.ces covers three main areas: information 
dissemination, eommissioni.ng of state a11d local officials, 
fllld gathering state resource data. The information dissemina-
tion involves communication on the latest: happenings in foods 
and drugs, for example recalls or new regulations. Three 
method.s of dissemination are used depending upon the urgency 
of the message. The faste ert is the TWX, which is used for 
urgent messages and are only one-way from the FDA to the 
states. HOI'lever, a new system is in the stages of deYelop-
ment;, NRSTEN (National Regulatory State Telecommunication 
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System), \~bich will provide "tt~o-way rapid communication. 
The second method is through the office tapes which handle. 
less R~gent information and are handstuffed in the mail. 
The third is by far the slowest, taking 20 days for receipt, 
as it goes through the department mailing keys and covers a 
broad segment of the state officials. 
The commissioning of state and local officials to conduct 
investigations for the enforcement of the F.D.&C. Act is 
authorized in Section 702. The Branch is responsible for 
their co!IJlllissioning. The states provide various services for 
the agency. For example, medicated feed inspections and food 
sanitation of the .final pr·oduct in restaurents are handled by 
the stat·e o.fficials as the FDA does not have the resom'(;es to 
carry out this responsibility, 
'l'he state· resource data are being compiled by the Branch 
bao,ed upon a ra:ndom survey of 'rlhat the states are doing in 
the regulation of foods and drugs. In the futtli'e, this survey 
\'lill exten.d to all states, thus providing a complete data base 
which vlill aid the FDA in planning \1here it should concentrate 
its resources. The Branch does aid the states in the execu~ 
tion of a better food and drug program 1 responds to inquiries, 
and maintains mru1.uals \~hich include a summary of the !~li~"~ 
~JQJz.:tfiJr requirements and the weekly recall, seiztiTe, and 
prosecution list. 
The Pr·ogram Development Branch handles the state con-
tracts, the work sharing agreements, and the information gh,.en 
concerning pending state food and drug legislation. The state 
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contracts (over 70 of them) are both developed and monitored 
in the Branch. Examples of the common contracts include 
food service .sanitation (inspections of facilities and 
an~ysis of samples), ru1d the methadone monitoring programs. 
Work sharing agreements are made with the.states so that 
resom•ces can be conserved. In the legislative area, the 
Branch informs states about federal plans, and encourages 
uniform food ru1d drug legislation. 
Field Operations 
The Division of Field Operations coordinates the day·~to·· 
day activi·ties in the field and serv.es their needs... Its 
bran.ches mirror those of the district of.ficern"· Investigations, 
Sciene"'' Compliance, and Consumer Coordina·t;or. These brru1c:hes 
provide a host of support services by ru1swer:ing technical 
questions, supplying experts to aid in solving problems, and 
developing inspectional techniques. \vi th the Bureaus, the 
Division prepares the investigational operations manual, 
coordinates multiregional activities, and represents the field 
personnel in dealing with the Bureaus. 
The ]'i.e J.d. Investiga~ions Branch is divided into four 
sections: Operations, Epidemiological Investigations, Foreign 
Inspections, and Quality Assurance. 'I'hese four parts relate 
to the district offices mainly through the Chief Investigator. 
Operations provides procedures and techniques (the investi-
gator's manual), coordinates manpower needs, and handles 
inspectional problems, with its "specialists" staff which 
includes experts in the areas of microbiology, complex 
manufacturing, antibiotics, an.d canning. 
' 1'+4. 
The Epidemiological Investigations group has the task 
of monitoring all reports of food and drug related disease, 
illness or injury. The group then coordinates the efforts 
of the Bureaus, :E.'DRO, the press, the Associate Commissioner 
for Compliance, Center for Disease Control and others through 
the stages of the report investigations. TheBe stages include: 
I. Alert. The initial receipt ofthe report; 
information without support data. 
II. ·Presumptive. Have some lab analysis, possibly 
clinicaldiagn()sis. 
III. Confirmed. Lab analysis, clinical diagnosis, 
and tracings to product. 
Action may be taken at either II or III depending upon the 
:natm.'e of i;he problem. If action is \·larranted on any px·oblerJ, 
ephlem:Lological investigations follovm up and makes certain 
the;t; all interested parties are in.formed. 
·The inspection of over 150 fore:i.gn drug firms primal'ily 
for antibioocics and New Drug Applications is coordinated 
through Foreign Inspections utilizing the best seasoned 
investigators from the field. .Antibiotic firms are inspected 
yearly, 1trhereas the firms ~lith l'illA' s are inspected on request 
from the Bureau of Drugs. Additional drug firms a:::·e visited 
<Ihen time and maupo>"er permit • 
Engineers are the chief componen°G of Quality AssuraJ1ce, · 
and they are available on request from the district to provide 
ad_vice in solving technical problems. The group has inj_t:i.ated 
an inspector's technical guide which includes suggestions for 
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handling problems that might occur in such areas as: steam 
pressure control for retorts and autoclaves, ultrasound in 
the :food, drug and device industry, and the calculations of 
initial gas concentration in ethylene oxide sterilization, 
and keeping them informed on the latest de·velopments. The 
group promotes qualit7 in activities of the district offices 
and industry. 
'I:he activities of the nineteen district laboratories are 
coordi.nated. through the Field Sciences Branch. The activities 
incl1.1de not only the routine analyses, but also the collabera-
tive studies run to develop methodology, research projects to 
avoid duplication, and the training programs that are designed 
to combat· obscelens<:ence of the labs. Quality .. assurance 
checks on. the lab are c.onducted by the Brarwh to determine· 
ar.y lab-lab va:dation. The training prograuw include not only 
cou.:r,ses in lab techniques but t~m others which connect the 
distric-t; lab with a nearby university: -the Science .Advisors 
and the Science Advisor Research Associate Program. ·Universi-
ties within corn..'Tlu.ting distances of the district offices are 
contacted, and ge:nerally, a professor in analytical chemistry 
is contracted to come to the labs and aid the scientists to 
keep currcmt. Al.·so, research proposals may be h1ade to the 
Science ~klviE.:ors school to do some .method development for 
the agencye 
1~e Field Compliance Branch provides for direction and 
counsel for thei~ counterparts in the field, develops the 
Regulatory Procedures and Import Manuals, and coordinates 
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emergency and recall operations. These services are divided 
j.nto four ar·eas a:1d assigned to either Regulatory Operations, 
Emergency and Recall Operations, Compliance Programs, or 
Import Operations.· Regulatory Operations tracks and monitors 
the information sent between the Bureaus and thG Field, 
evaluates what EDRO sends, and trains compliance officers 
in law and interpretation. Emergency and Recall Operations' 
name is descriptive of its function, to coordinate flood, 
hurricane, and recall effectiveness che.ck activities. Policy 
guidelines for the Field-Compliance sections a:re developed in 
Compliance programs in addition to its duties of monitoring 
and coordinating them. Chapter VIII of the F.D.&C. Act con·~ 
tai:ns the autho:i:'i ty of the dutie.s of Import Op?,ra-l:;io11s. T'nis 
section on Imports a<"ld Exports covers v<hat the FDA should do 
wi.th respect to the imports aild exports, and is ver:·y similar 
to the sections dealing with adulteration and misbranding. 
The Consumer A:i:fairs Coordinate~' hand.les the program 
pla.uning, budgeting, coordinating and adyising of the 52 
Consumer Affairs Officers thxoughout the country in their 
dutie.s of responding to consumer inquiries and keeping the 
press i:r>..f'ormed of FDA actions (e.g. recalls). 
Field Offices . 
There are ten regional offices of li'DA (Figure III) 
according to the divisions of the Department of Health, 
Education, and Welfare. .These are brolcen into nineteen 
district offices which in turn have various resident posts. 
(~L\T7!.F. nr~TRTCf) 
~~.. l -l 
!r--1 -1 
/r--{ vm r---- 1 
I I 
DC~\Ifl \_-1 
,o ......... 12.-·· -IX"\:> 
C>i 
(SA:~ fRA~C!SC/1 DI5TRtCT) 
® 





~I. "' ~-----' a 
\' 
),)~ ~ / ~0"''"' 
'( fOotl A>W , DWG_AO 0 trC~O,..A.t Of M_INISTR:ATION 
• !h•. bo.an ~[0S A~'"""'""""'"""'.,;: id..,tilr '">~. 
by Ill~ _,j, ·~ ... ~ ;,·o4j~;-~""''· 
...... ft~ ... ~. 
• O!~UK). Of'FICO 






·: ~:;:j<ou .. ,.. 
ll J -




($..;~ J:'AN !HSTR !I.) 
~ 
Figure 3· The Food and Drug Admini.st:t·ation Regions a...11d Districts. 
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The resident posts are located in cities without a district 
or regional office and involve from a single person to close 
to district size staffs. They have been set up to give the 
field offices a broader base from which to work. The district 
offices are divided into four branches: Administrative, 
Investigations, IJaboratory, and Compliance. The branches 
have chiefs which report to the Deputy Regional Tiirector 
(District Director) and he reports to the Regional Director. 
In the regional structure, there are the Consumer Affairs 
Office, the Federal-State Relations, and Recall and Emergencies 
~lhich coordinate the information from EDB.O with that of the 
district offices. 
The Investigations Branch handles the plant inspections, 
sample collections, and the other components oi' the compliance 
programs. The routine complj.ance inspect:i.c:t:ts (e.g. GJ.'Iii''s., 
QualH:;y- Assurru1ce1 :,)rograms) are set up by the district offices 
with some guidance and monitoring from EDRO. Special requests 
that come in from the Bureau of Drugs, from other districts, 
or from EDRO require modification of the time schedules and 
plan.n:i.ng. Recalls, too, can rearrec:nge the calendar. 
The Investigations Branch contains a Chief InveE:tigator 
and several supervisors over the investi.gators. The chiei' 
and supervisors meet daily to discuss the prevj.ous day 1 s 
activities (e.g., recalls, regulatory actions, inspectional 
findings) and to make the daily special request assignments 
to the investigators. Suggestions about how various problems 
should be handled are made. 
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The investigator for FDA is a person with a science 
background, for example, biology, zoology, microbiology, or 
pharmacy. The investigators attend an accelerated training 
course to learn the basics of inspectional procedures. In 
the .first .few years at t-he agency, the investigator is 
generally assigned to inspect food plants, drug manufacturers, 
blood banks, and all other areas under jurisdiction o.f the 
agency. This provides him \~ith a broad background in inspec-
tional procedures. Then, many o.f the investigators begin to 
specialize. This "specialization" whether in foods, drugs, 
e~~c., generally is accompanied \"lith another training course 
to teach additional inspectional procedures. 
There a:ce various ·types of inspections conducted by the 
agency, and i;h6y are loosely separated into t~ro categories: 
general and srJe-::o~i.fic. They can inclUde such a:ceas as: good 
manufacturing -practices f"or Nll.A approval, E'tatutory, or 
limited; adverse drug reactions or drug product d.efect report 
for follo\v-upi and quali t·y assurance for collecti.on of' sa;·nples 
for analysis. 
~1e inspection procedure requires an increasing amount 
o.f paper;·mrk. This paper\wrk can and .for the most part, does 
·include: 
1. Notice of Inspection: c:i.tes the authority 
o.f Section 70Lf. of the F.D.C • .Act that allo>is 
the FD.A to make inspections. 
2. Samples 
a. official: require that the integrity 
o.f the sample is maintained and that 
the interstate movement of either the 
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finished product or raw material is 
documented with an a.ffidavi t. The 
sample is assigned a specific number, 
placed in a container, and signed 
with the investigator's signatm·e .-
b. documentary (eg. large device such 
as a respirator, T.V.): need to get 
picture, shipping records, sales 
literature, diagrams, and any other 
information that describes the product 
to put into collection report. 
3. Receipt for samples: need information on the 
types, lot numbers, and charge as the FDA p~ys 
for all of its samples. 
4. Affidavit: -need to cite the responsible per-
. son, product sampJ,.ed (type, lot numbers, 
description of sample, document interstate · 
movement vrith shipping records, freight bill) 
and must be signed by responsible person and 
investigator. 
5. Collection report: report stat;h1g that the 
sample ~ms collectE:d. 
6. Form 2275: oboervations, that have b<:>en ma.de 
<;luring the investigations in '~b.:i.ch mw violB.-
ticnls e.re cited. A copy is given. to the 
responsible indi'Vidual after completion o:f 
the inspection. 
An example of' the procedures involved vrith one of the 
general inspections is_ the one required prior ·!;o the approval 
of a ne1.1 drug application. The purpose of the inspection is 
to c.heck .for thE: adherence of the f'irm to the specifications 
in the NDA, and their ability to manufacture this and other 
products according '!;o current good manufacturing practices. 
Rx:;3.mples of the types of things "looked for in the· NDA inspec- · 
tion incb;.de the qualifications of the people who 111ill be 
performing these tests, sampling plans, testing o:f raw 
materials, processing equipment adequacy, the traceability 
of the batch records, and the :final product assay procedures. 
i 
151 
At the end of the inspection, the deviations are accessed 
by the investigator, as to whether they are significant. 
They are vmighed and then a recommendation is made to the 
investigator's supervisor -vrhere the .findings are scrutinil!'.ed 
and discussed. The results of these discussions are sent 
to the chief investigator for his signature and then to the 
district director .from whom the report is sent to the Bureau 
of Drugs, Compliance. The report is relayed to the appropriate 
New Drug Evaluation division and incorporated into the chemist's 
revie>v .for the NJJA. 
On routine CGMP inspections, many of the things covered. 
in the NlJA inspection are also looked l'or, however, s.ll types 
of products are evaluated. \'lith. the larger firms Vl.b.ere 1nany 
produci~s a.re ma:m.i.fa.ctu:t'ed; certs.in signific.;m.t categaries a.re 
sel.eci::c-~d'-1! ]'or exarnple, those drugs ''Jhich m.--e of great· thera ..... 
peutic :i.m:portance, those Jc..nown to be problem products to manu-
facture, or those drugs vlhich are .administered in low doses 
thus creating nar~·ow ranges for error would. be considered as 
significant categories. · Drugs 11hich are not manufactured often 
in a firm >vould be scrutinized more closely· to ascertain wheth$r 
the production personnel are capaple of mak:i.ng the product • 
. Conversely, drug products 1:ihich are manufactm;ed Ve1~Y fre-
quently iqould also undergo special supervision to note certain 
production personnel are not becoming careless in the routine 
of maldng it. 
Many of the types of analyses the district; laboratories 
run on the various food and drug items are fascinating: from 
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looking for insect fragments in flour to testing·and smelling 
tuna, or soaking teacups in acetic acid to check the lead 
content of the paint. The chemists and microbiologists must 
be "generalists" in the Field Laboratories as there is such 
a wide variety of products under regulation by FDA that need 
examination. Samples are received from consumers, lnvesti-· 
gators, and from other FDA offices. Consumer complaints must 
be validated by lab analysis. The "official" samples collected 
by the investigators generally are part of a compliance pro·-
gram l?hich includes the lab vlOrk to be done, e.g. method vali--
dation for a NDA, or quality assurance. The officiality of 
the sample must be maintained, and the analyst must sign the 
seal ~1hen it is broken. Other FDA offices may call upon the 
la1)s tc participate in collaberati ve studies on method() logy. 
About one third of the analyst's time is spent in this and 
othe:t' mission oriented. research. 
A firm 1 s adherence to the :B'.D.&C. Act and the recommen-
dations of action whether regulatory letter, injunction, 
seizure, or prosecution to be taken for failure to comply 
· are decisions made by the Compliance Branch after the review 
of the <lata from the labs and the inspection reports. The 
recommendations for action are written up by the Consumer 
Sai'ety Officers in the branch, and then se11t to the Bureau of 
Drugs :for checks on the •Ltechnical completeness" and applica-
tion of the agency's policy. The FDA is one of the few, if 
not only, federal agencies which prepares its own legal docu-
ments utilizing people who are not lawyers. After the documents 
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have been processed through, they re·turn to the u.s. District 
Attorney, and proceedings a.re begtm immediately. Members of 
the district may be called to testify at these proceedings, 
and in prosecution cases. 
CHAPTER IV 
DISCUSSION 
Discussion of t):l.e Pilot Progra~ 
The residency experience flll'nished an excellent 
opportunity to gain information about the inner workings 
of the FDA unattainable from any other source. The dis"-
cussions with FDA personnel supplied·first--hand accounts 
of the responsibilities and activities of the agency in its 
regulation of drugs. As a pharmacist, participation in this 
program emphasized the importance of the existence of s. dJ:·ug 
regulatory agency, coupled ;d th the knoJ~lec'tge that its :reg-u.·· 
latory ac.tiv:i.ty ca.nnot assure the absolute quality of drue;r; 
due to the large number of drug manufacturers and the small 
FDA field force. This clearer unde:?.'standing of the complexi-
ties involved in assuring that drugs are safe, effective, of 
good qu.ality, and not misbranded will lead to a greater will-· 
:i.ngness to cooperate vii th the agency in PlLt'Sui t o:f its goals 
through the utilization of good quality control procedures, 
and will enhance collllllunication with patients and feJ.lo;; health 
p1•ofessionals in the explanation of" the. actic•ns of" the ageney. 
Additionally, the progra>n is valuable to the academic community 
in that it provides resource personnel to teach pharmacy 
students about FDA drug regulatory procedures, thus broadening 
154 
155 
the scope of cooperation between pharmacy ro1d th~ FDA. 
The work-study technique utilized in the pilot program 
proved to be very appropriate for the attainment of a com-
prehensive knowledge of the agency's responsibilities and 
functions. The principle assignment to New Drug Evaluation's 
Division of Surgical-Dental Drug Products presented several 
positive features. The length of time spent in the Division 
was greater than the suggested time in the Draf't Syllabus. 
This extension supplies enough time to acquire an adequate 
understanding of the Division responsibilities so as to par-
ticipate adively in their execution. The Division served as 
a home base \"here an orientation to the FDA, specifically the 
Bureau of Drugs was obtained, and from which the rotations to 
other areas.of the agency were planned and·implem.ented.. In 
addition, the length of. time allowed for' the acquisition of 
an indepth lmowledge of the comple:x::i.ties of' the procedures 
for premarket clear(?.nce for· safety and efficacy of ne>v dr-t1.gs · 
which were of special interest to the resident. 
For the academic portion of the program, the student 
'I<Ias requested to record activities and e:;.cperience during the 
residency within the agency. A daily log was maintained.. The 
initial impressions noted in the log provided a. baseline to 
determine >vb.at wras learned in the residency at the agency. 
These were expanded into periodic Progress Reports which were 
sent to the facult~ advisor, so that the performance of the 
student and the development of the program could be measu,":'ed. 
The Progress Reports, as far as applicable, addressed the 
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assigr~ent sections listed in the Draft Syllabus, and covered 
the areas of the FDA, Bureau of Drugs, Office of Scientific 
Coordination, and the Drug Product Reporting·System. The 
Reports contained a smnmary of functions and responsibilities 
· of the rotational areas, and formed the basis for the thesis 
"1hich included an indepth coverage of what was learned in the 
residency. Periodic telephone conversations bet\~een the 
student and her advisor provided an added line of communica-
tion. Ho•rever, to be a viable academic program, graduate 
studies at FDA must be given adequate faculty supervision at 
the agency during the time of residency. In this initial 
program, the faculty advisor made three visits to the Agency 
to provide needed direction for the development of the thesis, 
a task difficrul t to achieve through telephone con11ersations. 
In addition, the presence oi' the faculty advisor strengthened 
the cooperation between the Agency and the U:uivers:i.ty in t:he 
implementation of the pharmacy graduate studies program. 
Meetings \d th the key officials within the Bureau of Drugs 
·served to acquaint them with the progress of the program and 
to receive their comr.u.endation. Input from these officials 
served to lay the gro1mdwork for the continuation of the pro·· 
gram in other areas of research. 
The residency experience identified and provided indepth 
lmO\;rledge of several areas of cooperation between the FDA and 
the pharmacist. These include: recalls, drug product defect 
reporting system, current good manufacturing practices, d:rug 
efficacy study implementation, over-the-counter drug evaluetion, 
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antibiotic and insulin certification, methadone monitoring, 
drug product packaging and stability, maximum allowable cost 
and bioeqaivalence regUlations, and the IND/NDA new drug 
procedure. 
The effects of packaging material on the integrity of 
the drug product has become evident due to the work done 
under the supervisory chemist in the division. The materials 
can be leeched or extracted into the product, possibly lead-
ing to toxicity or stability problems. Firms, with drug 
products regulated under the new drug application, can be 
required to submit information about the possibility of the 
interaction bet11reen the paclcage and the drug, but most drugs 
do not have a new drug application on .fHe with the FDA. 
Ac'cd:Lt:i.ona.l::i.y, questions have arisen about what happens -J:;o the 
drug product \vhen it :i.s repackaged by the phe_'t"macist. If 
problems can occm:-. ~Jith the drug product ir; its original 
container, what effect on the stability and integrity of the 
drug product does the packaging used by the pharmacist have? 
The new Fre.edom of Information (FOI) regulations were 
published dm:·ing the student 1 s residency at the agency. These 
regulHtions specifically delineate what information the agency 
can release upon request, thus the pharmacist has a ne\• resource 
. for more detailed information on the dr,.<gs be dispense. 
Another set of regulations promulgated by the Department of 
Health, Education, and Welfare \vill decisedly affect both the 
FDA and the pharmacist. The Maximum Allowable Cost (HAC) 
regulations describe the amount pharmacists will be reimbursed 
for drugs dispensed under one of the government sponsored 
health plans, e.g. Medicare or Medicaid. This amount is 
determined by the minimum price for a given drug product 
that is widely available plus some dispensing fee. ~.'he 
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FDA must, therefore, assure that the generic drug products 
are of good quality and bioequivalent to the trade name 
products so there will be no problem with substitution. 
The recent proposed biopharmaceutics regulations promul·q 
gated by the Agency delineate the drug products which have 
the potential for bioequivalence problems and need additional 
in vi i{J:Q. or in vivo testing for consideration under the JV"J.AO 
program. 
Although the student bad a vague knowledge of the pro-
cedure by ~;.hich ne>• drugs are marketed, the residency pr(;vided 
i:udept:h u:nd.erstanding of. t!w complexities involved. 'I'he 
decisions that must be made are not based upon clearcut 
data, but rather the risks must be weighed against the bene-
fits. These decisions are further complicated by the 
voluminous amount ·of data submitted to support the safety 
and efficacy. The assimilation of the data ~!here a placebo 
has a high degree o:.f effectiveness is dif'f'icult. In addition, 
the proper interpreta.tion of the sometimes vague regulations 
to determine what information is adequate and sufficient is a 
.formidable task. 
Overall, the pilot program enjoyed successful implemen-
tation. The. goal.s of the program as described in the Draft 
Syllabus were accomplished in that it provided the background 
159 
research material for a graduate degree thesis and trained 
the author in FDA drug regulatory procedures. Additionally, 
from experiences gained in the program, a revised syllabus 
for subsequent residencies was developed. 
~commendations for the_R~idency 
Based upon the experience gained in this preliminary 
program, some modification of the Draft Syllabus should be 
inade. It is recommended that the length of time should be 
extended from 4-6 months to 6-8 months to allow for the 
rotations to the suggested areas. However, it will take 
the experience from several residencies to arrive at the 
mont suitable period for both the student and "the· agency. 
The length ruay va:ry from individual to individual alrd w:i.ll 
depend. upon the nature of their research :i.r; the agency. 
Due to the reorganization of the Bureau of' Drugs in 
late·se:ptember, 19?4, most rotational headings of the Draft 
Syllabus are. obsolete. 'l'll,e Residency Syllabus in Chapter V 
is consistent \vith the changes. The introductory tmits to 
FDA and the Bureau of Erugs ru~e to be included as part o~ the 
i.n.formation to be presented in the pr:i.nciple rotation for the 
first t;reek' s orientation. In addition, the Executive Director 
for Hegional Operations (EDRO) has been included as part of 
the rotational experiences. As the area of the agency enforc-
ing the F.D.C. Act and regulations :i.n the field, it is impera-
tive that the student have the opportunity to visit EDRO so 
as to allow him to integrate the enforcement procedures of 
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the field force with those. of t.he Bureau of' Drugs. 
There are two methods for understanding of FDA drug 
regulations, through didactic work and through the residency 
program. Whereas didactic work on FDA drug regulation meets 
the needs ·of the commun.ity or hospitaLpnarmacist in this 
area, those wishing to specialize in FDA drug regulation 
should supplement the. cover work by spending time in a resi~ 
dency program at the agency. At the present time, the 
residency program is most applicable to a graduate.pharmacy 
student. As part of a graduate studies program, the residency 
at the FDA may provide the research material for a thesis. 
The emphasis in New Drug E\7'aluation listed in the Dr;Ji'',:; 
Syllabus has been made flexible as noted in the Residency 
SyllEbus. Joint discussions among the student, t;he advisor, 
.and representatives of the agency would determine the prin-
ciple :r·otation ;.Jhich ivill provide the area of research. 
During the pilot program, consultations with officials indi-
cated the availability of a wide v·ariety of reseal:'ch topics. 
These could easily be incorporated into the program and ;~ould 
be both beneficial to the agencw and educational for the 
student. Examples of' such research topics could include: 
The effects of radiosterilization on drug 
products. 
The legal implications, if any, of drug· 
product labeling. 
Development of agency policy on particulate 
matter, additives, and sterilization of 
large volume parenterals. · 
Development of review guidelines to be 
utilized in review of timed··release dosage 
forms,-large volume parenterals, aerosols. 
Utilization of adverse drug reaction informa-
tion by the agency. 
Study of the implementation of bioequivalence/ 
bioavailabili ty regulations by the agency. 
Development of assay methodology. 
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The implementation of the over-the-counter drug 
monographs; i.e. for use by health professionals. 
Further discussions between officials of the agency and 
representatives of the university would expru1d upon suggested 
topics and lead to the development of the research area. 
~'he goals, methodology, and assignment sections were 
re~~ritten to correspond with the net~ rotational headings and 
the <axperier.ce gained in the pilot program.. f·1any of the 
agen.cy 1 e impoxtant . drug regulatory programs 1N'e::::·e not included 
in these sections of the Draft Syllabus. The goals a-re 
directed towards the 1.mderstanding of the prog,-rams designed 
to assu:ce that drugs are safe and effective, and the FDA's 
enforcemen·!; o.f the F .D.&C. Act and its regulations~ ~'he 
methodology xecomraended ps.rallels that used in the imple-· 
mentation o:f the pilot program. Discussions were held with 
key official.s within the Bureau of Drugs and the Executive 
Directo:C" for Regional Operations in which the i'm1ctions of 
their areas in relation to the regulation of drugs was 
explained. Severa1. divisions 1dthin the agency supplemented 
these discussions by allowing the student to review their 
work. The assignments in the Draft Syllabus served as guide-
lines for the kind of information to be included in the per-iodic 
Progress Reports. The Study Assignment;s in the Residency 
Syllabus are proposed to serve that same purpose. They 
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are directed towards developing the student's understanding 
of the relation of the functions and responsibilities of 
each of the rotational areas to the enforcement of the 
F.D.&C. Act and the regulations. These periodic Progress 
Reports should be a brief summary of the ro.tational experi-
ences. In addition, the progress of the research the student 
is doing in the agency should be included. They should be 
submitted to the faculty advisor within a month after the 
rotation, as a measurement of the performance of the student 
and the development of the research. 
In acldi't~ion t:o the information on FDA drug :regulation 
acquired duri.ng the residfmey period 1 the r;:tudcnt should 
attend a food and drug law course offered d.u:;:i.ng the time 
spent in :H'DA. This will serve to enrich the e:xpHrienco and 
enhance knowledge of the F.D.&C. Ac'!; and its enforcement. 
The potential of the off-campus educational programs 
within the FIJA has just begun to be recognized. The resources·· 
available within the agency and the interest of the staff 
participation i11 educati.onal prog:r·ams indicate. a capacity 
for increased :i.nteraci;ion between the FDA ar1cl phaL'macy edu-
cation. Programs such as these serve both the FDA and the 
profession of pharmacy through the improvement of communications .• 
The heightened awareness of the regulation by the FDA of 
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the drugs pharmacists dispense, acquired through the 
residency eJ~erience, has underscored the need for all 
pharmacists to have a reasonable understanding of FDA drug 
regula-tion and its impact on the practice of pharmacy and 
the products forming the basis of the profession. A pharma-
cist should know why a given drug product is safe, effective, 
not misbranded, and. of good quality. This encompasses the 
knowledge of how the F.D.&C. Act is enforced both through the 
promulgation of regulations by the FDA and. the development 
of its drug regulatory programs. The regulato:t'y tools 
utilized by the agency that need to be rmderstood incl.ude 
general prohibitions against adulteration. and misbr.anding, 
premarket clearance for new drugs, and the certification of 
antiM.ot;ics and insu.lin. 
The pha:r'macist should understand the basis for the 
determination by the FDA that a nmv drug is reasonably sai'e 
a11d effective. The k:no~Iled.ge oi: the limitations of clinical 
trials will allo·w him to ur1derstand better the possibilities 
of, for example, unexper;ted adverse reactions for a drug 
a.:fter it has been marketed.. Additionally, the knowledge of 
the importance of good record.,keeping \~hen handling investi-, 
gational new ctrugs 11ill be useful in praci;ice. 
The Drug Efficacy Study Implementation (DESI) and the 
Over-the-Courlter Drug Ingredient Revie11 are two programs 
having a significant effect on the products pharmacists dis-
pense. The results of the programs have been that mruzy 
products have been removed from the market and others have 
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been reformulated. The pharmacist should be aware of the 
reasons behind the removal of the products so as to be able 
to answer questions received from the physician and the 
pa·l;ient. 
The pharmacist should. understand his role in supporting 
the actions of the agency to protect the consumer from sub-
standa"t?d or hazardous remedies. Through the Drug Product 
Defect Reporting System, pharmacists mld the FDA work together. 
Acknowledging the fact that the agency works to control the 
quality, but cro1not assure the absolute quality of drugs, 
the pharmacist must share this responsibility through coopera-
tion >1ith the FDA. The practicing pharmacist must understand 
when and· why a drug product is not considered ,to be He.fe and 
effective·. A basic knowledge o:f both the reasons beh.ind and 
the implementation of a drug product reca.ll w:i.ll aid. in this 
determination. The importance of quality control in the manu-
facture of drugs is re:flected in the Current Good I1anu.facturing 
Practice (CGMP) regulations promulgated by the agency. This 
concept is applicable to the pharmacy. As the final check 
before the patient receives the drug product, the pharmacist 
should be alert to the problems in labeling and packaging of 
the drug product, coating and size of tablets, contamination, 
etc. 
The outcome of the controversy concerning the legality 
of the FDA-approved pacl;;age insert ~till have a marked effect 
on both physicians and pharmacists. Although the FDA claims 
that the package insert is merely an authoritative guide, it 
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has been used in malpractice cases as a definitive statement 
of the approved use of a drug. :B"'urther developments in this 
area will serve to better define the insert's use. Addi-
tionally, in the area of labeling, FDA is in the process 
of developing· patient paclcage inserts. The agency will be 
soliciting comments from health professionals and consumers 
about what types of information and £'or what drugs these 
should be included. This should give pharmacists an excellent 
opportunity for interaction ~~i th the agency. 
In response to increased consumer knowledge of drugs, 
the pharma.cist must be prepat-ed to ans\'ler patient questions 
about the actions of tl:J.e agency, as he is in-bet~leen the 
public and the FDA. Although it is the FDA's ~responsibility 
to assure that drugs are sa:fe, effective, and not misbranded, 
the agency's decisions are frequently misinterpreted. Often·· 
times, the cry of th(;l public has been that l"DA deprives them 
of dr·ugs capriciously, although the drugs have not been proven 
·to be safe and effective. Examples of these.outcries will 
become more evident as the OTC drug ingredient revimv panels 
publish more of their reports, · >vhich in turn will lead to 
regulations removing many mwafe or ineffective, but widely 
used, drug products form the market. 1'his furor has already 
been exemplified over FDA's proposed regulations classifying 
lac-ge doses of vitamins as drugs. The public needs the 
protection of the agency, but as opinions are frequently 
diametrically opposed on any given question, the agency acts 
in opposition to someone all the time. Only with a 
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compx·ehensive understanding of the procedures involved in 
FDA's regulatory activities can the pharmacist deal effec-
tively ~Jith his patients on these matters. 
The need for a comprehensive understanding of the drug 
regulatory procedures of the FDA can be met by providing a 
course as a component of the curriculum in pharmacy school. 
In such a course, the F.D.&C. Act and the regulations which 
give the agency its power to regulate drugs, and the programs 
developed and utilized by the Bureau of Drugs to implement 
them should be emphasized. The outline for such a course on 
FDA drug regulatory procedures is included in Chapter v. It 
.l.s expected that the descriptive material included in 




From the preceding discussion, a prototype of a course 
of study in FDA Drug Regulatory Procedures has been developed. 
In the following pages are included the objectives (Figuro lJ.), 
the catalog description and related information (Figure 5), 
and the outline for the didactic portion of the course of 
study. The Residency Syllabus for the practical ex-perience 
component which may form an optional component of the course 
of study follo~JS. 
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=r-----CODI:: --1-C-0_\J_R_S_E_· _N_O_. _________ -Lr.D __ E_P_,A.~-TM F. NT/DIVISION 
. 
COURSE TITLE 
FDA DRUG REGUJ~\TORY PROCEDURES~--------~.-----~--~~~~~~ 
I 
N.O. LECTURES/WEE!< I.ABORATORY HOURS/WEEK UNIT VALUE 
2 units . 2 lectures/week 
-----------~~~ 
COURSE OBJECTIVE AND GOAL: The student Shall demonstrate a_ knowledge 
of the regulatory control of drugs >vith respect to their safety, 
effieacy, and quality as governed by the J?DA; how regulations m'e 
promulgated and enforced to insure that only drugs which are·safe, 
efficacious, of good quality, and not misbranded are marketed. 
Perhaps most importantly, he should understand the responsibili-
ties of the phar-macist in supporting· those actions by >vhich the 
consumer is protected from substandm'd or hazardous remedies. 
·~---------------·----~-- . --~----~ 
ELEMENTS/SUB OBJECTIVES: The student shall be able to: 
1. Trace the history of the FDA, identifying the legislation 
that gives t;he agency its povter to xegulate drugs. 
2. Outline the organization and define the filllCtions of the J:<'Il.A, 
'l'lith emphasis on the Bureau of Drugs. 
3. Describe the procedures involved in the premarket clearance 
of ne~1 d.c'ugs, to include the material :r:eg_u:i.red in IND ond ND.A 
submissions. 
6. Explain the role of the FDA and the pharmacist in drug product 
xecalJ.s and. the procedures involved. 
?. Specify the penalties defined in the Federal Food, Drug and 
Cosmetic Act for means of its enf.orcement. 
8. Describe the various concepts of the re€,·ulation of d.rugs 
utilized b;7 the Bureau of Drugs in their programs vii th empha·· 
sis o:u Drug Efficacy Study Implementation, Over-the-Counter 
.Drug Evaluation, Biopharmaceutica, Drug Application E-valuation! 
Generic Drug l-lonograph.s, A."'ltibiohc .a:o.d Insulin Certification, 
a:o.d r1ethadone i'loni toring. 
9. Characterize the Drug Product Defect Reporting System, to I 
j_m:lude the roles of the phar-macist, the USP, and the FDA. 




FDA DRUG REGTJLATORY PROCEDURES (2) 
An introduction to the regulation of drugs by the Food and 
·Drug Administration "I-Ii th emphasis on the responsibilities of 
the pharmacist in supporting these regulatory activities. 
REQUIRED TEXTS: 
Federal_]?ood"- Drug an,d Cosmetic Act as amended January 
~U:B. Governmen·t; Printing Office, No. 1712-0126. 
Qlaimed Exemption for an Inve~tigqti~nal-New P-~~. Form 
17/T;J'Jei)artment of Health, Education, and \-Jelfare, 
Public Health Service, Food and Drug Administration. 
;N~\LJ1i:>ue;,..AJJplicati..2]1., Form 356H, Department of Health; 
Education, and \·/eli'are, Public Health Service, Food and 
Drug Administration. 
A Bti.?f' Legislative. Histo:I;';'L_Qf t_h~.P.ryg,_f)..lld Cosmetic 
jfr.f, Corumi ttee Print Ho. 1L~, Committee on Interstate and 
l!'oreign Commerce, Ja'1UaJ.'Y J. 974. 
RECONHENDED. ANCII,I.AllY TEXTS MID REFEiillNCES: 
· .Q.§..9£.§_..£-Yl~l ... r1§~.'ial£,._~~Foo~"92fLJ2~r.l~Ji~l'L'- .Cristop_her, 
Thomas ruKi. Goodrich, \'iilliam, Con!lllerce Clearing House, 
Chicago, 1973. 
Co,mpilll."ti.91l...S2.:f.~<l.te~,li,S. He11J...tl} Law.§., Joint Committee 
:Print for House Gommittee on Interstate and Foreign Commerce 
and the Senate Committee on Labor and Public \'lelfare, March 
1973, u.s. Governmen·i; Printing Office. 
P;!.J,}:£!_, Pr:ofi ts_,_,};Oj. .:~ ti.£.~, l'Iil ton Silverman and Philip 
t'ee, Universi·~-y of California Press, Berkeley, California, 
1974. 
STUDENT RATING SYSTEM: 
The grades \~ill be based upon the performance of the 
student on three hourly exams which will be of equivalent 
value. 
Figure 5. Catalog description and related information for 
the course in FDA Drug Regulatory Procedures. 
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FDA DRUG REGULATORY PROCEDURES 











o.;f drug regulation and the FDA 
Pure Foods and Drugs Act 
Shirley Amendment 
Sulfanilamide Elixir Tragedy 
Federal Food, Drug and Cosmetic Act 




Kefauver-Harris Drug Amendments 
Drug Listing Act 
B. Organization of the FDA and Description of 
the Ji'unctions of each of the areas 
1. Bt~eau of Foods 
2. Bureau of Drugs 
3. Bureau of Veterinary Medicine · 
4. Bureau of Radiological Health 
5. Bureau of Biologics 
6. Bureau of l<ledical Dev-;i.ces and 
Diagnostic Products 
7. National Center for Toxicological 
Research 
B. Executive Directo:r of Regi.onal 
Operations 
II$ REGULATORY RESPONSIBILITIES OF TRE FDA (2 hours) 




2. Prohibited Acts and Penalties 
3. Food 
4. Drugs and Devices 
5· Cosmetics 
6. General Administrative Provisions 





Code of Federal Regulations 
Federal Register: Notices, Proposed 
Rules, Rules and Regulations 
Parts l-9, 133, 138, 141-151, 310, 
312, 314, 328-330, 369·! IJ-29·-460, 
600-end 
C. Regulatory Philosophy 
1. Methods for regulation 
2. Premarketing vs. Postmarlceting 
3. Cost Effectiveness 
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D. Responsibilities of the Pharmacist 
1. USP/N1!' Dispensing requirements 
2. Dating 
;. Repackaging 
4. IND Drugs 
5 •. Adulteration and Misbranding 







sections of the FDC Act enforced-
201 (g) and 20l(p) 
301-307 
501-510 




1. Biometrics and Epidemiology 
2. Compliance 
;. ·Drug l\1onographs 
I~. Information Systems 
5. New Drug Eve-1uation 













Drug Application Evaluation 
Drug Quality Asm1:rance 
Over-the-Counter Drug b""'valuation 
Olin:i.cal Invef;ti.gat:ion :Svaluation 
Biopharmaceutics 
Drug Efficacy Study Implementation 
Drug Experience aJ1d 'L'rends Analysis 
Methadone· i'loni tor·ing 
Drug Listing 
Poison Control 
Prescription Drug Advertising 
IV. PREMARKET CLEARANCE OF NE~I DRUGS (4 hours) 
A. Claimed Ex:emption for an Investigational New 
Drug (IND) · 
1. Requirements 
2. \>/ell-controlled studies 
3. Phases I, II. and III 
4. Pharmacist's Involvement 
B. New Drug Application (NTIA) 
1. Requirements 
2. "Substantial Evidence" 








Importance: J_,egali ty 
Class I,abeling · 
Patient Package Inserts 




Review and DESI 
Procedures 
Enforcement 










F2•ocedure for development 
Contents · 





Good Nanufactro:'ing Practices 
Description 
Pm:pose 
Use by the Pharmacist 
B. Inspections 
1. Types 
2. Requirements · 
· · 3. Sampling 
c. Drug Product Analysis 
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1. Antibiotic and Insulin Certification 
2. National Drug Surveys 






2. MAC Regulations 
F. Corrective Actions 
1. Recalls 





VII. PROGRAMS SUPPORTIVE OF THE TOTAL EFFORT (2 hours) 
A. Methadone Honi'l;oring 
1. ProcedurGS 
2. Effect on the Pharmacist 
B. Poison Control 
1. Procedures 
2. Involvement of the Pharmacist 
C. Prescription Drug Advertising 
1. Advertising vs. Labeling 
2. Pharmacist 1 s Involvement 
D. Drug Listing 
1. Types of information required 
2. Importance 
E. Drug Experience and Trends A.'la.1ysis 
1. In:formation for Form 1639 
2. Pharmacist's involvement 
F. Drug Abuse 
1. Description of Program 
2. FDA and DEA 
VIII. llliSCELLA.lffiOUS (2 hours) 
A •. I'reedom 
1. 
2. 
of Information Regulations 
T;y-pes o.f information available 
Procedures for requests 
B. Bureau of Biologics 
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1. Contrast the FDC Act and regulation 
of' drugs with the PHS Act and. ragu·· 
lation of biologics 
2. Descript;ion of Programs 
C. Bureau of r-1edical Devices and Diag,Llostic 
Products 
1. Authority 
2. Prod.UctB regulated 
:;. Description of P:r:ogra.ms 
D. USP/NF 
1. Role as "official" compendia 
2. Involvement with the FDA 
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RESIDENCY SYLLABUS 
This syllabus represents guidelines for the continuing 
residency program at the Food and Drug Administration designed 
to train graduate pharmacists for specialization in govern-
mental drug regulatory procedures. The program utilizes the. 
work-study technique, as it applies to the development of a 
graduate study in preparation of a thesis for the Master of 
Science Degree~ 
Specifically, the goals of the program are: 
1. to provide background research material as part 
of a graduate degree program. · 
2. to create' a resour·::e pool of professionals trained 
in governmental drug ret,"Ulatory procedures. 
It; is anticipated that the program shall be of approxi-
materly 6··8 months duration, during •rhich time the. participat-· 
ing students will hold an appointment with the Food and Drug 
Administration. While they shall be salaried by that agency, 
it is the responsibility of the student to furnish transpor-,. 
tation and living arrangements. 
The program is to consist of th:C'ee areas:. rotational 
experiences, work assignments and graduate research. The 
rotational experiences are described in the follo~ling pages 
and constitute approximately 8 weeks of .the 6-8 month period 
of residency. The remainder of the time is to be spent in 
the area of emphasis agreed upon for the resident's time at 
the agency. This area is determined through discussions among 
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agency officials, the student, and the faculty advisory, 
and could include one of the divisions of Pharmaceu·t;ical 
Research and Testing, Biometrics and Epidemiology, Compliance, 
New Drug Evaluation, or Drug Monographs. The extended time 
period spent in the area of emphasis will allow the student 
to take an active role in the execution of the area's regula-
tory responsibilities, and. contribute to the agency's enforce-
ment mission.· The work assignments for the resident should 
be made by his supervisor in the area of emphasis. The area 
of emphasis ~;ill also provide the general background and 
possibly the specific title of the resident's FDA-related 
St,.ldents assigned to this program shall be screened by 
the Progre>~11 Director of' the. School of Pharmacy, University 
of the Pacific·, .and shall be subject to review by the Bureau 
of Drugs. The assigned students are expeci;ed to comply with 
the rules and regulations of the Bureau and will respect the 
confidentiality of matters being handled by that agency. 
Because this program >-rill be implemented most effectively 
through the work-study technique, working assignments should 
be made by ar·ea supervisors to supply study examples \1hich 
furnish models of genuine situations and problems. The 
Study Assignments outlined in this syllabus are designed to 
direct the student's course of study. However, flexibility 
should be maintained to accommodate changing needs and 
emphasis. lrny changes which are made should be cleared 
through the Program Coordinator and Liaison Officer of the 
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Bl.ll'eau, as well as the Program Director. Assignments vlill 
be evaluated by appropriate representatives of the Bureau 
and the University, but the responsibility for academic 
compliance will be assigned by the Program Director. 
The position of Program Coordinator should be assumed 
by one of the key officers within the Bureau of Drugs. He 
shall assist in making admin:i.strative provisions for the 
induction of the student and his assignment to·the various 
offices of the Bureau. A Liaison Officer who should be 
located in the resident's area of emphasis is appointed to 
provide scheduling of rotations throughout the Bureau and 
to assist in directing the student to specific activities 
within his term of residence. Further, the Program Coordinator 
or Liaison Officer may wish to designate staff members to 
serve as preceptors during the-periods which the student is 
studying within the various subdivisions. Designation of 
individuals to fill these two principal positions ~;i thin the 
progra.:n shall emanate from within the Bureau of Drugs. 
The student is expected to submit periodic reports of 
his study at the completion of the work in each of the units 
delineated within this syllabus. The Study Assignments s)lould 
serve as guidelines for these reports, and are directed towards 
developing tlte student's understanding of the relation of the 
functions and responsibilities of eac)l of the rotational areas 
to the enforcement by FDA of the Food, Drug, and Cosmetic .Act 
and its regulations. The progress reports should be a brief 
summary of the rotational experiences. Additionally, the 
progress of the research the student is doing within the 
agency should be included. These should be submitted to 
the faculty advisor within a month after the rotation, as 
a measurement of the performance of the student and the 
development of the research. 
1'77 
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ORGANIZATION AND F~roTIONS OF TEE FDA AND THE BUREAU OF DRUGS 
A. Ob;je.«Jti.~ 
1. Outline the organization of the total Food and 
Drug Administration. 
2. Identify the functions of the organization and 
its subdivisions with special emphasis on the 
Bureau of Drugs. 
3. Trace the history behind the development of the 
Federal Food, Drug and Cosmetic Act and di.scuss . 
the sections pertinent to the regulation of drugs. 
4. Explain the methods of implementation of drug 





Study the Federal Food, Drug, and Cosmetic Act. 
Re-view the 'ri tle 21 Code of Federal Regulations 
· sect:io:r;s that pertain to the r(;ogulation of drugs. 
ReYiew the structural chart of the organfzation. 
Survey the FDA Justifications of Appropriations 
Estimates for the Committee on Appropriations 
(budget) in which the FDA regula·t;ox·y programs 
are defined. 
1. What is the charge given to the ~~A by the 
legislation which created it? 
2. Describe the history behind this legislation. 
3. Describe the functions of each of·the components 
which contribute to.the accomplishment of the 
mission of the Agency. 
L~. Delineate· the sections of the Federal ]'ood, Drug, 
and Cosmetic Act which perte.:i.n to the regulation 
of drugs. 
5. Depict the structure of the agency and identify 
the key personnel reponsible for the operation 
of each of the subdivisions. 
PHARMACEUTICAL RESEARCH AND ~ISTING (minimum 1 week) 
A. flb,;jectives 
1. Outline the organization, functions, and 
responsibilities of the subdivisions of 
Pharmaceutical Research and Testing. 
2. Describe the procedures followed for the 
certification of antibiotics, insulin, and 
digitalis derivatives. 
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3. Discuss the interaction of Pharmaceutical 
Research and Testing with New Drug.Evaluation, 
Compliance, and. the Executive Director for 
Regional Operations. 
b.-. Characterize with the types of resea:rch done 
by the laboratories. 
1. Visit the divisions of Pharmaceutical ReseaL'ch 
and Testing. 
2. Interviev1 key officials within the divisionro: 
and asBist them in their lab work. 
3. Follow the processing of a drug product through 
the procedures involved in the testing f'or 
certification. 
c. §:!illQ.;y~if::;r-;.lll~ 
1. Delineate the organization of Pharmaceutical 
liesearch and Testing to include the branches 
of the divisions. 
2. Describe the functions of Pharmaceutical Research 
and Testing and their relation to those of New 
TJru.g :tvaluat;ion, Compliance, and :E.xecuti ve 
Director for Field Operations in FDA's mission 
to assure quality drug products. 
:?. Outline the procedures followed in the receipt 
of drugs, their testing and subsequent reporting 
of results in ·t;he certification processes. 
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IJ<:plain the organiz.ation of Biometrics and 
Epidemiology and the functions of its divisions. 
Specify the importance of the statistical evalua-
tion of the protocols imd data in INTI's, NDA's, 
and laboratory work; and the interrelationship of 
Biometrics with New Drug Evaluation and 
Pharmaceutical Research and Testing. 
Describe the contents of the adverse drug 
reaction reporting form FD-1639. Explain the 
categorization, computerization, and evaluation 
of the contents by the Division for Drug 
Experience. 
Discuss the function of the Division of Poison 
Control in compiling the poison incidence reports 
and their work with the poison control throughout 
the nation. 
B • ~\QQ.Ql.Q.ZZ 
1. notation within the Divisions of Biometrics, 
Pqison Control, and Drug Expe:r.ience to include 
interviews with the key personnel in the Ili visiom1. 
2. Review a statistics~ analysis of nm, NDA, or 
laboratory work. 
3. Accompany a statistician on assignment to the 
laboratories "and participate in discussions of 
the preparation of study'protocols that will 
generate data which can be analyzed statistically. 
4. Do a search for adverse drug reactions for an 
assign.ed. drug or drug category. 
· C. ptud;y; Asst,gn!!l~~ 
1. Prepac"ate written reports relating to some aspect 
of .adverse drug reaction reporting OI> poison 
control. 
2. Describe the functions and responsibilities of 
the divisions of Biometrics and Epidemiology with 
emphasis on their relationship to the other areas 
or the Bureau of Drugs. 
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COMPI,IANCE (minimum 2 weeks) 
A. 9_b;jecti ves 
1. Identify the organization, functions, and 
responsibilities of the divisions of Compliance. 
2. Specify the prohibited acts defined in the Food, 
Drug, and Cosmetic Act and the actions •~hich can 
be taken by the agency to enforce them. 
3• Describe the relationship of Compliance with the 
other areas of the Bureau of Druss, the Executive 
Director for Regional Operations,· and General 
Counsel. 
4. Discuss the Complia.TJce programs designed to 
assure drug product quality with emphasis on 
good manufacturing practices, drug product defect 
reporting system, drug efficacy study implementa-
tion, and drug quality assurance. 
B. k,Je,t]lpd.olog:r 
1. Reviei.,r case files of past and pending actions. 
2. Interview key persopnel in the various divisions. 
:?. Assist in the revievl of a case sent from the field. 
recommending legal action. 
4. Read the sections of the :b'ederal Food, Drug, and 
Cosmetic Act pertaining to the regulation of drugs. 
c. §tl!,gy __ *ssip.;nment.:.<1. 
1. Identify the principle subdivisions of Compliance 
and describe their roles in programs designed to 
assur.e drug product quality. 
2. Describe the Drug Efficacy Study Implementation 
progr8lll and compare it with the program for the 
enf'orceDJent of the drug monographs published from 
the over-the-counter drug review panel reports. 
;;. Delineate those sections of the Federal Food, Drug, 
ru1d Cosmetic Act that at'e frequently cited when 
legal action is taken. 
4. Define seizure, injunction, and prosecution in 
terms of their use in drug regulation. 
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EXECUTIVE DIRECTOR FOR REGIONAL 01-"'ERATIONS (minimum 1 week) 
A. Objective..§. 
1. Outline the organization of the ~xecutive 
Director for Regional Operations (EDRO) and 
compare the structure of the home office with 
the field. 
2. Define EDRO's responsibilities and understand 
its relationship with the Bureaus. 
3. Identify the types of drug inspections and 
understand the procedures involved in their 
implementation. ·· · 
4. Explain the relation of EDRO <ri th the state 
drug regulatory agencies.· 
5. Describe EDRO's role in the regulation of imports. 
1. Visit one of the field offices and i.nterv:i.ew.its 
key personnel. 
2. Accompany an experienced drug investigator on a 
Gl1P inspection of a drug firm. 
3. Intervie>1 key officials in the main office. 
C. Stuq;z, A?..:-"8-.z.nmen t §. 
1. Ilescribe the relationship of EDRO with the FDA 
Bureaus, with emphasis on t;he Bureau of Drugs. 
2,, Delineate the functions and responsibilities of 
each of the divisions in EDRO. 
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NEW DRUG EVALUATION (minimum 2 l-meka) 
A. Qbjectives 
l. Outline the organization and functions of the 
divisions in Ne~' Drug Evaluation. 
2. Describe the process by which new drugs are 
approved for marketing to include the I'equire-
ments listed in Form 1571 (IND) ru1d Form 356H 
(NDA). 
3. Identify the reviewers of the IND's, NDA's, and 
supplements and learn their responsibilities. 
4. Discuss the methods used by the Division of Drug 
Advertising to execute its responsibilities. 
B. ~thodolo©: 
1. · \vork assignment within New Drug Evaluation. 
2. Assist in the review of IND's ru1d NDA's as 
assigned by the staff. 
3. ·Attend advisory pru1el meetings ''llld Buree.u ()f. · 
Drugs nrounds 11 for the di visio.r:..s assig11e(Ly 
4. Intervi.ei'i' l'l'i th the personnel in the d.i visionrs, 
and include all those involved in the review 
process. 
5. Read portions of Title 21 Code of Federal 
· ReE,''Ulations pertaining to the regulation of 
new. drugs, and Section 505 of the FDC Act. 
1. llelineate the groups of drugs assigned to each 
of the divisions of New Drug Evaluation. 
2. Describe the essentials of a well designed 
protocol. 
3. Describe the effect of Ne\·1 Drug :E-valuation on 
the steps and procedures which must be followed 
in the taking a new compound from the "lab bench" 
to its final approval for use as a new drug. 
4·. Specify the role of the official compendia in 
the I~ID/NDA procedures. 
5. Describe the regulatory actions that fall 
wj.thin the aegis of New Drug Evaluation. 
6. Define "new drug", and determine who is 
responsible for making the decision ~1hether 
a substance is a new drug. 
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DRUG MONOt~RAPHS (minimum 1 week) 
A. .Qp__.iecti ve.§_ 
1. Outline the organization and functions of 
Drug Monographs and its relation to the 
enforcement of the FDC Act. 
2. Discuss the Over-the-Counter Drug Evaluation 
program and its implementation. 
3. Contrast the procedure required for approval 
of an Abbreviated New Drug Application with 
that of a New Drug Application. 
4. Specify the bioavailability requirements for 
NDA's and ANJJA's and the involvement of 
Biopharmaceutics in theirreview. 
B. Metho§.Q;to,g;y: 
1. Attend various over-the-colmter drug revie1v 
panel meetings~ 
2. Il\terview key officials ~lithin each of the 
Drug Monograph divisions. 
3. Study a bioavailabilit-.t review of either an 
ANJJA or NDA. 
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I~. Head the requirements in 21CFR:314.1(f.) for the 
submission of an ANDA. 
1. Revievl the objectives and current status of' the 
b'i.oavaiJ.abili ty program. 
2. Describe the process by which over-the-counter 
drugs.are reviewed for safety and efficacy. 
Contrast this process \vi th the one used in the 
NAS/NRC review. 
3. Define the differences between the ANDA and NDA •. 
In addition,.describe the effect of the proposed 
"old drug monographs" on the regulation of drugs. 
CHAPTER VI 
Sill'JMARY 
There exists an apparent lack of understanding of the 
functions and responsibilities of the Food and Drug 
Administration (FDA), the drug regulatory, by the pharma-
cist, the drug dispenser. In that the common goal of both 
is to assure that safe, effective, and good quality medica-
tions reach the patient, an interface between the FDA and 
the pharmacy profession should be created. A study established 
to develop a course in FDA drug regulatory proc:edu:ves for 
implementation in pharmacy school was complet.ed. Specifically, 
th$ objnctiv<> of the study vms to expand educational progr'itms 
for pha1:macy students througl'). the development of a c<l.I'ric·(1lar 
component in drug regulatory.procedures for pharmacy. The 
intent of this project was to design a formal course or 
CO'tl.I'Ses which may be offered for on-campus study and, because 
it; is predicted to be a necessity .for comprehensive understand~ 
ing of application and implications, to make recommendations 
for a period of residency within the agency. 
The study was accomplished by a graduate student's 
appointment to the FDA as a temporary employee for a period 
not to exceed one year in August 1974. The specific assign-
ment was within the Bureau of Drugs, New Drug Evaluation, 
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Division of Surgical-Dental Drug Products. Under the 
guidance of the supervisory chemist in the division, a 
working knowledge of the organh;ation, functions, and 
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regulations of the agency was obtained through participation 
in the division's .responsibility for reviewing data submitted 
on new drugs to prove their safety and efficacy. Additionally, 
rotations to other areas within the Bureau of Drugs and the 
Executive Director for Regional Operations served to provid.e 
the studen-t; with a comprehensive understanding of all of the 
various facets of drug regulations by the FDA. 
Throughout the residency experience at the FDA,.the areas 
of cooperation between the phax·macist and the agency 1~ere 
0· 
emphasized. The FDA, as the drug regulator, does not have 
the capabilities to assure absolute quality of drugs, but 
rather works to control the quality bY setting standards and 
monito:dng .compliance to these standards. Therefore, the 
pharmacist, as the drug dispenser, ·must recognize his respon-
sibility to ::>upport the agency in its protection of the con-
sumer from substandard or hazardous remedies. 
Based upon the knowledge gained and the experience 
acqui:L'ed while >Jerking at the FDA, the author recommends 
that t:he pharmacy school curriculum· should include a course 
on l!')JJi. drug regulatory prpcedures. The methods utilized by 
the FDA to promulgate and enforce the regulations written 
m1der the Federal Food, Drug and Cosmetic Act should be pro-
vided in such a course with emphasis on the responsibility of 
the pharmacist in supporting the actions of the FDA. 
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.Specifically, the course should conta:i.n information on the 
programs of d1.'Ug production quality assurance, biopharma-
eeutics, drug application evaluation, antibiotic and insulin 
certification, methadone monitoring, OTC drug evaluation, 
and the drug efficacy study implementation handled by the 
agency. For those students wishing to specialize in FDA 
drug regulation, the residency program at the agency is 
recommen.ded. 
The full significance of this study can only be appre-
ciated after several studies at the agency have been achieved. 
Addi tion.al data gathered from the experienced of graduate 
students engaged in research i11 other areas of drug regula-
tion at.the agency will provide a broad base for evaluation 
of the importance of the residency program. J:!'ee•dback froiD 
the stucl.E.HJts errr·olled in the course in FDA drug reg>.1latory 
prOC'fdU!.'es vill a::i.d in determini11g the usefulness of such a 
course. 
ADDEIID Uti! 
The course described :i_n this thesis was ·!;aught to 21 
upper division plHJrmacy students in the fall of the academic 
year 1975-76. The information presented in the course was 
that included in Chapters I and III of this thesis. Three 
exmos t~ere administered to the students to measure the 
aehievement of the course objectives (Appendices H, I, & J). 
The average scores of the class for the exams l'lert~: #l··-89.1>%, 






This syllabus represents guidelines for study in a 
proposed program designed to train graduate pharmacists 
for specializ·ation in governmental drug regulatory pro-
cedures. The proposed program utilizes the work-study 
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technique, as it applies to the development of a graduate 
study in preparation of a thesis for the l'iaster of Science 
degree. Tt is designed with the intention of developing a 
continuing program that others might follow in pursuing 
this area of specialization. 
Specifically, the objectives of this program are: 
l. to provide background re;3earch material as par-t; 
of a graduate degree program~ 
2. to develop an efficient and meaningful program 
which may be utilized on a continuing basis for 
seriicr or grad:uat;e pharmacy students. 
3. to create a resource pool of professionals trained 
j_n governmental drug regulatory procedures. 
It :i.s anticipated that the program shall be of four to 
3ix months' duration, during which time the participating 
students will hold an appointment with the Food and Drug 
Administration. \vhile they shall be salaried by that Agency, 
it is the responsibility of the student arJd/or the University 
of the Pacific to furnish transportation and living arrangements. 





Program Director of the School of Pharmacy, University of 
the Pacific, and shall be subject to review by the Bureau 
of Drugs. The assigned students are expected to comply 
\'lith the rules and regulations of the Bureau and will respect 
the confidentiality of matters being handled by that Agency. 
Because this program will be implemented most effectively 
through the work-study technique, working assignments should 
be made by ~cea supervisors to supply study examples. which 
furnish models of genuine situations and problems. Assignments 
outlined in this syllabus ro.·e desi.gn.ed to direct the student's 
course of study. However, flexibility should be maintained 
to accommodate cha.nging needs and emphasis. J..:ny changes which 
are ma.de should b~) cleared through the Program Coordinator 
and Liaison Officer of the Bureau, as well as the Program 
Director. Assignments will be evaluated by appropriate 
representatives of the Bureau and the University, but the 
responsibility for academic compliance will be -assumed by 
the Program Director. 
The position of Program Coordinator should be assumed. 
by one of the keyof'ficers within the Bureau of Drugs. He 
shall assist in maldng administra.tive provisions for the 
induction of the student and his assignment to the various 
offices of the Bureau. A Liaison Officer is appointed to 




to assist in directing the student to specific activities 
trithin his term of residence. Further, the Program 
Coordinator or Liaison Officer may "'rish to designate 
,. 
staff members. to serve as preceptors during the periods 
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;-rhi.ch the student is studying within the various subdivisions. 
Designation of individuals to fill these two principal posi-
tions \'li thin the program shall emanate from within the B1.rr·eau 
of Drugs. 
The student is expected to submit reports of his study 
at the completion of the work in each unit, as·· delineated 
within this syllabus. 
(4) 
A."PPEND IX A 
DRAFT 
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UNIT I. ORGANIZATION AND FUNCTIONS (1 week) 
A. 9b.jectives 
1. Learn the organization of the total Food and 
Drug Administration. 
2. Identify the functions of the organization ru1d 
its subdivisions with special emphasis on the 
Bureau of Drugs. 
3. Identify the key persoxmel responsible for the 
operation of each of the subdivisions. 
B. NethodQlQ&. 
c. 
1. Interviews with administrative officers of the 
several principal div-isions within the Agency. 
2. Attend orientation sessions for net:1l;r assigned 
personnel. 
Assir.:nments ___ ,...,._......,_, .. __.. 
1. \llhat is the charge given to the F.D.A. by the 
legislation which created it? 
2. Prepare an organizational chart of the Food and 
Drug Administration, indicating chief officers 
of the various subdivisions. 
3. Describe the functions of each of the components 
which contribute to the accomplishment of the 
mission of the Agency. 
4. Review the interrelationships the Assistant 
Commissioners for Administration, Planning and 
Evaluation, Program Coordination and Public 
Mfairs with the Administration and its Bureaus. 
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DRAFT 
UNIT II. BURF~U OF DRUGS (1 week) 
A. Objecti ve,'i 
1. Acquire a ~10rking knowledge of the functions 
and responsibilities of the Bureau of Drugs. 
2. Understand the methods of implementation o:f 
drug regulation as it relates to the safe-
guarding of public health. 
B. ,t"~;thpdolog;z 
c. 
1. Review Title 21 Code of Federal Regulations, 
Part 130-146e. 
2. Interview key personnel responsible for 
administration of the Bureau of DFugs. 
1. Delineate the organization of the J3ur<3au indi-
cating the responsibilities of its adminitrative 
officers. 
2. Briefly, but concisely, describe the ro.•eas of 
responsibilit-y and activities delegated to the 
several Offices forming the Bureau of Drugs. 
3. Describe any special proj.ects or programs >vhich 
fall \1i thin the Bureau of Drugs and not included 
within the responsibility of the Offices. 
l).. Review the various communications issued by the 
Bul.'eau, identifying those responsible for their 
preparation and distribution. 
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UNIT III. ·OFFICE OF COMPLIANCE (1 week) 
A. Objectiv~ 
1. Identify completely the organization,.functions, 
m1d responsibilities of the Office of Compliance. 
2. Determine resources available for accomplishment 
of the mission of the Office of Compliance. 
1. Study organizational charts representing current 
organization of the Office. 
2. Review procedm.'es manusals and regulations tmder 
which the Office of Compliartee vlOrks. 
:;. Intervie1r1 key perfJonnel \1i th the Office. 
4. Review case files of past actions. 
5. Assist in preparation of the current sta:ff action 
f'or completion, summarization and recommendai;ions. 
c. Assiggments. 
1. Identify the principal subdivisions and perso1mel 
of the Office. and their areas of responsibility. 
2. Describe the major functions and specific activi-
ties of the Office in implementing provisions of 
compliance. 
:;. Review actions vlhich may be required in cases of 
noncompliance, p:roc:edures normally followed, and 
pro-visions for enforcement. 
4. Prepare a resume' of a completed action taken by 
this office (to be assigned by supervising 
officer). See Methodology No. 5. 
5. By ~~hom and on what basis is the decision made 




UNIT IV. OF]'IGE OF PHARMACEU'l'ICAL RESEARCH AND TESTING (time TBA) 
A. pbject~§. 
1. Determine functions and specific responsibilities 
of the Office of Pharmaceutical Research and 
Testing. 
2. Und.erst:and the procedm·es followed by this Office 
in the fulfillment of its mission. 
B. fle1hoQ,QlQ& 
1. Visit the Office of Pharmaceutical Research arJd 
Testing. 
2. Visit .the National Center for Antibi.otic Analysis. 
3 •. Follo~l the processing of a product <m1;Jmitted to 





Delineate the organization of the Office of. 
Pharmaceutical Research and Testing and its 
subdivisions. 
Describe the functions of the Office o·f 
~uarmaceutical Research and Testing. 
Outline the Procedures followed in approving 




UNIT V. OFI!'ICE OF SCIENTIFIC COORDINATION (1-2 weeks) 
A. Objectives 
1. Familiarization with organization of the Office 
of Scientific Coordination. 
2. Learn the functions and responsibilities of the 
Office of Scientific Coordination and the pro-
cedures by which these are accomplished. 
B. Methodolog;z 
c. 
1. Work assignmen-t; within the Office of Scientific 
Coordination. 
2. Participate in the evaluation of statistical 




Prepare written reports rolat:i.ng to (a) some 
a. s:pect of adverse drug reaction reporting .. and/or 
(b) drug manufacturing Emd usage studies •. 
Revie~l the objectives and current status of the 
bioavailability program. 
Prepare statistical evaluation of data suhm:L tted 
on an NDA or HID. (Specific assignment to be 
made by Director of Division of Statistics.) 
Describe the program for the establishment and 




UNIVT VI. OFFICE OF SCIENTIFIC EVALUATION (4 months) 
A. Objectl.,~ 
1. Gain thorough understanding of the organization, 
functions, and procedural sequence followed by 
the Office of Scientific Evaluation in the execu-
tion of its responsibilities. 
2. Acquire working knowledge of FDA's responsibility 
for drugs, beginning with their early development 
and continuing through their clinical trials and 
marketing. 
B. l"letho.dology 
1. \~ork assignment with the Office of Scien'l;ific 
Evaluation. 
2. · Utilize •~orlcin:; transactions 11Jithin Office as 
1~arning tools, i.e. assist in revie~J' of IND'-s 
a;.1d NDA 1 s as assign<>d by s'~af'f. 
3. Prepare reports as required in completing reviews 
abmre. 
C. }>s §ig)lmen:!i.§. 
1. Delineate the groups of drugs assigned to each 
of the divisions of the Office. 
2. Describe actions and studies falling within the 
aegis of this Office • 
. 3. Describe, in detail, the essential components of 
a well designed protocol. 
4. Describe, in detail, the steps and procedures 
which must be followed in taking a new compound 
from the "laboratory bench" to its final approval 
for use as a new drug. What aspects of this con-





5. What provisions are made·for continuing 
evaluation of drugs on the market? 
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6. Who is responsible for making the decision 
whether a substance is a new drug under 
definition by the Food and Drug Administration? 
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APPENDIX C 
STATEMENT OF DUTIES AND RESPONSIBILITIES 
OF THE PHARMACY GRADUATE STUDENT 
,IID'R9DUC'riON 
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Incumbent serves as Assistant to the Assistant Director for 
Chemical Review providing him with the scientific and tech-
nical expertise in the pharmacy area necessary to accomplish 
the program's mission. 
DUTIES P.JID RESPONSIBILITIES 
Perform special studies relating to manufacturing techniques, 
drug distribution and utilization in r·etail and hospital 
pharru.ac:Les. Assigned projects are s.elected to represent ·· 
overaJ.l functions of OSE in reviewing nm' s and NDA' s. After 
assi.gnm<!lnt of broad project, prepares work plans, time 
schedules, and performs the routine steps of eve.luating the 
safety and efficacy information as to use of the drug product 
in humans. · Following completion of this evaluation, prepare 
a c.ri tique of .the process and evaluates the degree to ~:hich 
education a11d experience apply to the fw1ction. Prepares 
suggestions for curriculum modification based on practical 
expe:c·ience. Prepares suggestions and recommendations to the 
Bureau on meeting, selecting, training and utilization of 
undergraduates and recent graduates of Schools of Pharmacy. 
Attends professional and administrative meetings to develop 
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kno\1ledge of the interdisciplinary approach of the Bureau 
of drug regulations. Develops project presentations .for · 
these meetings as assigned. 
SUPtJRVISION P~CEIVED __ _..., 
The incumbent works under the direct supe!~ision of the 
Assistant Director for Chemical Review. Supervisor assists 
in identification of the problems and is available to assist 
with unusual developments. Work is evaluated on the basis 
of demonstrated ability to develop professional competence 
in the field of pharmacy. Periodical r(;ports are discussed 
\ti th the incumbentand with the incumbent's college advisor. 
/ 
'· 
uc:.r-'•1"11 M!:.N 1 •..rr- Mt'-AI... Itt; l:.UUCATIOtl, P.NO'WELFAR:E 
PU£1llC HEALTH SERVICF-




OJ,fB Nc, .57-R0030 
CLAIMED INVESTIGATim'IAL EXEMPTION 
FOR A NEW DRUG 
Name of Sponsor __ 
Address 
Date 
Name of Investlg.ati.onal Drug 
Commissioner 
Food and Drug Administration 
Bureau of Drugs ( BD-26) 
5600 Fishers Lane 
Rockville, Maryland 20852 
Dear Sir: 
The sponsor,-::-.,---:--:---:-----,---,------:-.,---:---:· ------------, submits 
this notice of claimed. investigational exemption for a new drUg under the proviswns of section 505(1) of the 
Federal Food, Drug, and Cosmetic Act and !130.3 of Title 21 of the Code of Federal Regulations. 
Attached heretc, in triplicate, are: 
1. The best available descriptive aame of the drug, 
including to the extem known the chemical name and 
structure of any new-drug substance~ and a statement of 
how it is to be administered. (If the drug has only a c-ode 
name, enough information sho!Jld b~. supplied to identify 
the <kug.) 
2. Complete ll$t of components ·of the drug, including 
any re:e..sona~le altern:..'.tes for ir.activ-.e components. 
3. Complete .stv.teulent of quanti.t;:ltive composition of 
d!'ug, ill.clud.ir.g rea!"~cnab.le variation~; that may be exrected 
during tt.~ .luv~.cttigatiomtl :Hage. 
4. Description oi source and pxe:fJaration oft any new-
\drug sub~~tan.ce~; u;.;':':d as c.l':lmp{m~i1ts. including the name 
and acldn:·ss of ·.!.'1.::S. s~~r:Plier or pro:::"essor,· other than the 
spons.or;,··of Cl\ch h~;w;.Jrug·subStance: 
5. A .;natem~nt of the mcrhods, facilities, and controls 
used for the manufaCrm:ing, processing," a:nd packing of the 
new drug to establish a.nd maintain appropriate staridards 
of identity, strength, quality, and purity as needed for 
safety and to give significance to -clinical investigations 
made with the drug. 
6. A" statement covering all information available to 
the spo.nsor derived from J?teclini.cal investigations and 
·any clinical studies and experience with the drug as .fol-
lows: 
a •. Adequate information about the preclinical investiga-
tions, i;tcluding stHd.ies made on laboratory animals, on 
the basis of which the ;l".ponsor has c&nduded that. it is 
1eascn~bly :Hlft::. to initiate clinlca1. investigations .with 
the drug: Such information shQ.uld indude identification 
of the person who conduc~ed each investigation; iden[ifi-
catiod nod qu'l.li.fic~nion.s of the individm1.l" who_evnluated 
--the -resufts-an-d-CoUC.:lUd"t;Ji1_a_t_1t __ is ~e-.ason:...b-iy sate to 
initiate clinic:ll investigati,Jns with the drug and a state-
ment of whue the investigations were conducted and where 
the records arc available for inspection; and enough de-
tails about the investigations to permit scientific review. 
The preclinica t investigations shall ·not be considered 
adc::quat•.! to justify clinical testing unless they give proper 
attention to the conditions of the proposed clinical test-
ing. When this information, the outline of the plan of 
clinical pharma"colo~y .. or any progress report on the clini-
cal pha_rmacology, imli<.,Hes a need for full review of the 
preclinical data before a clinical trial is undertak('n, the 
Department \"\!ill notify the sponsor to submit the complete 
prt~cl.bi.cai data and to withhold clinical t!ials until the 
re·rie-·;<.' is completed and the ·sponsor notified. The Food 
s.nd D~ug Administ;~tion will be prepared to conf~.r with 
the sponsor concerning this aC"tion. 
b. H the d~·ug has been marketed \-vmmt:rcially or in-
ve~Higared (.;-.. g. oucside the Unit<;:d States}. complete 
info~m~tion ~'bnut such distribution ~r inve~:i,gution shall 
be submitted.: along with a com.r,ine bi.bli.o.graphy of a·ny 
publications about the drug. 
c. If the dn;..g'· !:;; a ccmbin<ltion of pceJ.•ioli!':!~' inVesti-
g<!ted or market(:;d ·drugs, an 3.dequ;.,.tt: summary of pre-· 
existinG" infgrrnu_1;1on from pre_clinic:al. and. ·ci:inic:aLin.vesti.~ 
gation-s and· experience with its components, inc.luding 
all reports available to the spOnsor suggesting side-ef-
fects, contra"indications, and ineffectiveness in uo.e Of 
such components: Such summary should include an ade-
qua~e bibliography of public.ations abo\a the components 
~.nd. <may incorporate by refetence any informati<Hl concern-
in,g such c-omponents previously submitcc-d by the StJOnsor 
to the Food and "Drug'"Administration: IOclude a :;t-,~·ti--fneO.t 
·of the exPected pharmacological effecr.s of the .:ombi.o.a~ 
don. 
7. A total of three copies of all informational material, 
including label and labeling, which is to be supplied to 
each investigator; This shall in~lude :~.o accurate descrip-
tion of the prior investigations and experience and their 
results pertinent to the safety ·and possible usefulness of 
the drug-under the conditions of r.he investigation. It shall 
not represent chat the safety or usefulness of the drug has 
been established for the ,purposes to be· investigated •. lt 
shall describe all relevant hazards, contrn.indications, 
side·effects, and precautions suggested by prior iJwestiga-
tions -itnd experience with the drug undCr investigUriOn anCf 
related drugs for th,e information of clinical investigators. 
8. the scientific trainin.g "and' experi~.,'ce considered 
appropriate by the sponsor to qualifY the investigators as 
suitable e.xperts to investigate the safety of the drug,"bear-
ing in mind what is known about t~e pharmacological 
action of tht~ drug and [he phase of the investigational 
program thnt is to be undertaken. 
FD FORM 1571 (5/71) PREVIOUS EDITIONS ARE OBSOLETE. 
9. The names and a sUmm.ary of the tr<'Wlf•g and elC~ 
pccience of each investigator and of the indivi(iu~d charged 
wJth monitoring the progwss of the investigation and eval-
uating the evidence o( safety and effectiveness of the drug· 
r<s it is received from the investigators, together with a 
statement that the spon_sor has obtained froffl each inves-
tigatr.H a completed and signed form, as provided in sub~ 
paragra.;h {12) or (13) of this paragraph, and that the inves~ 
··dgatocts··qualificd· by scientific training and· experience 
as ·an approrrir.te expert to undenakc the phase o{ the in-
vestigation outlined in section 1.0 of the "Notice of Claimed 
Investigational Exemption! for a New Drug."l (In crucial 
situations, phase 3 investigators may be added and this 
form Supplemented by rapid cominunication -methods, and 
the signed form FD 1573 shall be abtained·p.rompo:ly them~ 
after,) .. 
10. An outline of any phase or phases of the planned 
investigations and a description of the institutional review 
committee, as follows~ 
a. Clinical ph::amacology. This is ordin11rily divided 
inLo two F'hases: Phase 1 starts when the new drug is first 
introduced into man--only animal and in vitro data are 
available--with the purpose of determining human toxicity, 
·metabolism, absorption, elimioatie>n, a-nd other pharmnco-
logicn.! action, preferred route of administration, and safe 
dosage tange; phase 2 covers the initial trials on a limited 
number of patients for specific disease control or pro-
phyiaxis purposes. A general outline of these phases 
shall be submi.tt-ed, identifying the investig-ator or inves-
tigators, th~~ hospitl:lb: or research ft~c.ilitie$ whe.re the 
clinicnl pharmacotogy will be undertaken, any expert com~ 
mittces or panels to be utilized; the maximum number· of 
subjects to be involved, and the estimated duration of thes.~ 
early phases o£ i:wc~ti{?.Q.tion.' Mod~fic-ati-on of th~ exp-eri· 
menr.al desigr, em the bes1s cf exper!ecce ga~ned O-'eed be 
reporterJ only in the progress reports on thes-e early pbases 1 
or in the <1evdopmer1t 0f th.e plan fo:r ~he clinical trial; 
phase 3. The: first t"<;\'0 phases m~~·· overl11p and, when in-
dio::ated, may ceqeire a!:!ditl.onal· ani!:!"laJ d;a:;a before· these 
phases can he ct~mplNc1. O!: phase ':} can be und~rt:aken. 
Sttch a~1i.m;:-.l tests ~hall be desi.~n.ed to t-ake into account 
the expecte::d duration of A.dmin.i..stration ohhe drug to human 
beings, the age grcmps and. physical statu·s, as for example, 
infants, .rregnant women, premenopausal women, of those 
hurnan beings to whom the drug may _beadministe.ced, unle~s 
this has alceariy been doric in the origin·al animal studie.s. 
b. Cltnical trial. Tbis ph:-~se 3 provide>S"·:the assessment 
of the drug's sa!~~:y and eifecti·vene~;s and -optimum dosage 
schedules in the d.itlgnosis, tr~Altment1 o·r {'rophylaxis of 
groups of ~ubjects involving a given di.s.ease or condition. 
A .r<>~''.Se>r.?.ble }HOtccol is developed on the basis of the facts 
f\Ccun·.ulated in the e;;.dier phases, inch:zdi-ng completed and 
submitt~d anim;;.l studies. This r·ha.c;e is -c-on·ducted by sep-
afatc gtours following "the )j·a . .:.~.e p.ro~ocol (wii:h reasonable 
va.rlar.ions _and ~dtern:.:.tivcs r-e.-:mittcd by the plan) to produce 
well~controlled dinicnldata. F:)r 'his phase, the fOllowing 
c!atc sh~ll be submitted: 
i.- The names :1.nd addr('SS~s of the i-ove·stigatorS. (Addi-
tional il1vestigators may be added,) 
ii. The specific ·nature. of che investigations to be con~ 
ducted, together with ioformt\tion or case 'teport forms to 
show the scope and detail of the planned clinical observa-
tions and the clinical laboratory tests to be ·made and re-
portelt 
.. iii. The approximate· number of subjects (a reasonable 
range of subjects is permissible and additions may be 
made), and criteria propos-ed for subject selec-tion by o\ge, 
sex, and conditinn, 
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iv. The t•siimated ·duratiOn of the clinical trial and the 
interv11ls 1 not exceeding .1 ·year, lit whi.ch prog:ess reports 
showing the results of the investigations will be submined 
·tO the Food and Drug Administration, 
(The notice of. cl~imed investigational exemption may be 
limited to any one or more phases, prov.ided the outline of 
the additional phase or phases is submitted before such ad-
ditional phases begin. This does not preclude ·continuing 
a Subject on the drug from phase 2 to phase 3 withou~ int.er· 
rupdon while the plan for phase 3 is being devCloped,) 
Ordinarily, a plan for clinical trial w!ll.not .. be regarded 
as reas.onable unless, among other things, it. provides for 
more than -onC independent competent investigator to maiP,-
tain adCquate Case histories of an adequate number of sub~ 
jcct.s, designed to_ record observations and permit evalua~ 
tion of any and all discerO.ible effects attributable to the 
·drug in each individual treated, and comparable records on 
any individuals employed as controls. These records shall 
be individual cecwds for each subject maintained to include 
adequate in-formation pertaining to each, including age, sex:, 
conditions treated, dosage, frequency of administration of 
the drug, results of all relevant clinical observations and 
laboratory examinee ions made, adequate_ 'information con~ 
coerning any other treatment given and a full statement of 
any adverse effect"> and useful results observed, togf:ther 
with an opinion ~~s to W1;etner such effects or results are 
attributable to the drug under investi.gation. 
· c, lnstitutional.!eview committee. If the phases of clin-
ical· study as described-under lOa and b above are conducted 
on institutionalized subje<rts or are conducted by an ind!~ 
vidual affiliated With an institmlon which a_.gre~"'s to :assmne 
responsibility for the stud_y, o..ssurac.tte rl\<J-i.;t be giv;:n that 
an inst\n:tional revit:·r·J C~!'.'lmittet: i~ resr-onsibl.~ hr L~icid 
-aud continuingrevie~.v and -appWYal C)f rhe propcsedc1i,:-:.ica! 
study. "!he membership must bf.: campoL:·e-d o1 sufficient 
members of varyingb~\ckr;ro'.lnd, that is, la'XYf::s, clergy.n~!:'!l, 
or l<O.ymen a$ well <<s sci.e.ntists, to ·«.s~uH.: CO\npi.::tt· und 
adequ:He review of the re:search project. The rneml:>crship 
mu.-:;t possess not oniy br':'ad competence ta compt·-::h~r.d (he 
nature of' the pro fe"ct-,. b\it also other competencies nec!:'!ssary 
to judge the acceptability of the projector llCtivity in terms 
of institutional regulations, relevant law, standards nf pro;. 
fessional practice, and community acceptilnce. Assurance 
must. be I>resented that neither the sponsor npr the inves-
tigator has participated in selection of co~mittec ·members'; 
that the reyiew committee does not allow participation in 
its review and conclusions by any individual invoived in 
the cotiduct of the research 11ctivity under review (cxce:pt 
to provide information to the committee); that the investi-
gator wil_l report to the committee for review any emerger.t 
problems, serious advt:rse reactions, or proposeci procedurB.l 
changes whi~h may -affect the status of the investigation 
and that no such change will be rnade without committee 
approval except where necessary to eliminate apparent im-
mediate hazards; that reviews of thP. study will-be conducted 
by the review committee at intervals appropriate to the de-
gtee Of risk, but not exceeding 1 year, to assure that the 
research project is being conduded in compliance with the 
committee's understa-nding and recommendations: that rhe 
review committee is provided all the information on the re-
sea~ch project necessary for its complete review of the 
project; and that the revie·w committee maintains adequate 
documentation of its activities and devebps adequate pro~ 
cedures for reporting its findings to the institution. The 
documents maintained by the committee are to include the 
names and qualifications of committee members,:. tccords of 
info:·mauoo provided to subjects in obtaining informed con-
~ent, committee discussion on substantive issues and their 
resol1,1tion, cQmmittr.e recommendations, and dated report$ 
of successiyc reviews as they a.re performed. Copies of all 
doa.,~ments are to be retained for a period of 3 years past 
the completion or discontinuailce of the_ study and are to be 
rtlflde available upon request to duly authorized represen~ 
tatives of the Food ~nd Drug ~dministradon, (Favorable 
recommendations by the committee are subject to further 
appropriate review and rejection by ins~itucion O:fficia_ls. 
Unfavorable recommendation-s, t(:Strictions, or conditions 
may Rot be 01(erruled by the institution offiCials.) -._Proced-
ures for the organization and operation of institutional 
review committeeS are contained in guidelines isSued pur-
suant to Chapter 1~40 of the Grants. Admini~;ttation Manual 
of the U.S. Department· of Health, Educatiott 1 and Welfare, 
available from the- U.S. Government Printing Office. It is 
recommended that these 'guidelines be followed in estab~ 
lishing insti:utional review committees and that the com-
mittees function according to the procedures described 
therein. A signing of the· Form FD .1571 will be regarded 
as providing the above necessary assurances. If the insti~ 
turion, however, has on file with the Department of Health, 
Education, and Welfare, Division of Research Grants, Na-
. tional Institutes of Health, an naccepted general assur-
ance, 11 and the same committee is to review the proposed 
s~udy using the same piocedures, this is acceptable in lieu 
~of the above assurances and a statement to this effect 
should be provided with the signed FD- 1571. (In addition 
to sponsor's- continuing respor.sibility to mOnitor the study, 
the Food and Drug Administration will u~dectake inv~stiga-
Very truly yours, 
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tions in institutions periodically to determine whether th~ 
~ommittees are operating in accord with the assurances 
given by the sponsor.) 
11. !tis understood that the sponsor willootify d.e Food. 
and Drug Administration if the investigation is discontin-
ued, and the reason therefor. 
·l2. ltis understood-that the sponsur will notify each in~ 
vestigatoi if a oew~drug. appli.catlon is approved, or if the 
·investigation is dis<;:ontin11ed. 
13. If the drug is to be soid, a full cx:plunation why sale 
is required and- should not be regarded a::-: the commercial-
ization of a new drug for which an application is not ap~ 
proved. 
14. A statement that the sponsor assures thor clinical 
studies i.n humans will not be init-iated prior to 30 days 
after the date of receipt of the riot ice by the Food and Drug 
Administration and thm he will condnue to witi"wld or to 
restrict clinical studies if requested to do so by the Food 
and Drug Adminisuation prior to the exPiration of such 30 · 
days. If such request is made, the sponsor' wiil be pro-
vided sp~ci.fic information as to the deficiencies and will 
be afforded a c.onference on request. The_30-day delay may 
be waived by ;he Food and Drug Administration upon a 
showing of good reason for such Waiver; and for investi-
gati"(;ms subject to institutional review committee approval 
·as- described in item lOc ~hove, an additional statement 
assuring that che investigation will not be initiated prior 




(This notice may be amended or supplemented from time to time on the bosis o.f the experience gained with 
the new drug. Progress rep~rts may be used to update the noti.:e.) 
ALL NOTICES AND CORRESPONDENCE SHOULD llE SUBMITTED IN TRIPLICATE. 
3 
DEP-ARTMENT OF HEALTH, EDUCATION, AND. WELFARE 
f'UOLIC iiEAL.TH SERVICE . 
F'OOD AtiD DRUG ADMINISTRATION APPENDIX E 
Form Approved 
OMB No. 57 -R0003 
f'IOCKVILLE, MARVLAN~ 208!12 
HEW DRUG APPLICATION (DRUGS F0£1 HUMAN USE) 
(Title 21, Code of Federal Re_gulatiom,•, 'V130.4) 
Name of applicant 
Address 
Date ---------------------------------------~---------------------------------------------------
Name of new drug ____________________________ __ 
0 Original application (regulation § 130.4). 
0 Amendment to origin~l. unapproved application 
(regulatbn § 130.7). 
D. Abbreviated appiication (regulation § 13Q.4(f) ). 
0 Amendment to abbreviated, unapproved application 
(regulation § 130.7). 
D Supplement to an approved application (regulation· §'130.9). 
:0 Amendment to supplement to an approved application. 
·The undersigned submits this application for _a new drug pursuant to section· SOS(b) of the Federal Food, 
Drug, and Cosmetic Act. It is understood that when this application is approved, the labeling and advertising for 
the drug will- prescribe, recommend, or suggest its use only under the conditions stated in the labeling which is 
part of this application; and .if the article is a prescription drug, it is understood that any 1 abe 1 in g whlch 
furnishes or purpmts to furnish information for use or which prescribes, recommends, or suggests a. dosage for 
u~e of the drug- will contain the s·ame information -for its use, including indications, effects, dosages, routes, 
methods, and frequency and duration of administration, any relevant warnings, hnzards
1 
contraindications, side 
_ ~ffects 1 and pr~cautions, as that contained in the labeling Whi-ch is- part of this application in accOrd with § 1.106(b) 
(21 CFR 1.106(b)). It is uil_derstood that all representations in this applicrJ.tio:-t e~pp-1.y to ·the: drug prcduced L~nti1 
.an approved supplement. to the application p:.-ovides fnr a change or the ch~,:Ige is made i_n confotmance VJith ot}1er 
provis~ons·of §130.9 of the new-drug regulations. 
Attached he!"eto, submit·~ed in the form described 
a part of this appli·:at.ion are the following: 
1. Table of coments. The -t_able- of contents should 
spec-i-fY""""the::v~IuiD;n.~~~b~r---and---the----paf,e--number-in whic-h 
.the comp!ete and de~g,il,"!d item is located and che volume 
number and the page number in which the- summary of th<lt 
item is located (if any). 
2. Summary. A summary demonstrating that the aPplica~ 
tion is well-o~ganized, ;:tdequa~ely tabulated, statis.tical1y 
analyzed (where appropriate), and coherent and that it 
presents a sound basis for the approval requested. The 
summary should include the following informacion: (In 
lieu of the outline described below .and the_ evaluation 
described in 1tem 3, im expanded summary and eva!uacion 
as outlined in § 130.4(d) of the new-drug regulations may 
be submined to faciiitare 1the teview of this application.) 
a. Ch~mistry. · ' 
i. Chemical struct,.lral fo!mub· or descripLion for any 
.new-drug suhstanc~t 
ii. Re1ati_c·nshi_r} to other chemically or pharmacologi·· 
cally related d:ugs. 
iii. Description of dosage fotm and quantitative com-
position. 
b. Scientific rationale and purpose the drug is to serve. 
c. Reference number of the investigational drug no-
cice(s) under which this drug was investigated and of any 
notice, new-drug application, m: master file of whic-h any 
contents are being incorporated by reference co support 
this applicatiori. 
d. Preclinical studies, (Present all findings including 
all adverse experiences which may be interpreted as 
incidental or not drug•related. Refer to dace and page 
number of the investigational drug notice(tl) or the volume 
and page number o( this application where complete data 
and reports appear.) 
i. Pharmacology (pharmacodynamics, en<,locrinology,. 
· Inetnbolism, etc.). 
in § 130.4(e) of the uew·-dmg ree;t.:ia:ions, and- constituting 
ii., Toxicology,and pathology: Acute tox1c1ty st,..:dit:cj 
_subacut-e_. ar...d chr.onic_toxicity st.udies; ___ reproduction ... and __ 
teratology studies; miscellaneous scudies . 
e. Clinical studies. (All m·aterial should refer spedfi· 
cally to each clinical investigator and to the volume and 
_page number -in the application· and any documents i.nu 
corporated by reference where the complet.e data and re-
ports may be found.) 
i. Special studies not described elsewhere. 
ii. Dose-range studies. 
iii. Controlled clinical studies. 
iv. Other clinical studies (for example, un·controlled or 
incompletely controlled studies). 
v . . Clinical I laboratory studies related to effectiveness. 
vi. Clinical.laboratory studies related to .safety. 
vdi. Summary of literature and unpublished reports avail-
able_t_o the applican_t. 
3. Evahtation cf safety and effec!_~~ess. a. Sum-
marize sep::t:-ately the favorable and unhntorable evidem.e 
for each claim in the P<-1ckage labeling. Include references 
ro the volume and paEe number in the appli~ation :>.nd in 
any documents incorporated by reference where the com..: 
plete data and reports may be found. 
b. Include tabulation of all side effects or adverse 
experience, by age, sex, and dosage formulation, whether 
or not coO.sidered to be significant, showing whether ad-· 
m·inistration of the drug was stopped and showing .the 
investigator's' name with a reference to the volume and 
· pilge number in the application and any documents in" 
corporatcd by reference ·where the complete data and ~e· 
ports may be found. Indicate those side effects or adverse 
expcrit:ncet: considered to be drug"'[elated. 
4; Copies of the label and all othe-r labelinp: to be used 
for thC drup (a total of 12 copies 1{ in final printed form, 
4 copies if in draft form): 
a. Each· b'bci, or other iabelin"g, should be dcao:ly 
identified to show .its position on, or the manner io which 
it accompanies, the aia.rket packa_ge. 
b. lf the drug is to be offered OV(!f the counter, labeling 
on or within the retail package should include adequ~te 
directions for use by the laymt:~.n under all the conditions 
for which the drUg is intended ior "la.y use or is w t.e 
prescribed, re(.ommended, or suggested in any labding or 
ad\>ertising sponso!ed by or on behalf of the applicant 
and directed to the layman. !f ::h!O' d[ug_ is intended or 
offered- for uses under the profe.s.siOnal supervision of a. 
practitioner licerised by la·N to administer. it, the applica .. 
tion should also contain labe.iing that includes adequate 
infprmation for all such uses, including all the purposes 
for which the over-the·counter drug is to be advertised to, 
or represented for use by, physicians. 
c. lf the drug is limited in its labeling ~o use under 
the professional 5l1}'ervision of i practitione.t licensed by 
law to administer it, its labeling should bear information 
for usc under which such practitioners can use the drug 
for the purposes for which i"' is intended, including all 
the purposes for which ii: is to be advertised or repre-
sentod, in acco.d with §1.106(b) (n CFR l.lOG(b)). The 
application should_ include "2-0Y l-abeling for the drug 
i.ntcnded to be made available to the layman. 
d • . If no- established name exists 'for a new-drug sub-
stance, the applicP.don shall propose a ._nonproprietary 
name for usC aS the established name for the subste.nce. 
e. Tyl-'ewrittcn or other draft labeling copy may be sub-
mitted for preliminary consideration of an application. An 
application will not ordinari-l;r be approved prior to the 
submission ·of the final printed label and labeling _of the 
drug. ·· 
/. No application may be approved if the labeling is 
. false or misleading in any particular. 
(When mailing pieces, any other lab-::ling, -Ot ~dv~1tis in.g 
cOpy are devi.sed for p:omocio:1 of th{! ne-w drug, samples 
shall be -su.br'lliH~·d v.t the ~itne of ioitl:,,.l dissemination cf ( 
silch labdir.:g t:~-nd. a~ the ;;in::.c of .i.c!!i~"l ?lacement of a.l::J l 
such ~dvettjsit;g fot a prescription drug (see §130.13 -of .. 
the new-...{.:;:-ug .tegw.latior.s).-- Apptc>v_al of a :supplemcn:nl 
new-drug il,_-ppli.c:ation i~ r~quited prior to use of r,ny :pic•-
sn.otionr-.1 dahl~ oct covered \.;y the -approved application.) I 
5. A stn<:t::ffi{~nt £S to whether the d.rue; is {or is fi()t) I 
!§~j~;dTni~·s kbeli:_ljL_~d by this apPlication tO u·se 
l!flder the vrofessiona.l supervision of a practitioner 
ficensecfby i;,; to ad~1T;i1>ter it. 
-6:1\Tul.IlGt-;,t the ar-ticles us-ed as components of 
!_l.l_':_ __ §~.- This--list should include all substances used 
in the syn~hesis, e:rtrection, or other method of preparmiou 
of any ocw.J.ru13 subst~\ncc, and in the preparatio-n of the 
fiJ,ished- do& age fo.nn, rt::ga.rclle-ss of whether they undergo 
chemical ~~ang-:! or are r~~rooved .i.a the P,HH':ess. Each 
suh:~tance should be identified by its cstabli~hed name, 
H any, or complet-e c:her11.ical £lame, usin.g structural 
fonnvlas wht!n n.e~;:eggary for specific identifice.tion. If 
any pro1rrietar'y pn:po.:c~tion is used as a component, ·the 
proptietary oa'lne should be !fJllow.~d by a complete qusn-
titfltiv~ s,tatement of composition. Reasonable a.lt_ernativcs 
for nny~listed substanCe may be specified. 
7. A full statement of the composition of th-e dr~g. 
ThT~~Sharf-sC"t-forth the narue and ~mount of 
ca:ch ingredient, whether active or ·not, contained in a 
stated quantity of the drug .in the form in which it is to be 
distrib\•.ted (for example, amount per· tablet· ot per mil-
liliter)- and t.\ batch formula representative of that to be 
employed fo-e the manufacture of the _finished dosage form. 
AU components should be included in the batch formula 
regardless of whether they appear in the finished product. 
Any calculated excess of an ingredient over the label 
declaration should be designated as such and percent 
excess shown. Reasonable vai:i~tions may be spe_cified. 
2 
···c:ut5 
!h_~·full_Jescriptioh of the methods U!Wd in, and the 
f~tciEties and con.trols used for, the mar:ufacture, procesS• 
ft~l"r~~cking o( the drug. lnclud,:d iil thts descripti-;;-;1 
should be full information with respect to any n~w-drUg 
~ubstancc and to the new-drug do~age form, as follows, 
in sulfident detail to permit evaluation of the adequacy 
oi the descl:ibed methods of manufacture, processing, and 
packing and the described facilities and controls to 
determine -and pxeserve the idend,ty, strength, qunlity, 
and purity of the drug: 
a. A descrip_tion of the· physical facilitic~ including 
building and equipment used in manufacturi1~g. processing, 
packaging-, labeling, storage, and control operations. 
b. A description of the qualificatiOns, including educa:-
tional background and experience, of the technical and 
professional personnel who are responsible for assuring 
that the drug has the safety, identity, strength, _quality, 
and purity it purports or is repre.sented to possess·, and a 
statement of theit responsibilities. 
c. The methods use:d in the synthesis 1 extraction, 
isolai:ion, or purification of any "new--drug substance. When 
the specifications and controls applied to such substance 
are inadequate in themselveS to determine its identity, 
strength, quality-, and purity-, the methods should be. 
described in sufficient detail, ·including quantities used, 
times, ter.-lperatures, pH, solvents, e!c., to determine 
these ch:itactedstics. Alternative rriethods or variations 
in- methods witl;in reasonable limits that do not affect 
such characteristics of the substance rilay be specified. 
d. :Precautions_. to assure proper. identity, strength, 
quality, and pmity ~f the raw mate"rials, whether acti-ve or 
not, including the speclfications. for acceptance ~wd 
methods of testing for eac:h lot of raw material. 
e. Whether O! not each lot of raw materials is given a 
seria~ number to identify it, and the us•:: made of sucj_l 
nwnbf:rs -io subscq_UC!lt plant crpemt!cns. 
-f.-· H the .appli::ant- does not himself r-edonn. ~J_l th~ 
m~.nufacturiug, ._;1HH:essing, rackagins, ir>.bding, and con-
t.::ol o:pcn1tions ft.';: ~ny hevt..J:ug substnncoe or th~ nev.f-·.,Jn:s 
dosnge foiro, his stut~ment id~:ntifyinR. esch person -who 
will pedorro any part of Su~b oper:1ticus and deaignating 
the part; &nd a sign~4 st_:iterne;:ct from -f:ach such p-erson 
fully desc1·ibin:g, directly or- by --refe{eD.ce, tht:: "methods, 
facilities~ and contrOls in his par~ of the· operativn. 
g. Method- of prceparation of the mas ret forro.ula records 
.and individ11al batch records and nta.nner in which thes~ 
reCords ate used. 
h. "'fhe instr_uctions used in'the manU:fac:turing, proc..;->:ss~ 
.!ng, pa<::l..::aging, :and labding of each dosage form· of the 
new drug, including ·any Special precautions observed in 
the operations. 
i. Adequate infor.m..'1.tion with respect to the char.:<\ctc·l"~· 
i:;;tics of and the test aiethods employed for the coo.ta.in.er, 
dosure; or other compone-.u· parts of i:he drug pac.~age to 
essure t~eir. suitability fot the intended use. 
f. Numbe~;· of individuals checking weight or volume of 
er.ch individual ingredient entering into each batch of the 
dn'S· 
~. W'nether or not. the total weight or volume of each 
b.e.~ch is determined at any stage of the man~tacturing 
process subse-quent to making up n batch according to the 
formula card acd, if so, at what stage and by whom it ·is 
done. 
1. Precautions to check the actual package yield pro-
duced from a batch of the drug with che theoretical yield. 
This should include a description of the accounting for 
oUch items as discards, breakage, etc., and the criteria 
used in accepting or rejecting batches Of drugs i.n the 
event rJ. an unexplained discrepancy~ 
m. Pr-eca~tions to assure that each- lo"t of the drug is 
~a-ckaged With th"e proper label and labeling, including 
provisions for labeling storage and inv~ntory control. 
n. The analytical con~wlS used during the vadous 
stages of the manufactt.ting,' processing, packaging, and 
lab~ ling of thr;> drflg, including a detaill!d -dc:;cription of 
the collection o.f sampl(!s and the analytical procedures to 
which they are subjected. The analytical procedures 
should be capable of d,'!terminin·g the active component~ 
within a reasonable degree of accuracy and of assuring 
the identit.}"· of Su-ch components. lf the article is one that 
is repres~nted to be sterile, .the same information with 
regard to. the m~oufacturing, processing, packagir.g, and 
the cc•llec::don of samples· of the drug shOuld be given for 
sterility C;}ntml.s. include the standards used for ac-
CP.pta!ACe _nf each !ot of the finished drug. 
o. An explana[ion o£ the exact signifiCance of the 
ba.tch control nttmbers used. in the "manufacturing, proCess· 
ing, packaging, and· labeling of the drug, including the 
control numbers that appear -on the label of the finished 
article. Sta.te whether these numbers enable determina-
tion "of the complete manufacturing history of the prqduct. 
Descri_be any methods •.\sed to _permit dct(~tmination of the 
distribution of any batch if its recall is required, 
p. A complete dcRcription of, and data derived from, 
studies of the stability of the drug, including i"nformation 
showing the suitability of the analytical methods used. 
Descdbe any additioaal stab~lity studies underway or 
contemplated. StabiHty data should be submiti:ed for any 
new.J:rug substance, for the finished_ dosage form of the 
drug in the container in which it is to be marketed,: in-
cluding any proposed muitiple-dose: container, and if it is 
to be put. into soh\:i.on at the time of -dispensing,_ for t\1~ 
solution prepared as directed. State the expiratioa" date(s) 
that will be used on the label to preserve the identity, 
strength, quality, and purity of the drug until it iS used.· 
(lf no expiratioD. dat_e is ·proposed, the !lpplicant must 
justify its ~b.sence.) 
· q, Addit).(mai procedures employed which are designed 
to ptc"J"ent conte;minat;.on ?>lld otherwis·e assure proper 
contwl o: the 1•::.:.:-do.ct. 
{A.rl a p p 1 i i..~ at i. f' 11 mn.y be tf:.'ftlsf·d. !tnles.a it in~ludes 
adequme ·ir.fMmation .'3'howing that dlf! methods used in, 
ftn.d -the f?.~ilities and controls used.for, the:_ manufacturir1g, 
P.roccssi.ll_g,. and p.<J.ckilglng of th\~ drug ~ttc ·l1d;qui.te tO 
r·resetve i.u- ide:ntity, strl!tlStb, •:~,uality, and· puri_ty in con-
formity with good manufacturiny, practice and identihe.s 
each ·establishment; showing the location of the plant 
_conducting. these. operations.)_ 
9. Sa§2.1!'.~.L~~!_l-~ug "<'.n~ articles used as cpmp~­
!!.:.nts, a~ _ _i:~llow.'?.: ,,._ T11e -following samples shall be subd 
miued wirh thP. -application or as. soon thereafter :as.they 
bec-ome ev~ilablc. Each sample shall consist of !Our 
identical, sepr..rcttc ly pac.bged subdivisions, each con-
taining <:\t least three time-s "th-e a.roount required to per-
form the ·taboral:o.ry tes-t. 11rocedures described in the ap· 
plication to duerrr.iae compl.iaoce with its control speci-
flcfl.tions fcc id·~ntity and ~.s<;;t.y.s: 
i. A repres~o·< ... tati·<e s<Wlf-te or sumJlles ct th~ finish-ed 
dosage f;:mu(s) pL"op.:>sed in t\lf~ application and ernployed 
in tLe: di\1ka.l i1WI"'stigations ~od a representative sample 
or snmples of each o.ew~~~ru,; substance,_ as defined in 
§130.l{g), f:~a1 thE bar.ch(es) employed in the prOduction 
of such closo:\ge fotm(s). 
ii, A re1·uesentative sample or samples of finished 
111arket p;;;·ckages of each dos~ge form of the drug prepared 
for initial marketing and, if any such sample is not from a 
commercial ... scale production batch, such a sample from a 
reptesenr.ative commercial•scale production batch; and a 
representl:'.tive sample or samples of each new-drug sub-
stance as defined- in §130.l(g), from the batch(es) em ... 
played in the production of such dosage form(s.). 
iii. A sample or samples of any reference standard and 
blank used in the procedures described iil the application 
for assaying _each new-drug substance and -other assayed 
~IJ':J 
components of the finished drug: Provt"dt~d, b-uwever, "That 
samples of iderence standards recognized in.· the official 
U.S. -Phamw.copcia cr The National I~ormulary' need ·nor. 
be submitted unless requested. 
b. Additional samples shall be submiti:ed on r·equcst. 
c. Each of the _samples submitted shall be appropri .. 
ately packaged and labeled to preserve it~> Characteristics, 
to identify the ·material and the quantity in each sub-
division of the sample, and to identify each subdivision 
with th~ q,ame of the applicant and the new.-<:lwg applica .. 
tion to which it relates.- . 
d. There shall be included a full list of the samples 
submitted pursuant to Item 9a; 'l statement of the addi-
tional samples that ·will be submitted as soon as avail-
able; and, -~:ith respect to ea(.:h sample Submitted, full 
information with respect to it~ identity, the origin of any 
new-drug st1bstance contained therein O.ncluding in the 
case of new-..d.rug substances, a statement whether it was 
produced on a laboratory, pilot-plant, or full-production 
scale) and detailed results of all laboratory tests made to 
determ.ine the identity, strength,· quality, and purity of 
the batch lepresented by the sample, including assays. 
Inc-lude for any reference standard a complete description 
o£ its preparation and the res).llts of all laboratory tests 
on it. If the test rn.ethods used differed from those de-
scribed in the application, full details Of the methods 
employed in obt?.ining the reported results shall be sub-
mitted. 
e·. The ·reqllirements ·of Item 9a may be waived in 
whole or in pe.!t on request of the "applicant" or otherwise-
when.an.y such samples are not neces-sarY. 
f.- If samples of the drug are setH under separate 
cover, they should be addressed to the ?.._ttentioo of the 
Bureau of- Medicine and identified on the outside of the 
shippip.g C<lftt:li'. w.ith the naffie of the_ "'"ppHcu.nt !lnd th>!': 
·na.tne of the drug a$ .!'lh:own on the appLkadon; 
--10 •.. Full-tepo!t~> of-D:ecliuicul in•n::stip,~'l.tions thM -hat•e 
be ec·roa de t0$hO:.VV:·l~nero?n-O'~tr;~:;-~;l,:-:-·r;-;:;e·· to{ us;;-
;;ddfer:t0~:;-·;;:;-use. a. An appti~:atF:rt;;;_y~-:;:~l•.;;;; 
uplmitc;;;;:i:.,~.in.~-full repeort£ of ndeq<.~ate predi.nical 
te.';-ts by all methc,ds teasan!t"oly a-ppEc~.b\c tc a determlna· 
tion--of- ~he _safety and- eff~c'.:i~·~nes.> of tbe dn~g undc[ the 
conditior1s of use suggested (:"• che PWI'Osed· labeling. 
b~ Detailed reports of th:~ - ·;·clini·cal investigations, 
including· all studies mad-"" :~~!5oratory animals, the 
met~ods used, ~nd the result~ ·ined, should" be clead.y 
set forth. Such information .:;~,:· .. \d include. identification 
of the person who -conducted ~'~~~..:h investigation, a state-
ment of where· i:he investipt.i.l)ns were cond\;cted; and 
where the=·unde!lying data are t'\:vailable for inspection. 
The anilr.al studies may rtot, bt~ considered ad·equatc unless 
t~e_y give proper attention. to the c.onditions of use tccom~ 
mended in the ptoposed lab!.>ling, for the drug such as, for 
example, ·whether the drug is fot· sho.rt- or longptenn ad~· 
m.inisuation or wherher it is to be used in infants., chil-
dr-en, .pregnant women, or women of chiid·bearing potential. 
c. Detailed reports of any pertinent microbiologi.cal 
P.nd ·in vitro studieS. 
d. Summa.t".ize and provide- a list of literature refer-
ences (ii available) to all other preclinical information 
known [Q the applicant, whether published or unpublished, 
that "i~ pertinent to a.n evaluation of the safety or effec-
tiveness cl.. the drug. 
11. List of investigators. a. A complete list 0£ all 
investigators supplied with the drug including the name 
and post office address o[ each.investigator and, following 
ea~h nar!l.e, the volume and page referenCes to the in-
vestigator's _ teport(s) in this application 'and in any docu• 
ments i~cor.por-ated by reference, or the _explanation of the 
omission o( any reports. 
b. The unex:plnincd omission of any reports of in-
vestigations made with· the new drug by the·applicant, o.:;: 
submitted :o him by ~n investigator, or the t:ncxpi-aincd 
om iss ion of any pertinent reports of investigations or 
clinjcal c.Y.pericnce received or otherwise obtaincJ by the 
ap!-'licant from published literature or other sourc:ce 1 
whether or not it would bias an evaluation of the safety 
of the drug cr its effectiveness in use, may constitute 
grounds for the refusal or withdiawal of the approval of 
an application. 
12. Full reports of clinical investigations that_~ 
~~-made to shm'.'_ whether or not_ the drus is safe for_ use 
and effective in use. a. An application may be refused 
unless it contains full reports of adequate tests by all 
methods reasonably applica blc to show whethe.r or not the 
drug is safe and effectiv~ for use as suggested in the 
labeling. 
b. An application may be -refused unless it includes 
substantial e~lidcnce consisting of adequate and well~ 
colltrolled investigations, including clinical investiga-
tions, by experts qualified by scientific training and ex-
pedence to evaluate the effectiveness of the drug in-
volved, on the basis of which it could fairly and respon-
sibly be concluded by such experts that the drug will have 
the effect it purports cr is represented to have under the 
conditions of use prescribed, recommended, or suggested 
in the proposed la-beling. 
c. Reports of all clinical tests sponsored by the ap-
plicant or received or otherwise obtained by. the applicant 
should he attached. These repor.ts should include· ade~ 
quate information concerning each subject· treated with 
the drug or employed as a control, including age, sex, 
conditions treated, dosage, frequency of admini:HraLion 
of the drug, :esults of all relevant dinical observ:!tions 
and laboratory e-xar.1inations made, fuJi information con-
ccrni:c\g_ :::ny other treatmcn~ given previously or cor.cur.-
r.;:l>dy1 :ilnd :.1 f11H stgtemem of arboerse effects and use-ful 
results o~~s·NveG, t\)gecber with an opinion as to whe~he.r 
such effects o.-:- results are <1_ttribntable to the drug under 
investig-3.t.i .. :m anr:('a Statement of where .the undcr_!yi:ng · 
data are a.v:aibble for inspection. O~:dinarily, the teports 
of clinical studi';~S will nut. be regarded as adequde 
unless they inch<de reports -from more than one inde-
pendent, competent investigator who maintains adequate 
case histories of an adequate number of subjects, de-
signed to record observations ~nd per.ffiit evaluation of 
any and all d.i.scernible efbcts attributable to the drug in 
e~ch individual t:eated and comparable records on any 
individuals er<1ployed a,; controls. An application for a 
combination drug mn.y be refused unless there is 5ub-· 
stantial e-vidence that each ingredient designated as 
active makes a contribution to the total effect claimed 
for the drug cllmhinai:it'n. Except when the disease for 
which the drug is being te.sted occw:s with such infre-
quent y in the ll!lit~d States · a.s to make testing im-
practkal, some of th!.! investigations should be oerformed 
by C<..'ffi!=Jeteut investigators with!n the United Stat~s. 
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d. Attach as a separate section a completed Form 
FJ)-!.639, Drug Experience Report (obtainable 1 with i~~ 
;str:Jctions, on request from the Department of HEW. Foo-d 
and Drug Administration. Bureau of Drugs (BD-200) Rock-
ville, Maryland 20852), for each adverse experience or, if 
feasible, for each· sub.ject or patient- experiencing one or 
more adverse· effects, described in Item 12c·, whether or 
not full information is available. Form FD~l639 should 
be prepared by the applicant if the adverse experience 
was not reported in such form by the investigator. The 
Drug Experience Report should be cross-refercn-::ed to 
any narrative description included in Item 12c. ln lieu of a 
FD Form 1639, a computer-generated report may be submit-
ted if equivalent in all_ elements of information with the 
identical enumerated sequence of events and methods o( 
completion; aU-formats proposed for such use will require 
initial review and approval by the Food aP.d Drug Adminis-
tra Hon-
e. All information pertinent to· an evaluation of the 
safety and effectiveness o£ the drug received or otherwise 
obtained by rhe applicant from any source, including 
information derived from other investigations or com-
merical marketing (for example 1 outside the United_ States), 
or reports in the scientific literature, involving the drug 
that is the subject of the application and related drngs. 
An adeq:1ate summary m3.y be acceptable in lieu of a 
reprint of. a published report which only supports other 
data snbmitted. Reprints are not required of reports in 
designatE;cl journals, listed in §130.38 of the new-drug 
regulntions 1 about related drugs; a bib.\iography will 
suffice. Include -!:!ny ;;;,-va1Uat£on of tbe saie;:y or f:ffe-=-
tiveness •Jf the dntg that h•lS be!!n made by the a.ppiico.ni.'s 
medic-al department, expert Com!nitt~e, (l: consultarH:.', 
/. H _t'ne drug is a combination d previously in\'esti~ 
gated oi· marketed t-ltogs, an adeqtu;H(~ summary nf pre-
existia; informati0n frortt. precli.nic<'d ;:.n-1 cli.nicai i.wt~sti· 
gatic,.n and ~xp~ri,:-nc,._; with i<:s- ccmyon.:or.ts, i.:1duding. all 
reports re~:eived or ot))crwise vinaitwJ br th0 f<.pplicant 
sLtggestiO.g side -ei£eclS, c·ontraindications;- and ineffC!c-· 
tivelless in use- of such components. Such summary should 
include an adequa.te bibliography of publicatioris about 
the· components and may iO.corporne by reference infonnn .. 
tion concerning such components previously- submitted 
by the a.pplicant to the Food and, Drug Adrninisuafion. 
g. The complete composition and/or method of manu-
facture of the new drug used in each submitted report of 
investigation should be shown to the extent necessary to 
-establish its identity, strength, quality, and purity if it 
differs from the description in Item 6, 7, or 8 of the ap-
plication. 
13. 1f this is a supplemental appli.catio·n, full. informa-
tioc on each ptopos,;d ch~e cOnc;:_rniog any statem~;t 
ma~!: in tl!_~f£!.9_ved .£-_p.2!j_cation. 
Observe the provisions Of §130.9 of the new~drug regul-a-
tions concerning supplemental applicat.ioos. 
(Applicant) 
Per --·-~-:c---=--=--,..,,-----;,---­(Responsible official or agent) 
(Indicate authority) 
(Warning: A willfully false statement is a criminal offense. U.S-.CoTitle 18, sec. lOOL) 
NOTE: This i!.pplication must be signed by the applicant or by an authorized attorney·, agent, or official. If the applicant 
or such authorized rt.!presentativc_ does not cc s i d c or have u. place o{ business within the United States, the n.pplication must 
also furnish the uamc and p.:>st office address of nnd must be countersigned by an authorized attorney, agent, or official resid-
ing or maintaining a pluce of business wilhin the United St,\tes, 
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-------~~------~--------- ~------~----~------------·-· ---
COMMUNITY PHARMACIST'S DRUG DEFECT REPORT 
1, TRADE NAME, DOSAGE fORM, STRENGTH 
2. LOT NUM9ER (s) 
3, DATE PURCHASED (If known)· 
4. SOURCE OF P-RODUCT (IYbetP. purch<ner!, il knoWn) 
5. NAME AND ADDRESS OF DRUG MANUFACTURER 
6. REPORTING PHARMACIST'S NAME: 
7. NAME ANO ADC!P.E~:S QF PH'ARMACY Unclude ZIP Code)jj 
8, PHONE NUMSE.H -(!w::Jude Arua Code) 
. . 
9.- DEFECTS NOT~D AND SUS~-ECTED 
1---'-"-'-"C.'"c;'_:.!~fJprvv.,d: (l,\1F~_!f.u. 57-JWO~~ 





l/ Addith>11nl form.s and po-"tll#IB·[lt:id l'tJvelopo.s will be rnt~llud to rou nutomtHict~lty at thi~ atldrcss wlwn t1Jis report Is reco/ved, 
United States Pharmacopeia 
RETURN TO 12601 Twinbrook Parkway 
Rockvil\e, Maryland 20852 
Attention: llr. joseph G. Valentino 
'------~-------;__. :,_____________ , ___ , ______ _ 
P orm .Apptovod 
Ol!ict! ol Msna,gt.tment end Dud~or No. 57 .. R0004 
~~------~----~------~=---~-.------~----~----------------CE:PARTME:NT o.F I 
H~~~1H;..~6'~~~6'c;.~·~~~~;~EALft~;;e DRUG EXPERlENCE RI!PC'Ri 
W.ASHJNGiON, D.C. 20204 ' 
ATE SE:NT 1:fl 1~-<ITIAL REPORT ~;;;. PA.T!i?:N't' INiTIAL'S AND IDI:N1'1F'ICA"f!C.N Ni..Jt,l6E:R. 
to, c!c.y, yr) ....._, I l -~ r 
C'.J FO:..LOW UF REPOR"!'" . - j 
-. -,-.-x-":···. •; .. c-"-... ,-_-,-_-,·,-G"H""'T-""'--.c.\i-... ,."-,;-::,;;;,;_cc-;,":,";:..,_.,;,,::_~iitt~!f;'~~Jl/\j?;!;:~J.~;~:~t,t>illJSi•(6¢iA.:(-••'i}gfi.d(iitl{·if FI#Fcii/ /WiW:}idtUJ'f@i;&\% C\ ( ,Y\) • .--':,;. 1-<'/.1:''~,:.;~~· ,C-'c-:,:, ""'". mo ldoy --rr·;--~ AMERICAN O I I , .. o 
l 
:=J M c=l ::' ins. Ib~.l ·l . j 0 CAUC 0 N!::~RO 0 cn!>:::NTAL 0 INDIAN · OTHER 
.soURCE OF REPOR-T (Mig, ]Jospl!a!, a!c)(i".;am~ o! reportl~b Physici!ln is 1~0. AOO;~-;s-0-;-;c:-~~ (Give Street, City, Stete, and Zip Coda.) I 
"'anal.) I 
., oay _ IY' 
---...-J.-,--- j 
I. CESCMISE SUSPECTED ADVERSE RE.ACTI0~4(&) "AND ANY POSSiBLE ASSOCIATION WJTH THE OP..L!G(S) !NVO"-VEO lt2. OUTCOME OF R~AOTION TO I 
DATE 




0 STILL. UNDER TREATMENT 
"0 DIED (Glvo date and cause) 
.> LIST ALL THERAPY IN ORDER OP' SUSPICION (f'IJ•1r1tJ!£J~~Utcr,o LIS~ NDA or 11\'D NO.) ,, ".'·"-,.,.. .,.,·• '>, 
!~ME OF ORUGS 
14. 0\SOROER OR REASON FOR USE OF DRUG 
M"ANUFA,."""URI::"RC: !DOSAGE I I ROUTE I WURATION 'l . ··:\: ,·"1\ 
'-'I - - FORM TOTAL , / I I •OATES OF 
CONTROL Nt), i•'lllb .::ap OAII~Y (po, lm, J'\ ":O:I~:~~·~J--:.:.. .. ·:A~D~M~~·N~·~S~T~R:..__A~T~·~O~N---l----,--------,---------------~ ' ' '! DOSE iv ofc), ,_THE -.APV• l . etc.) l • · .:..---
1 j., / 1~\··,1 '- I 
"R.ADE (Generic) 
A j\ I .;':I. . j 
., I ·'' ! I 
.. \ ·:.;,-:,-.~ ----~ 
..• _:._, __ ·:1, II -.. \ II I I 
'· \ '·I ! 
,, ,, ,, '''""' "'"''''.,_¥'',:: '''''"'' tJ.,,...i_W,_~'-'"'~''""'"''"-''"'""' I SUBSTANTIATING LAB·~~,;. TORY STUDI~cv;;;;;j" L~~'i;;;;atory, Aulopsy, X-R.~y, etc:) . -~- CLINICAL A,B: u DONE U ATTACH~C' CJ NOT DONE 
BIOPSY/AUTOPSY: 0 DONE ~ ATTACHED n "'OT DON'.:: 
LIST PO TEN Tl ALL. V NOX 10US 0-R. 5;-N V!-R01-.J-~,{E·N-fA ~ F-ACT-6~~-_s- ([ilciUd!3 l1ousehold p~i:ldu~l~, indu;t;J;f;n··;d~n;::;g;n;;·cOu:CI;;t;;uO,aCI;-;c;,I,Oc;;m;,;;.cCn;l;:s'J---------~---------'---------j 
EXISTING OR PRIOR DISORDERS AND PAST DRUG REACTION OR ALLERGIC H!S1"0HY PREVIOUS EXPOSURE. TO SUSPECTED 
DRUG OR RELATED COMPOUND 
I] YES" D NO 
(a) IF F£Mh.LE (b) IF PREGNA>•IT ·-r i·;J. MAY THE SoURCE OF' THIS REPORT 6£ 
I INSTITUTE C:•F PATHOLOGY? 
RELEASED TO ThE. ARMED FORC-e::;"'" 
GR;.VtDITV I \ ! PARITY 1 I ! w::.::: OF Gi::STATION ! I ! -- 0 V£5 CJ 
__ ,_ _____ _rF:oOR FDA USE ONLY ! FOR MFG USE ONLY I 
. REAC1'1CN FACTORS (Check D/F ll,'J'lh"cnblo bOxes} -~ .. . I ---
~:=; c!O:::::o!>.•PoslTtcN a;:: ·oRuG CJ ~r~-rt=:RACTtON oF Two oR t-.10RF.: oRu,;;s 0 DRUG NOT u<>~.;.c Ac·(;oRDtNG TO LABELING D DRUG ouTDATED \ 
·-! "'R~!~ P!:OIJ~cn :COY PAo:;;:~lT i.l cvr::HDOSACE c-=J Dflu.:; M:Sl_AOELr-.o : . :.J CO~JTAII.W,!l>"T>.:'N OF O:<:.JG [J otHER ;;,nuG i'.r.i$USE Pz•oc"if)'} . 
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October 9, 1975 
MULTIPLE CHOICE. Circle All correct answers. (30 points) 






2. This first federal food and d.rug lm·r established which 
of the following: 
a. premarket clearance. of new drugs for seSety. 
b. definitions of food and drugs. 
c. c.urrent good me.nui'r~cd;uring prttctices. 
d, standards for food.s and drugs through the 
definit·ions of adulteration and rnisbr•ru:tdint!;. 
E:. drug factory inspections ever·y two ;years~ 
3. \lhat legal mechanisms are defined in the Federal I!'ood, 
Drug, and Cosmetic Act to serve as the tools for its 
enforcement? 
a~< seizure, recall, injunc-,;~on. 
b. proseeution, recall. 
c. seizure, prosecution, injunction. 
d. sEd.zure, pros0cv.tion, recall, injunction. 
4. The Federal i!'ood, Drug, and. Cosmetic Act, in the form 
passed in 1938, provided for whieh of the follov1ing: 
a. adverse drug reactions must be reported to the 
FDA by the firms. 
b. premarket clearance for the safety of new drugs. 
c. all antibiotics must be batch tested and certified. 
d. premarket clearance for the safety and efficacy 
of new drugs. 
e. increased labeling requirements for drugs to . 





5. The 1962 Kefauver-Harris Drug Amendments added several 
significant requirements With respect to the regulation 
of drugs. These included: 
a. informed consent of patients prior to the use 
of an investigational new drug. 
b. all antibiotics must be batch tested and certi-
fied prior to marketing. 
c. premarket clearance for the safet-y and effica.cy 
of new drugs. 
d. drug factory inspections required every 2 years. 
e. current good ma~ufacturing practices for dr~gs 
established • 
.SHORT .ANSWER. 
1. (2 pts.) 
2. (3 pta.) 
;. (7 ptso) 
4., (2 pts.) 
(2 pts.) 
What incident stimulated the passage of the 
Federal }!'ood, Drug-, and Cosmetic~. Act of 1938? 
1Tie FDA rec.eiv,?B its enforcemen-t; renponsibili-
ties from what tbree pieces of legisiat:i.on? 
The FDA has jurisdictj.on over What products? 
(7 categories) 
What event, in 1962, turned the Kefauver com-
mittee from its study of the economics of the 
drug industry to the stud;7 of the safety of 
investigational new drugs? 
How does the concept of "person" ~1i th regard to 
violations of the Federal Food, Drug, and Cosmetic 
Act differ from other legal concepts of liability? 
(3) 215 
APPENDIX H 
6. (2 pts.) \fuat is the "government ne•11spaper"? 
7. (2 pts.) Define 21 CFR. \rlhat is its relationship to 
the FD.il.? 
8. (8 pts.) Draw the orga~izational chart of the FDA to 
include the 8 major areas. 
MATCHING~ (2 points ea.cb.) 




---"""' "r'"> • • • ___ -, 
J',pJ.<l.eiDJ.OLOgy 
.;.,.__ Drug Monographs 
---·· New Drug Evaluation 
Pha:r·mac~eutical Research 
& Testing 
A. . Revie;,rs INL' s m1d 
·B. r,aboratory analysis of drug 
produc·~s, to include the 
testing of a11tibiotics and 
insulin for certification. 
C. Enforcement of the la',rs 
th:.cough seizure, inj1mction, 
and prosecutions. 
D. Statistical support for the 
Bureau's ac"!:;ivities; includes 
monitoring of adverse drug 
reactions and poisonings. 
E. Support for the Bureau •lith 
library and library research 
i'acili ties. 
F. HHndles OTC drug inrsredient 
review panels, biophm:·rna-
ceutics data, and abbreviated 
new drug applications. 
(4) ' 216 
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2. Match the Project Management System Program with its 
description. 
-·- Drug Application Evaluation 
Drug Efficacy Study 
Implementation 
---··- OTC Drug Evaluation 
___ Drug Pharmaceu·!;ics and 
l'lethodology 
______ Drug Experience Information 
__ Drug Abuse and Methadone 
Monitoring 
..._.,___ Drug Inventory 
·--- Poison Control 
•. ~. , .• Prescription Drug 
Advertising 
~,,.. . .,.,.. .. l'!iedical Communication & 
Drug Abuse i'rends 
Analynis 
A. ·Post-market monitoring 
of the effects of (lrugs 
in an Ul1Controlled setting. 
B. Supplies drug information 
to health professionals 
through the "Drug 
Bulletin" and "Dear Dr. 
letters". 
C. Implementation o.f the NAS/ 
NRC recommendt',tioml on the 
safety & efficaey of the 
new drugs marketed between 
1938-1962 • 
D. Monitor new drug investi-
gations, evaluate data. 
from these investigations, 
and make recommenda.tions 
as to the safety and 
efficacy of new drugs. 
E. Provides data base on 
poisonings ar1d dissemi...,. 
nates informEltion to poison 
co11trol centf.::rs across the 
nation. 
F. ~brough the surveillance 
of medical publications, 
prescription dru.g adver-
tisements are monitored. 
G. Implementation of the Drug 
Listing Act of 1972. 
H. Analysis and evaluation of 
drugs in the la.b, and 
develops methodology. 
I. Monitoring o:f studies on 
drugs with abuse potential 
and the limited distribu-
tion of methadone. 
J. Coordination of the evalua-
tion for over-the-counter 




?. Match the level of regulation with an example. 
_ __._ 
I. Inspector at all plants. 
II. 
III. 
Certification batch by 
batch of the products 
produced. 
Certification of the firm 
to make a particular 
product. 
IV. Certification of the firm 
for.a type of production. 
V. Collection of samples on 
the marketplace and 
analysis for violations. 
A. New drugs: Ne\~ 
Drug Application. 
B. Large volume 
parenterals: 
· Specific Good 
Manui'acturing . 
Practices. 
c. Most drug produc·i:;s. 
D. USDA meat inspection. 




FllA Drug Regulatory Procedures 
l!~am #2 -------------------------·---
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MULTIPLE CHOICE. Circle All correct answers. (55 points) 




c. duration of administration. 
d. dosage form. 
e. route of administration. 
2. The statutory time limit on the FDA for the review of a 
new drug application is: 
a. 90 days. 
b. 60 da,.ys. 
c. 2 years. 
d. l yea:r. 
e. 180 days. 
3. FToper prescription dr1~ labeling should: 
a. predict TtJhat might occur w:L th the use of a drug. 
b. reflect all significant date. about a drug. 
c. be prompt in accomodation of changes in knowledge 
about a drug. 
d. provide prescriber with the essential information 
to use the drug safely and effectively. 
e. contain adequate information on the side effects 
m1d contraindications • 
. · 4... There are various types and forms of labeling. After 
reevaJ.uating the objectives of prescription drug labeling, 
the J:i'DA has decided to utilize a more effect:i ve means of 
providing health professionals \vith information to use the 
drug safely and effectively. This method will be: 
a. package insert vii t;h unique labeling. 
b. package insert with generic labeling. 
c. national drug coropend.ia with class labeling. 
d. national drug compendia with generic labeling. 
e. national drug compendia with unique labeline;. 
(2) 
APPENDIX I 
5. Class labeling can be defined as: 
a. one document for the same basic drug from 
different manufacturers. 
b. one document accounting for all members of 
a given therapeutic class or subclass. 
219 
c. one document for each individual drug product. 
d. several documellts for the· same basic drue~ from 
different manu_facturers. 
e. several documents for an individual drug product. 
6. Corrective measures that may be taken when a firm violates 
prescription drug advertising regulations include: 
a. deletion of the ad from further use. 
b. fine of $10,000. · 
c. sending "Dear Doctor" letters to physicians 
across the nation to explain that the advertise-
ment was false and misleading. 
d. publishing retraction in the magazine in •1hicli 
the original ad was run to explain wh,_y the ad 
\'/as false <md misleading. 
e. at least one year in prison. 
7. 'I'he NAS/NRC evaluaticm of drugs reviewed: 
a. all drugs on the market at the time • 
. b. drugs put on the mm·ket pi•ior to 1938. 
c. drugs which has new drug applications app:coved 
between 1938-1962 • 
. d. prescription drug ingredients that were used 
prior to 1962. 
e. OTC drug ingredients. 
8. ~'he NAB/NRC review was criticized because: 
a. reports were too lengthy and ambiguous. 
b. panels met in secret. 
c. panels supposedly composed mainly of "academic 
experts" that lacked clinical eJ.);erience. 
d. panels contained too many FDA personnel. 




9. Several issues were raised by the JITAS/NRC revie\>1 that 
led to changes in policy within the agency. These 
issues included: 
a. the presentation of an unusual hazard with 
combination drug products. 
b. the difficulty in the regulation of "generic" 
or "me-too's" of approved new drug products. 
c. the need for the restructure of.the Bureau of 
Drugs. 
d. the lack of efficacy of about three-fourths 
of all over-the-counter drugs reviewed. 
e. the fact that most drugs that were reviewed 
were effective. 
10. A drug is considered adulterated for which of the 
folloVIing reasons: 
a. methods used in manufacture do not conform 
to Current Good t1anu:facturing Practices. 
b. does not meet compendial standards. 
c. contains ru1y filtb.y substance. 
d~ held under ins ani ta:r.y condi t:i.on.s e 
·9o col.Qr additiVe is unsa.fes 
11. A dJ~ug is cor1sidered misbre.r;.decl for \vhich of the 
following reasons: 
a. if prepared in an urn~eg:i.stered. esi;ab1ishrrwnt< 
b. .the label is false and misleading. 
c. if the drug is dangerous when used in t;he 
dosage on the label. 
d •. if the drug is an antibiotic or insulin and 
has not been certified. 
e. if the drug is pr·escription, and the advertising 
does not contain the established name, quantit:a.-
tive ingrediE-•nts, a...'1d a st1mmary of the side 






A050LUleL~ !RUE! •· 
UNDE.~IAilL~ FALSE! . 
VNQUE:>110NA6L~ TRUE! •; 
RSASONA6l.~ 1RUE! . 
\RREFVTABUI""TRUE' !·'· 
UNDSR5i,~NOASL~ FAL5Ef 
INTRIN-5iCI\LL ~ FAL5Ef 
INHERE~TL~ F.~LSE! 
CKAR,\\INGL~ TRUE! · 
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The FDA has the authority to cite violations of the 
ne\'1 drug section of the FDC Act af'ter the drug has 
legally come to rest following interstate commerce; 
i.e. a physician can be cited bythe FDA for viola-
tions of the FDC Act for prescribing a drug for an 
indication not included in the labeling. 
Prescription drug advertising must be approved by 
the FDA prior to publication. 
3 •. OTC drug advertising is regulated by the FDA. 





One way in vlhich the OTC drug revie"l-'1 cU.ffers fro:n 
the NAS/NRC r·evie>l is that; drug :i.ngredi>mts rather· 
th<m drug products are b-:d.ng reviewed., 
DESI is defined as Drug Efficacy Study Implementation 
tmd ·is a program designed to impJ.emr~nt the I'(:Womt\\en-· 
dations of the OTC drug reviel'l :panels. 
The o~ec drug revi.e\v \vas initiated because· the NAB/NRC 
revie\'1 revealed that many OTC drug products v1ere not 
effective • 
.A double-blind study refers to one in v1hich both the 
the patient and the physician do not know wha:t; medi·· 
cation i.s being administered. 
The primary review team for the .review of the informa-. 
tion in IND's ~~d riDA's consists of the chemist, medi-
cal officer, and microbiologist. 
The last step in the approval process for a new drug 
application is the approval of the final printed 
labeling. 
If the sponsor of an IND has not received word from 
FDA 30 days following the receipt of the IND by the 




SHORT ANS\IJER (P.5 points) 
1. Define new drug. (4 points) 
2. Wb,at is the purpose of the IND? (3 points) 
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Describe the three phases involved in the investigation 
of a new drug. (6 points) 
4. The r.·esults of a clinical trial should bo <:onrpe.:t.·ed wi.th 
a t:;ont:r.ol. Define the following types of control com-




5. Define what is considered to be the "drug lag". (3 points) 
(6) 
APPENDIX I 
6. FDA has been accused of both overregulation end 
unde=eg~.llation. After reading the article "FDA, 
Politics, and the Public", and from '\<ihat you have 
learned in class, what, in your opinion, wouldbe 
the best description of the agency's performance? 
(3 points) · 
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APPENDIX J 
FDA Drug Regulatory Procedu.-res 
Exam #3 
December 12, 1975 
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MULTIPLE CHOICE. Circle All correct answers. (50 points) 
· 1. A Class I recall: 
a. is a priority situation which may be immediate 
or long-range. 
b. is a routine situation with a remote possibil:i.ty 
of a threat to life. 
c. is an emergency situation with imminent danger. 
d. example would be defective heart valve. or pacemaker. 
e. example would be broken tablets or leaking capsules. 
2. 'l'he dept:t, of the monitoring by the FDA of recalls t 
a. can be to distributors, pharmacies and even to 
the consmuer level. 
b. depends upon the severit7 of the problem. 
c. is elassifiecl in le·vels to effe{)tively utilize 
FDA field personneL 
d. is the same for all classes of recalls. 
e. j_s 100% for Class III recall<.,. 
'l~e criminal prosecution: 
a. involves prohibiting the firm from manufacturing 
its goods. 
b. is a lengthy procedure which is initiated based 
upon a firm's record of faulty past performances. 
c. can be instituted against those persons in control 
of the firm, e.g. the president, the vice-
president, or the head of quality control. 
d. can be either a misdemeanor or felony depending 
upon the severity of the violations. 
e. is the seizing of' adulterated or misbranded goods. 
4. In its survey of marketed drugs, the FDA 1r1ill collect ran-
dom samples end analyze certain categories. The categories 
are determined based upon the following: 
a. impact. of the drug, e.g. low dose-high potency 
drugs. 
b. wide use. 
c. therapeutic significance, i.e. life-saving. 
d. date of approval of the NDA. 




As defined in the FDA's bioequivalence regulations, the 
best (one answer) determination of the bioavailability 
o:f'a' drug product is: 
a. measurement of an acute pharmacologic effect 
as a f~~ction of time. 
b. measurement of concentration in blood, plasma, 
or other body fluid as a function of time. 
c. measurement of safety and efficacy from well-
controlled clinical trials. 
d. measurement of the in vitro dissolution rates. 
6. The r1a-x:imum Allowable Cost (MAC) regulations promulgated 
by HE\1/: 
a. designates the price for r-eimbursing products 
d:i.spensed under Hedica:i.d and r-~edicare as being 
the.i; currently paid by providers in a package 
sb;e most frequently purchased. 
b. are ceilings imposedby the federal government 
on reimbursement to the pharmacist for produr;ts 
dispensed under Hedicaid I:'Xld l'ledicare. 
c. rely upon. the :B'DA to assure that drugs to be 
r;i VEoll1 a "filA en e.re b:i.oe,qui valfmt. 
d. contains provisions for single Bom~ce drug 
products to have e.n estimated. acqui.s.i tion •:::est. 
e\J des:l.gnate ·the prict:; r:;ett;:i.ng structure to be a 
conunittee composed of members of l'NA, Al?hA, and. 
HAim. 
7. 'l:he Freedom of Ini·ormation Act of 1972 was passed by 
Congress to "open up" government files to release more 
ir.cformation to the public. The· regulations promulgated 
by the FDA specify information which can be held as con-
fidentia.l. These include: 
a. manufacturing and quality control procedures in 
an approved NDA. I 
b. commercial or financia.l information about a firm. 
c. existence of an IND. 
d. personnel or medical files. 1 











B. FDA's Drug Abuse Staff in the Division of 
Neuropharmacologic Drug Products works closely with 
the Drug Enforcement Agency in the enforcement of 
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the Controlled Substances Act in which of the follm·l-
ing areas: 
a. restrictions on dispensing. 
b. registration of handlers. 
c. record-keeping. 
d.. manufacturing quotas. 
e •. determination of what substances should be 
controlled. 
9. The Bureau of Biologics differs in its regulation of 
b:\.ologics from the Bureau of Drugs' regulation of drugs 
in that: · 
a. biologicals are regulated solely on the basis 
of misbranding and adulteration violations. 
b. each of its prQ(lucts mus-e be licensed prior 
to marketing. 
c. no prema:rketing clearance is req1.1ired for any 
biologic. 
d. all of its products must be ce:Pt:i.fied. 
e. inspections of firms are every tvro years. 
10. Th•,;; FDA's bioequivalence regulations :Cave been criticized 
in Congressional hem.'ings in v1hich of the following ways: 
a. the regulations are worded in such a wa:y so that 
it \'Iould appea-r that a large number of' drug 
products on the max·ket a-re bioinequivalent. 
b. the regulations are too lenient. 
·c. the implementation of the regulations could 
lead to the elimination of some of the smaller 
i'irms that can not afford to do the tests. 
d.. the listing of' the 193 drugs \~ith potential 
problems has put doubt into the advisabilit-y 













1. The :fi'DA can r.ecall products fi-om the market as 
one of the regulatory mechanisms defined in the 
Food, Drug 9 and Cosmetic Act. 
2. The procedure of sending regulatory letters l'llas 
i:o.i tiated because O'ier 909& of the seizm·e actions 
never went to court and the cost of regulation 






A seizure is a civil action taken against the goods, 
rather than the firm of personnel. 
The injunction action is t:olll:en ~1hen inspe.ctionul 
reports indicate the firm has a history o:f v:i.ols.-
tions of the F.D.&C. Act. 
All antibiotics e.nd insulin must be batch certified 
by the FDA prior to marketing. 
Only a.bout 1% of 1;he batcbes of antibiotics teiJted 
are rejected. 
·The FDA handles th0 support of the activities of 
poiso11 control ce:ti.ters through its national 
Clearinghouse for Poison Control. 
Prior to 1972, the FDA did not have the authority 
to require producers of cb:·ugs to supply the agency 
with a J.ist of those drugs ma.nillactured. 
!"lethadone is the first drug. to have a limited dis-
tribution requirement set by the FDA. 
The l~f.cx:imum Allovmble Cost regulations allow each 
state to determil1B the dispensing fee for Medicaid 
and Medicare drugs based upon periodic surveys of 
pha-rmacy operating costs. 
___ 11. ~~e average time interval between FDA inspections of 




The regulations o:f medical devices and diagnostic 
products is based upon the adulteration, misbranding, 
and premarlcet cleara~ce provisions of the F.D.&C. Act. 
Biological products are regulated by FDA under the 






1. Define injunction. (3 points) 
2. Describe the drug product defect reporting system. 
(5 points) 
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:;. Senator Kennedy has introduced legislation that ,,muld 
split the I!'DA :i.nto t11lo separate agencies: Drugs and 
Devices, and Food and Cosmetics. With all of the regu·-
latory respon.sibilities of the agency (i.e. jurisdj_ction 
over biologicals, radiologicalst foodr:;, drugs, cosmeticr:;, 
medical devices and diagnostics), do you feel this is a 
good recommendation? 
BlB:COGRAPHY 
1. "FDA Justifications of Appropriation Estimates for 
Committee on Appropriations," U.S. Department of 
Heal"t;h 1 Education, and Welfare, Food and Drug 
Administration, Fiscal Year 1975, p. 11. 
2. Neal, H. E., "The Protectors: the Story of the Food 
and Drug Administration," Julian Messner·company, 
New York, N. Y., 1968, pp. 12-13. 
3. Linton, F. B., Federal Food and Drug La~TS·· Leaders 
~lho Achieved Their Enactment and. Enforcement, EzQ!b. 
A£.ug 2 a.nd · C~etic JourD;.al reprint, Commerce Clearing 
House, Chicago, Ill., 1949, pp. 2-6. 
5. "A Brief I.egislative History of the Food, Drug, and 
Cosmetic Act," u.s. Cong;ress House Committee on 






Linton, F .. Bot, Federal TI100.d and_ D1~ug La~lfJH- Leade:cs 1~·J:h.o 
}.cb.iov~d 'l'heir Enactm~nt and Enfo::cceme:at, f~2ltc.. I!£.~"--·?:-.tlli. 
£9.E.1Jll'~!.1.!?-r}out1,l& repn.n.t, Com1ne:r·ce C1ea:t•:rng ~.iO'JSe, zihicago, 
Ill.' 19,+9, p. 11. 
Milestones in U.S. Government Food and Drug La>v History, 
u.s. Department o:f Health, Education, and 1tle1:fa"t'e, No, 
(FDA) 7.3-1018, 1972. . 
Neal, R. E., . "The Protectors: 'J'he' Story of the Food and 
Drug Administration," Julian Nessner Company, New York, 
N.Y., 1968, p. 21. 
Tug\~cll, R., Recollections of '33 and Later, FDA P.QLQ.E:§., 
2~1!-(June) 1968. 
;[p.iQ... • pp. 5-8. 
Linton, 1'. B., Federal Food and Drug Laom- Leaders \fuo 
Achieved Their Enactment and hn.forcement, Ji.'o_9d, DrJ!& and 
CosmetJc ,Journal reprint, Commerce Clearing House, Chicago, 
Ill., 194·9, pp. 66-68. 
Depew, F., Evolution of a Law, FDA Papers, 2:lO(June) 1968. 
229 
230 
13. "Federal Food, DI·ug, and Cosmetic Act as amended," 
u.s. Government Printing Office, No. 1712-0126, (Aug.) 
1972, p. 6. 
14. Depew, F., Evolution of a Law, FDA Pa~, 2:11 (June) 
1968. 
15. "A Brief Legislative History of the Food, Drue~, and 
Costmetic Act," U.S. Congress House Committee on 
Interstate and Foreign Commerce, (January) 1974, pp. 4-6. 
16. loid., pp. 6-7. 
~ 
17. Jbid., pp. 8-9. 
18. J-bid.' P• 10. 
19. Depe\~, 
1968. 
F.' 11'vo1ution of a JJa"', m1L1'..2.~· 2:14(June) 
·20. "A Brief Legislative History of the Food, Drug, and 
Cosmetic Act," u.s. Congress House Committee oninterstate 
and Foreign Commerce, (January) 19('1~, pp. 15-18. 
21. "FDA Jus"l;ifications of Appropriation Estimates i'or 
Committee on Appropriations," u.s. Department of Health,. 
l':ducation, and 1tlelfa-ce, Food and Drug AdministTc,ticm, 




















p. 138 • 
p. 309• 
29. "Staff Hanual Guides, FDA Supervisory Organization & 
Delegation," u.s. Government Printing Office, (Mal:'ch) 
197.3. 
~0. Sormedecker, G., "Reimington' s Pharmaceutical Sciences," 
J.Li-th ed., Mack Printing Company, Easton, Pa., 1970, p. 13. 
31. Deno, R., Rowe, T., and Brodie, D., "The Profession of 
Pharmacy, 11 J. B. Lippincott Company, Philadelphia, Pa., 
1959, p. 38. . 
231 
32. Ibi1., pp. 31-33. 
33. Kremers, E. , and Urdan.g, G. , "The History of Pharmacy, " 








n.1Q..., p. 306. 
Swintosky, J., Pharmaceutical Education in the United 
States of America-Professional and Graduate," American 
Journal of Pharmacy, ll•6:76-77 (Hay-June) 1974. 
Deno, R., Rovle, T., and Brodie; D., "The PI·ofession of 
Pharmacy," J. B. Lippincott Company, Philadelphia, Pa., 
1959, pp. 38-39. 
Elliot, E., director, "Findings and Recommendations of 
the Pharmaceutical Survey of 1948," The Pha.rmaceutical 
Survey, American Council on Education, Washington, D.C., 
19ll-8, p. 46. 
Deno, R., Rowe, T., and Brodie, D., "The Profession of 
Pharmacy 1 
11 J. B. Lippincott Company, Phila.delphia, Pa., 
1959, p. 29. 
Ell:i.ot, E., director, "Findings. and Recommendations of 
the Pharmaceutical Survey of 19Le8," 'I'he Fharmaceu.tical 
Survey, Ame.:r:·ican Council or) Ed.ucntion, \vashington, D. c., 
1948, p. 1-!-0. 
Goyan, J., :l!:a.e Education and .Abilities of the Clinic. ally 
T-:c·a.i1:ed Phar··mfwist, Oponing address for the ConfBrFJnce on 
"The Expanding Role of the Pharmacist," u.c. Davit~, 
October 18, 1972, pp. 1-4. 
"Report to the Spealter of the Assembly by the Advisory 
Commission on Pharmacy, 11 California State Legislature 
Advisory Commission onPharmacy, November 8, 1974, p. 55. 
"Report of the Committee on Curriculum,". Americal1_.ifo~rnal 
srf..J"h~macueti_cal Education, 32 :J~35(Aug. )-1968. 
Statement of Organization, Functions, ·and Delegations of 
Authori:t;y, ~o. od and Drug Administration, Feders.l Regi:;;~r_, 
39:343li3-Y~:519(Sept. 24) l97L1·. 
"Federal Food, Drug, and Cosmetic Act as amended " U.S. 
Government Printing Office, No. 1712-0126, (Aug.) 1972, 
pp. 41-42. 
45. Cristopher, T., and Goodrich, W., "Cases and Materials on 
Food and Drug Law,11 Commerce Clearing House, Chicago, Ill., 
1973, pp. 422-424. 
46. 
232 
"Federa.l Food, Drug, and Cosmetic Act as amended," 
U.S. Government Printing Office, No. 1712-0126, {Aug.) 
1972, pp. 41-42. 
Werble, W., ed., FDC Reports: The Pink Sheet, 37: T&GlO 
(Aug. 19) 1974. · 
48. Claimed Exemption for an Investigational New Drug, 
Department of Health, Education, and Welfare, Food and 
Drug Administration, Form 1571. 
49. Schmidt, A., Statement before the Subcommittee on 
Health, Committee on Labor and Public iielfare, u.s. 
Senate, September 25, 1974. 
50. 
51. 
Finkle, M., and Zatman, J., Investigational ru1d New 
Drugs, FDA Papers, 4:32-33(Nov.) 1970. 
Refusal to Approve the Application, Title 21 Code oL 
,E~eral ReguJ,..~.i9J1£., Section 314.111, 19'/4. 
52. Nevi Drug Application (Drugs for Human Use), Department 
o.f Heal~ch, Educa,tion, and l'lelfare, Food and Drug 







"Federal Food, Drug,. and Cosmetic Act as amended 
Government Printing Office, Ho~ 1712-0126, (Aug.) 
p. lJ-3. 
u.s. 
1 '"''") • '::,J (L.' 
J:,asagnc,, I •• , and Wardell, 1;1., The :FDA, Politics, ruld. 
the Public. ,Journal of the American Ned.ice.l J\ssociat:i.on. 
232:141-142CKpr:-m:r-srt~--------·---·-·-··-· 
\ilerble, W., ed., FDC Re orts: The I'ink She§:.i, 36 :Bl·-B20 
(Aug. 19) 19?4. 
"FDA Justifications of Appropriation Estimates for 
Committee on Appropriations, 11 U.S. Department of Health., 
Education, ruld Welfare, Food and Drug Administration, 
Fiscal Year 1975, p. 93. 
"Federal Food, Drug, nnd Cosmetic Act as amendedt" U.S. 
Government Printing Office, No. 1'712-0126, (Aug.; 1972, 
p. 2. 
Goldenthal, E., Current Views on Safety Evaluation of 
Drugs, FDA Paoers, 2:16-l?(Ney) 1968. 
Pasto, D., and Johnson, c., "Orgnnic Structure 
Determination," Prentice-Hall, Inc., New Jersey, 1969. 
60. Human Drugs Containing Vinyl Chloride or Packaged in 
Polyvinyl Chloride Containers, ~eral Regi.st_2.E,, 
39:14238-14239(Apr. 22) 1974. . 
233 
61. Cristopher, T., and Goodrich, W., "Cases and Materials 
on Food and Drug Law," Commerce Clearing House, Chicago, 
Ill., 1973, pp. 581-586. 
62. "Federal Food, Drug and Cosmetic Act as am.ended," u.s. 
Government Printing Office, No. 1712-0126, (Aug.) 1972, 
p. 9. 
63. "United States Pharmacopeia XIX," Mack Printing Company, 
Easton, Fa., 1974, p. 711. 
64. Bryan, P., DESI vfuo?, FDA Consumer, 6:11-15(0ct.) 1972. 
65. "l!'DA Justifications of Appropriations Estimates for 
Committee on Appropriations," u.s. Department of Health, 
Education, and Welfare, Food and Drug Administration, 
Fiscal Year 1975, p. lOL~. 
66. Werble, W., ed., ~~i~~t';..Sll~, 37:3-8 
(Jtme 23) 1975. 
